

REFINITIV

## DELTA REPORT

### 10-Q

DVA - DAVITA INC.

10-Q - MARCH 31, 2024 COMPARED TO 10-Q - SEPTEMBER 30, 2023

The following comparison report has been automatically generated

**TOTAL DELTAS** 1976

■ CHANGES	297
■ DELETIONS	456
■ ADDITIONS	1223

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 10-Q

---

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly Period Ended **September 30, 2023** **March 31, 2024**  
or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File Number: 1-14106

---



**DAVITA INC.**

**Delaware**  
(State of incorporation)

**51-0354549**  
(I.R.S. Employer Identification No.)

**2000 16th Street**  
**Denver, CO 80202**  
**Telephone number (720) 631-2100**

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class:</b>	<b>Trading symbol(s):</b>	<b>Name of each exchange on which registered:</b>
Common Stock, \$0.001 par value	DVA	NYSE

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
Emerging growth company	<input type="checkbox"/>		

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes  No

As of **November 3, 2023** **April 26, 2024**, the number of shares of the registrant's common stock outstanding was approximately **91.3 million** **87.7 million** shares.

---

DAVITA INC.  
INDEX

## PART I. FINANCIAL INFORMATION

Item 1.	<u>Condensed Consolidated Financial Statements:</u>	
	<u>Consolidated Statements of Income for the three and nine months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023</u>	1
	<u>Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023</u>	2
	<u>Consolidated Balance Sheets as of September 30, 2023 March 31, 2024 and December 31, 2022 December 31, 2023</u>	3
	<u>Consolidated Statements of Cash Flow for the nine months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023</u>	4
	<u>Consolidated Statements of Equity for the three and nine months ended September 30, 2023 March 31, 2024 and September 30, 2022 March 31, 2023</u>	5
	<u>Notes to Condensed Consolidated Financial Statements</u>	76
Item 2.	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	2320
Item 3.	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	4038
Item 4.	<u>Controls and Procedures</u>	4139

## PART II. OTHER INFORMATION

Item 1.	<u>Legal Proceedings</u>	4240
Item 1A.	<u>Risk Factors</u>	4240
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	4240
Item 3.	<u>Defaults Upon Senior Securities</u>	4240
Item 4.	<u>Mine Safety Disclosures</u>	4240
Item 5.	<u>Other Information</u>	4240
Item 6.	<u>Exhibits</u>	4341
	<u>Signature</u>	4442

**DAVITA INC.**  
**CONSOLIDATED STATEMENTS OF INCOME**  
(unaudited)  
(dollars and shares in thousands, except per share data)

	Three months ended September 30,	Nine months ended September 30,		
Three months ended March 31,				
Three months ended March 31,				
Three months ended March 31,				
			Three months ended March 31,	
	2023	2022	2023	2022
			2024	2023

Dialysis patient service revenues	Dialysis patient service revenues				
		\$2,951,950	\$2,846,494	\$8,602,669	\$8,372,874
Other revenues	Other revenues	169,382	102,200	391,731	320,132
Total revenues	Total revenues	3,121,332	2,948,694	8,994,400	8,693,006
Operating expenses:	Operating expenses:			Operating expenses:	
Patient care costs	Patient care costs	2,067,315	2,085,555	6,181,348	6,120,872
General and administrative	General and administrative	376,883	365,447	1,072,513	975,486
Depreciation and amortization	Depreciation and amortization	188,423	194,414	550,166	538,534
Equity investment income, net	Equity investment income, net	(7,228)	(8,509)	(22,502)	(24,696)
Gain on changes in ownership interest					
	Total operating expenses				
	Total operating expenses				
Total operating expenses	Total operating expenses	2,625,393	2,636,907	7,781,525	7,610,196
Operating income	Operating income	495,939	311,787	1,212,875	1,082,810
Debt expense	Debt expense	(98,080)	(99,680)	(302,361)	(256,057)
Debt extinguishment and modification costs		—	—	(7,962)	—
Other loss, net		(19,650)	(4,898)	(14,525)	(7,968)
Other (loss) income, net					
Other (loss) income, net					
Other (loss) income, net					
Income before income taxes	Income before income taxes	378,209	207,209	888,027	818,785
Income tax expense	Income tax expense	68,848	42,515	161,621	163,757
Net income					
Net income					
Net income	Net income	309,361	164,694	726,406	655,028
Less: Net income attributable to noncontrolling interests	Less: Net income attributable to noncontrolling interests	(62,729)	(59,328)	(185,536)	(162,731)
Net income attributable to DaVita Inc.	Net income attributable to DaVita Inc.	\$ 246,632	\$ 105,366	\$ 540,870	\$ 492,297
Earnings per share attributable to DaVita Inc.:	Earnings per share attributable to DaVita Inc.:				

<b>Earnings per share attributable to DaVita Inc.:</b>						
<b>Earnings per share attributable to DaVita Inc.:</b>						
Basic net income						
Basic net income	Basic net income	\$ 2.70	\$ 1.16	\$ 5.95	\$ 5.24	
Diluted net income	Diluted net income	\$ 2.62	\$ 1.13	\$ 5.80	\$ 5.07	
Diluted net income						
Weighted average shares for earnings per share:						
Weighted average shares for earnings per share:						
Basic shares	Basic shares	91,322	91,160	90,937	93,959	
Diluted shares	Diluted shares	94,041	93,263	93,317	97,153	

See notes to condensed consolidated financial statements.

**DAVITA INC.**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**  
(unaudited)  
(dollars in thousands)

		Three months ended September 30,		Nine months ended September 30,	
		2023	2022	2023	2022
Net income	Net income	\$ 309,361	\$ 164,694	\$ 726,406	\$ 655,028
Net income					
Net income					
Other comprehensive (loss) income, net of tax:	Other comprehensive (loss) income, net of tax:				
Unrealized gains on interest rate cap agreements:					
Unrealized gains		6,996	41,312	28,305	95,660
Reclassifications of net realized (gains) losses into net income		(21,198)	1,033	(55,895)	3,100
Other comprehensive (loss) income, net of tax:					
Other comprehensive (loss) income, net of tax:					
Unrealized gains (losses) on interest rate cap agreements:					
Unrealized gains (losses) on interest rate cap agreements:					
Unrealized gains (losses) on interest rate cap agreements:					
Unrealized gains (losses)					

Unrealized gains (losses)					
Unrealized gains (losses)					
Reclassifications of net realized gains into net income					
Reclassifications of net realized gains into net income					
Reclassifications of net realized gains into net income					
Unrealized (losses) gains on foreign currency					
translation:					
Unrealized (losses) gains on foreign currency					
translation:					
Unrealized (losses) gains on foreign currency	Unrealized (losses) gains on foreign currency				
translation:	translation:	(47,644)	(66,100)	27,878	(95,064)
Other comprehensive (loss) income	Other comprehensive (loss) income	(61,846)	(23,755)	288	3,696
Other comprehensive (loss) income					
Other comprehensive (loss) income					
Total comprehensive income					
Total comprehensive income					
Total comprehensive income	Total comprehensive income	247,515	140,939	726,694	658,724
Less: Comprehensive income attributable to noncontrolling interests	Less: Comprehensive income attributable to noncontrolling interests	(62,729)	(59,328)	(185,536)	(162,731)
Less: Comprehensive income attributable to noncontrolling interests					
Less: Comprehensive income attributable to noncontrolling interests					
Comprehensive income attributable to DaVita Inc.	Comprehensive income attributable to DaVita Inc.	\$ 184,786	\$ 81,611	\$ 541,158	\$ 495,993
Comprehensive income attributable to DaVita Inc.					
Comprehensive income attributable to DaVita Inc.					

See notes to condensed consolidated financial statements.

**DAVITA INC.**  
**CONSOLIDATED BALANCE SHEETS**  
**(unaudited)**  
**(dollars and shares in thousands, except per share data)**

	September 30, 2023	December 31, 2022		March 31, 2024		March 31, 2024		December 31, 2023
<b>ASSETS</b>	<b>ASSETS</b>			<b>ASSETS</b>				
Cash and cash equivalents	Cash and cash equivalents	\$ 449,458	\$ 244,086					
Restricted cash and equivalents	Restricted cash and equivalents	95,667	94,903					
Short-term investments	Short-term investments	11,713	77,693					
Accounts receivable	Accounts receivable	2,024,827	2,132,070					
Inventories	Inventories	109,620	109,122					
Other receivables	Other receivables	352,965	413,976					
Prepaid and other current assets	Prepaid and other current assets	91,109	78,839					
Income tax receivable	Income tax receivable	—	4,603					

Total current assets	Total current assets	3,135,359	3,155,292	
Property and equipment, net of accumulated depreciation of \$5,650,912 and \$5,265,372, respectively		3,097,483	3,256,397	
Property and equipment, net of accumulated depreciation of \$5,921,761 and \$5,759,514, respectively				
Operating lease right-of-use assets	Operating lease right-of-use assets	2,509,416	2,666,242	
Intangible assets, net of accumulated amortization of \$37,738 and \$49,772, respectively		185,403	182,687	
Intangible assets, net of accumulated amortization of \$37,053 and \$38,445, respectively				
Equity method and other investments	Equity method and other investments	565,394	231,108	
Long-term investments	Long-term investments	45,320	44,329	
Other long-term assets	Other long-term assets	302,142	315,587	
Goodwill	Goodwill	7,088,223	7,076,610	
		\$16,928,740	\$16,928,252	
<b>LIABILITIES AND EQUITY</b>	<b>LIABILITIES AND EQUITY</b>			<b>LIABILITIES AND EQUITY</b>
Accounts payable	Accounts payable	\$ 435,417	\$ 479,780	
Other liabilities	Other liabilities	808,000	802,469	
Accrued compensation and benefits	Accrued compensation and benefits	770,184	692,654	
Current portion of operating lease liabilities	Current portion of operating lease liabilities	393,440	395,401	
Current portion of long-term debt	Current portion of long-term debt	108,558	231,404	
Income tax payable	Income tax payable	22,331	18,039	
Total current liabilities	Total current liabilities	2,537,930	2,619,747	
Long-term operating lease liabilities	Long-term operating lease liabilities	2,342,170	2,503,068	
Long-term debt	Long-term debt	8,285,146	8,692,617	
Other long-term liabilities	Other long-term liabilities	184,944	105,233	
Deferred income taxes	Deferred income taxes	753,871	782,787	
<b>Total liabilities</b>	<b>Total liabilities</b>	<b>14,104,061</b>	<b>14,703,452</b>	
Commitments and contingencies	Commitments and contingencies			

Noncontrolling interests subject to put provisions	Noncontrolling interests subject to put provisions	1,445,403	1,348,908
Noncontrolling interests subject to put provisions			
Noncontrolling interests subject to put provisions			
Equity:	Equity:	Equity:	
Preferred stock (\$0.001 par value, 5,000 shares authorized; none issued)	Preferred stock (\$0.001 par value, 5,000 shares authorized; none issued)	—	—
Common stock (\$0.001 par value, 450,000 shares authorized; 91,348 and 90,411 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively)		91	90
Common stock (\$0.001 par value, 450,000 shares authorized; 89,822 and 87,703 shares issued and outstanding at March 31, 2024, respectively, and 88,824 shares issued and outstanding at December 31, 2023)			
Additional paid-in capital	Additional paid-in capital	552,651	606,935
Retained earnings	Retained earnings	715,357	174,487
Treasury stock (2,119 and zero shares, respectively)			
Accumulated other comprehensive loss	Accumulated other comprehensive loss	(68,898)	(69,186)
Total DaVita Inc. shareholders' equity	Total DaVita Inc. shareholders' equity	1,199,201	712,326
Noncontrolling interests not subject to put provisions	Noncontrolling interests not subject to put provisions	180,075	163,566
Total equity	Total equity	1,379,276	875,892
		\$16,928,740	\$16,928,252

See notes to condensed consolidated financial statements.

**DAVITA INC.**  
**CONSOLIDATED STATEMENTS OF CASH FLOW FLOWS**  
 (unaudited)  
 (dollars in thousands)

Nine months ended  
September 30,

Three months ended March 31,				Three months ended March 31,	
	2023		2022		
Cash flows from operating activities:	Cash flows from operating activities:			Cash flows from operating activities:	
Net income	Net income	\$ 726,406	\$ 655,028		
Adjustments to reconcile net income to net cash provided by operating activities:	Adjustments to reconcile net income to net cash provided by operating activities:			Adjustments to reconcile net income to net cash provided by operating activities:	
Depreciation and amortization	Depreciation and amortization	550,166	538,534		
Loss on extinguishment of debt		7,132	—		
Stock-based compensation expense					
Stock-based compensation expense					
Stock-based compensation expense	Stock-based compensation expense	82,313	77,904		
Deferred income taxes	Deferred income taxes	(17,767)	(35,637)		
Equity investment loss (income), net		40,121	(417)		
Equity investment loss, net					
Gain on changes in ownership interest					
Other non-cash charges, net	Other non-cash charges, net	1,633	16,035		
Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:	Changes in operating assets and liabilities, net of effect of acquisitions and divestitures:				
Accounts receivable	Accounts receivable	118,148	(135,632)		
Accounts receivable					
Accounts receivable					
Inventories					
Other current assets	Other current assets	32,132	43,739		
Other long-term assets	Other long-term assets	1,101	(49,326)		
Accounts payable	Accounts payable	(33,837)	38,870		
Accrued compensation and benefits	Accrued compensation and benefits	65,279	35,491		

Other current liabilities	Other current liabilities	10,822	87,248
Income taxes	Income taxes	(1,878)	(37,770)
Other long-term liabilities	Other long-term liabilities	(7,945)	(13,219)
Net cash provided by operating activities		1,573,826	1,220,848
Net cash (used in) provided by operating activities			
<b>Cash flows from investing activities:</b>	<b>Cash flows from investing activities:</b>		
Additions of property and equipment	Additions of property and equipment	(409,011)	(409,391)
Acquisitions	Acquisitions	(7,990)	(43,811)
Proceeds from asset and business sales	Proceeds from asset and business sales	24,907	116,088
Purchase of debt investments held-to-maturity	Purchase of debt investments held-to-maturity	(30,419)	(94,602)
Purchase of other debt and equity investments	Purchase of other debt and equity investments	(6,693)	(3,322)
Proceeds from debt investments held-to-maturity	Proceeds from debt investments held-to-maturity	94,414	40,660
Proceeds from sale of other debt and equity investments	Proceeds from sale of other debt and equity investments	3,930	3,763
Other		—	(782)
Purchase of equity method investments			
Purchase of equity method investments			
Purchase of equity method investments	Purchase of equity method investments	(276,006)	(28,176)
Distributions from equity method investments	Distributions from equity method investments	3,364	2,490
Net cash used in investing activities	Net cash used in investing activities	(603,504)	(417,083)
<b>Cash flows from financing activities:</b>	<b>Cash flows from financing activities:</b>		
Borrowings			
Borrowings			

Borrowings	Borrowings	2,468,335	1,705,913
Payments on long-term debt	Payments on long-term debt	(2,992,248)	(1,557,358)
Deferred and debt related financing costs	Deferred and debt related financing costs	(53,466)	—
Purchase of treasury stock	Purchase of treasury stock	—	(802,228)
Distributions to noncontrolling interests	Distributions to noncontrolling interests	(203,381)	(188,592)
Net payments related to stock purchases and awards	Net payments related to stock purchases and awards	(41,155)	(42,248)
Contributions from noncontrolling interests	Contributions from noncontrolling interests	11,579	11,382
Proceeds from sales of additional noncontrolling interests	Proceeds from sales of additional noncontrolling interests	50,962	3,673
Purchases of noncontrolling interests	Purchases of noncontrolling interests	(7,875)	(20,770)
Net cash used in financing activities		(767,249)	(890,228)
Net cash provided by (used in) financing activities			
Effect of exchange rate changes on cash, cash equivalents and restricted cash	Effect of exchange rate changes on cash, cash equivalents and restricted cash	3,063	(6,283)
Net increase (decrease) in cash, cash equivalents and restricted cash		206,136	(92,746)
Net (decrease) increase in cash, cash equivalents and restricted cash			
Cash, cash equivalents and restricted cash at beginning of the year	Cash, cash equivalents and restricted cash at beginning of the year	338,989	554,960
Cash, cash equivalents and restricted cash at end of the period	Cash, cash equivalents and restricted cash at end of the period	\$ 545,125	\$ 462,214

See notes to condensed consolidated financial statements.

DAVITA INC.

**CONSOLIDATED STATEMENTS OF EQUITY**  
 (unaudited)  
 (dollars and shares in thousands)

Three months ended March 31, 2024

Three months ended March 31, 2024

Three months ended March 31, 2024

Three months ended September 30, 2023

DaVita Inc. Shareholders' Equity

	Non-controlling interests subject to put provisions	Common stock			Treasury stock			Accumulated other comprehensive loss	Total	Non-controlling interests not subject to put provisions
		Shares	Amount	Additional paid-in capital	Shares	Amount				
Balance at June 30, 2023	\$ 1,423,549	91,271	\$ 91	\$ 555,680	\$ 468,725	—	\$ —	\$ (7,052)	\$ 1,017,444	\$ 188,626
<b>Balance at December 31, 2023</b>										
Balance at December 31, 2023										
Comprehensive income:										
Comprehensive income:										
Comprehensive income:	Comprehensive income:									
Net income	Net income	44,572			246,632			246,632		18,157
Net income										
Net income										
Other comprehensive income							(61,846)	(61,846)		
Other comprehensive loss										
Other comprehensive loss										
Other comprehensive loss										
Stock award plan										
Stock award plan										
Stock award plan	Stock award plan	77		(4,750)				(4,750)		
Stock-settled stock-based compensation expense	Stock-settled stock-based compensation expense									
Stock-settled stock-based compensation expense	Stock-settled stock-based compensation expense									
Changes in noncontrolling interest from:	Changes in noncontrolling interest from:									
Changes in noncontrolling interest from:	Changes in noncontrolling interest from:									
Changes in noncontrolling interest from:	Changes in noncontrolling interest from:									
Distributions	Distributions	(52,382)							(26,821)	
Distributions										
Distributions										
Contributions										

Contributions										
Contributions	Contributions	4,493								140
Partial purchases	Partial purchases		(179)			(179)			(27)	
Partial purchases										
Partial purchases										
Fair value remeasurements										
Fair value remeasurements										
Fair value remeasurements	Fair value remeasurements	25,171		(25,171)					(25,171)	
Purchase of treasury stock										
Balance at September 30, 2023	\$ 1,445,403	91,348	\$ 91	\$ 552,651	\$ 715,357	—	\$ —	\$ (68,898)	\$ 1,199,201	\$ 180,075
Purchase of treasury stock										
Purchase of treasury stock										
Balance at March 31, 2024										
Balance at March 31, 2024										
Balance at March 31, 2024										

Nine months ended September 30, 2023											
Non-controlling interests subject to put provisions	DaVita Inc. Shareholders' Equity									Non-controlling interests not subject to put provisions	
	Common stock			Additional paid-in capital		Retained earnings		Treasury stock			
	Shares	Amount		Capital		Earnings		Shares	Amount		
Balance at December 31, 2022	\$ 1,348,908	90,411	\$ 90	\$ 606,935	\$ 174,487	—	\$ —	\$ (69,186)	\$ 712,326	\$ 163,566	
Comprehensive income:											
Net income	131,523					540,870			540,870	54,013	
Other comprehensive income								288	288		
Stock award plan	937	1		(53,353)						(53,352)	
Stock-settled stock-based compensation expense				80,579						80,579	
Changes in noncontrolling interest from:											
Distributions	(133,656)									(69,725)	
Contributions	10,102									1,477	
Acquisitions and divestitures				13,077						13,077	
Partial purchases	(700)			(5,361)						(5,361)	
Fair value remeasurements	89,226			(89,226)						(89,226)	
Balance at September 30, 2023	\$ 1,445,403	91,348	\$ 91	\$ 552,651	\$ 715,357	—	\$ —	\$ (68,898)	\$ 1,199,201	\$ 180,075	

See notes to condensed consolidated financial statements.

**DAVITA INC.**  
**CONSOLIDATED STATEMENTS OF EQUITY**  
**(unaudited)**

**(dollars and shares in thousands)**

Three months ended September 30, 2022											
Non-controlling interests subject to put provisions	DaVita Inc. Shareholders' Equity									Non-controlling interests not subject to put provisions	
	Common stock			Additional paid-in capital		Retained earnings		Treasury stock			
	Shares	Amount		Capital		Earnings		Shares	Amount		
Balance at December 31, 2022	\$ 1,348,908	90,411	\$ 90	\$ 606,935	\$ 174,487	—	\$ —	\$ (69,186)	\$ 712,326	\$ 163,566	
Comprehensive income:											
Net income	131,523					540,870			540,870	54,013	
Other comprehensive income							288	288			
Stock award plan	937	1		(53,353)						(53,352)	
Stock-settled stock-based compensation expense				80,579						80,579	
Changes in noncontrolling interest from:											
Distributions	(133,656)									(69,725)	
Contributions	10,102									1,477	
Acquisitions and divestitures				13,077						13,077	
Partial purchases	(700)			(5,361)						(5,361)	
Fair value remeasurements	89,226			(89,226)						(89,226)	
Balance at September 30, 2023	\$ 1,445,403	91,348	\$ 91	\$ 552,651	\$ 715,357	—	\$ —	\$ (68,898)	\$ 1,199,201	\$ 180,075	

												comprehensive		
		Shares	Amount					Shares	Amount		loss		Total	
Balance at June 30, 2022	\$ 1,385,821	98,179	\$ 98	\$ 578,272	\$ 741,268		(5,973)	\$ (603,058)	\$ (111,796)	\$ 604,784	\$ 170,390			
Comprehensive income:														
Net income	39,205				105,366					105,366		20,123		
Other comprehensive loss										(23,755)		(23,755)		
Stock purchase shares issued														
Stock award plan		20			(986)							(986)		
Stock-settled stock-based compensation expense					27,619							27,619		
Changes in noncontrolling interest from:														
Distributions	(48,275)											(22,002)		
Contributions	1,996											270		
Acquisitions and divestitures												867		
Partial purchases	(215)				(3,339)							(3,339)		(193)
Fair value remeasurements	(7,779)				7,779							7,779		
Purchase of treasury stock						(2,122)				(184,796)		(184,796)		
Balance at September 30, 2022	\$ 1,370,753	98,199	\$ 98	\$ 609,345	\$ 846,634	(8,095)	\$ (787,854)	\$ (135,551)	\$ 532,672	\$ 169,455				

Nine months ended September 30, 2022														
	Non-controlling interests													Non-controlling interests not subject to put provisions
	subject to put provisions	Common stock		Additional paid-in capital		Retained earnings		Treasury stock		other		Accumulated comprehensive loss		
	Shares	Amount		Shares	Amount	Shares	Amount	Shares	Amount	loss		Total		put provisions
Balance at December 31, 2021	\$ 1,434,832	97,289	\$ 97	\$ 540,321	\$ 354,337	—	\$ —	—	\$ (139,247)	\$ 755,508	\$ 180,640			
Comprehensive income:														
Net income	113,157				492,297					492,297		49,574		
Other comprehensive income										3,696		3,696		
Stock award plan		910		1	(55,359)							(55,358)		
Stock-settled stock-based compensation expense					77,835							77,835		
Changes in noncontrolling interest from:														
Distributions	(125,534)											(63,058)		
Contributions	9,300											2,082		
Acquisitions and divestitures	2,392				939							939		867
Partial purchases	(11,633)				(6,609)							(6,609)		(193)
Fair value remeasurements	(52,218)				52,218							52,218		
Other	457											(457)		
Purchase of treasury stock						(8,095)						(787,854)		
Balance at September 30, 2022	\$ 1,370,753	98,199	\$ 98	\$ 609,345	\$ 846,634	(8,095)	\$ (787,854)	\$ (135,551)	\$ 532,672	\$ 169,455				

Three months ended March 31, 2023														
	Non-controlling interests													Non-controlling interests not subject to put provisions
	subject to put provisions	Common stock		Additional paid-in capital		Retained earnings		Treasury stock		other		Accumulated comprehensive loss		
	Shares	Amount		Shares	Amount	Shares	Amount	Shares	Amount	loss		Total		put provisions
Balance at December 31, 2022	\$ 1,348,908	90,411	\$ 90	\$ 606,935	\$ 174,487	—	\$ —	—	\$ (69,186)	\$ 712,326	\$ 163,566			

Comprehensive income:												
Net income	36,692				115,547				115,547		18,429	
Other comprehensive income								14,280		14,280		
Stock award plan	239		1	(9,523)							(9,522)	
Stock-settled stock-based compensation expense				24,847						24,847		
Changes in noncontrolling interest												
from:												
Distributions	(35,550)										(19,287)	
Contributions	3,748										977	
Acquisitions and divestitures				13,023						13,023		30,718
Fair value remeasurements	45,031			(45,031)						(45,031)		
Balance at March 31, 2023	\$ 1,398,829	90,650	\$ 91	\$ 590,251	\$ 290,034	—	\$ —	\$ (54,906)	\$ 825,470	\$ 194,403		

See notes to condensed consolidated financial statements

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

Unless otherwise indicated in this Quarterly Report on Form 10-Q, "the Company", "we", "us", "our" and similar terms refer to DaVita Inc. and its consolidated subsidiaries.

## 1. Condensed consolidated interim financial statements

The unaudited condensed consolidated interim financial statements included in this report are prepared by the Company. In the opinion of management, all adjustments necessary for a fair presentation of the results of operations are reflected in these condensed consolidated interim financial statements. All significant intercompany accounts and transactions have been eliminated. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets, liabilities, contingencies and noncontrolling interests subject to put provisions. The most significant estimates and assumptions underlying these financial statements and accompanying notes generally involve revenue recognition and accounts receivable, certain fair value estimates, accounting for income taxes and loss contingencies. The results of operations reflected in these interim financial statements may not necessarily be indicative of annual operating results. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended **December 31, 2022** (**2022 December 31, 2023** (**2023** 10-K)). Prior period classifications conform to the current period presentation. The Company has evaluated subsequent events through the date these condensed consolidated interim financial statements were issued and has included all necessary adjustments and disclosures.

## 2. Revenue recognition

The following tables summarize the Company's segment revenues by primary payor source:

		Three months ended September 30, 2023			Three months ended September 30, 2022			
		Other —		Other —				
		Ancillary		Ancillary				
		U.S. dialysis	services	Consolidated	U.S. dialysis	services	Consolidated	
Dialysis patient service revenues:	Dialysis patient service revenues:	Three months ended March 31, 2024						
					Three months ended March 31, 2024		Three months ended March 31, 2023	
		U.S. dialysis		U.S. dialysis		U.S. dialysis	Other — Ancillary	
		Medicare and Medicare Advantage		Medicare and Medicare Advantage		Medicare and Medicare Advantage	Other — Ancillary	
		Medicare and Medicare Advantage		Medicare and Medicare Advantage		Medicare and Medicare Advantage	Consolidated	
		Medicare and Medicare Advantage		Medicare and Medicare Advantage		Medicare and Medicare Advantage	Consolidated	
Dialysis patient service revenues:	Dialysis patient service revenues:	\$1,515,860		\$1,515,860	\$1,535,680	\$1,535,680		

Medicaid and Managed Medicaid	Medicaid and Managed Medicaid					
Other government	Other government	207,327	207,327	193,853	193,853	
Commercial	Commercial	90,549	\$128,980	219,529	86,852	\$116,084
		965,331	68,192	1,033,523	880,812	56,170
Other revenues:	Other revenues:					
Medicare and Medicare Advantage	Medicare and Medicare Advantage	137,149	137,149	78,345	78,345	
Medicare and Medicare Advantage	Medicare and Medicare Advantage					
Medicaid and Managed Medicaid	Medicaid and Managed Medicaid					
Medicaid	Medicaid	331	331	412	412	
Commercial	Commercial	16,063	16,063	6,484	6,484	
Other <sup>(1)</sup>	Other <sup>(1)</sup>	6,239	11,832	18,071	6,056	10,903
Eliminations of intersegment revenues	Eliminations of intersegment revenues	(24,289)	(2,232)	(26,521)	(22,957)	—
<b>Total</b>	<b>Total</b>	<b>\$2,761,017</b>	<b>\$360,315</b>	<b>\$3,121,332</b>	<b>\$2,680,296</b>	<b>\$268,398</b>
						<b>\$2,948,694</b>

(1) Other consists primarily of management service fees earned in the respective Company line of Company's U.S. dialysis business as well as and research fees, management fees, and other non-patient service revenue from revenues in the Company's U.S. integrated kidney care (IKC) and other Other - ancillary services and international operations.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

	Nine months ended September 30, 2023			Nine months ended September 30, 2022		
	Other — Ancillary services		Consolidated	Other — Ancillary services		Consolidated
	U.S. dialysis	services		U.S. dialysis	services	
<b>Dialysis patient service revenues:</b>						
Medicare and Medicare Advantage	\$ 4,538,264		\$ 4,538,264	\$ 4,529,300		\$ 4,529,300
Medicaid and Managed Medicaid	629,118		629,118	570,380		570,380
Other government	265,119	\$ 376,530	641,649	253,731	\$ 349,633	603,364
Commercial	2,676,758	183,578	2,860,336	2,570,054	164,302	2,734,356
<b>Other revenues:</b>						
Medicare and Medicare Advantage		317,624	317,624		255,204	255,204
Medicaid and Managed Medicaid		1,296	1,296		1,181	1,181
Commercial		20,888	20,888		16,029	16,029
Other <sup>(1)</sup>	18,822	38,108	56,930	18,124	29,584	47,708
Eliminations of intersegment revenues	(66,698)	(5,007)	(71,705)	(64,516)	—	(64,516)
<b>Total</b>	<b>\$ 8,061,383</b>	<b>\$ 933,017</b>	<b>\$ 8,994,400</b>	<b>\$ 7,877,073</b>	<b>\$ 815,933</b>	<b>\$ 8,693,006</b>

(1) Other primarily consists of management service fees earned in the respective Company line of business as well as other non-patient service revenue from the Company's U.S. integrated kidney care (IKC) and other ancillary services and international operations businesses.

There are significant uncertainties associated with estimating revenue, many of which take several years to resolve. These estimates are subject to ongoing insurance coverage changes, geographic coverage differences, differing interpretations of contract coverage and other payor issues, as well as patient issues, including determination of applicable primary and secondary coverage, changes in patient insurance coverage and coordination of benefits. As these estimates are refined over time, both positive and negative adjustments to revenue are recognized in the current period.

*Dialysis patient service revenues.* Revenues are recognized based on the Company's estimate of the transaction price the Company expects to collect as a result of satisfying its performance obligations. Dialysis patient service revenues are recognized in the period services are provided based on these estimates. Revenues consist primarily of payments from government and commercial health plans for dialysis services provided to patients.

*Other revenues.* Other revenues consist of revenues earned by the Company's non-dialysis ancillary services as well as fees for management and administrative services to outpatient dialysis businesses that the Company does not consolidate. Other

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

revenues are estimated and recognized in the period services are provided, the performance obligation is met, subject to applicable measurement constraints. The Company's integrated kidney care (IKC) revenues include revenues earned under risk-based arrangements, including value-based care (VBC) arrangements. Under its VBC arrangements, the Company assumes full or shared financial risk for the total medical cost of care for patients below or above a benchmark. The benchmarks against which the Company incurs profit or loss on these contracts are typically based on the underlying premiums paid to the insuring entity (the Company's counterparty), with adjustments where applicable, or on trended or adjusted medical cost targets.

For its IKC business, the Company recognized revenues for performance obligations satisfied in previous years of \$19,450 and \$12,821 during the three months ended March 31, 2024 and 2023, respectively. The delay in recognition of these amounts resulted predominantly from measurement limitations and recognition constraints on our VBC contracts with health plans, many of which are complex and relatively new arrangements. The Company's revenue recognition for its government Comprehensive Kidney Care Contracting (CKCC) program also remains constrained for plan year 2023.

Measurements of revenue for the Company's IKC risk-based arrangements are complex, sensitive to a number of key inputs, and require meaningful estimates for a number of factors, including but not limited to member alignment data, third-party medical claims expense, outcomes on various quality metrics, and ultimate risk adjustment factor (RAF) scores. Information and other measurement limitations on these factors may constrain revenue recognition for a risk-based arrangement until a period after the Company's performance obligations have been met.

### 3. Earnings per share

Basic earnings per share is calculated by dividing net income attributable to the Company by the weighted average number of common shares outstanding. Weighted average common shares outstanding include restricted stock unit awards that are no longer subject to forfeiture because the recipients have satisfied either the explicit vesting terms or retirement eligibility requirements.

Diluted earnings per share includes the dilutive effect of outstanding stock-settled stock appreciation rights and unvested stock units as computed under the treasury stock method.

The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:

	Three months ended March 31,	
	2024	2023
Net income attributable to DaVita Inc.	\$ 239,649	\$ 115,547
Weighted average shares outstanding:		
Basic shares	87,775	90,497
Assumed incremental from stock plans	2,772	1,986
Diluted shares	<u>90,547</u>	<u>92,483</u>
Basic net income per share attributable to DaVita Inc.	\$ 2.73	\$ 1.28
Diluted net income per share attributable to DaVita Inc.	\$ 2.65	\$ 1.25
Anti-dilutive stock-settled awards excluded from calculation <sup>(1)</sup>	391	1,295

(1) Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**

**(unaudited)**  
(dollars and shares in thousands, except per share data)

**The reconciliations of the numerators and denominators used to calculate basic and diluted earnings per share were as follows:**

	Three months ended September 30,		Nine months ended September 30,	
	2023	2022	2023	2022
Net income attributable to DaVita Inc.	\$ 246,632	\$ 105,366	\$ 540,870	\$ 492,297
Weighted average shares outstanding:				
Basic shares	91,322	91,160	90,937	93,959
Assumed incremental from stock plans	2,719	2,103	2,380	3,194
Diluted shares	<u>94,041</u>	<u>93,263</u>	<u>93,317</u>	<u>97,153</u>
Basic net income per share attributable to DaVita Inc.	\$ 2.70	\$ 1.16	\$ 5.95	\$ 5.24
Diluted net income per share attributable to DaVita Inc.	\$ 2.62	\$ 1.13	\$ 5.80	\$ 5.07
Anti-dilutive stock-settled awards excluded from calculation <sup>(1)</sup>	271	1,260	615	878

<sup>(1)</sup> Shares associated with stock awards excluded from the diluted denominator calculation because they were anti-dilutive under the treasury stock method.

#### 4. Short-term and long-term investments

The Company's short-term and long-term debt and equity investments, consisting of debt instruments classified as held-to-maturity and equity investments with readily determinable fair values or redemption values, were as follows:

	September 30, 2023			December 31, 2022			March 31, 2024			December 31, 2023		
	Debt securities		Total	Debt securities		Total	Debt securities		Total	Debt securities		Total
	Debt securities	Equity securities		Debt securities	Equity securities		Debt securities	Equity securities		Debt securities	Equity securities	
Certificates of deposit and other time deposits	Certificates of deposit and other time deposits											
	deposits	\$ 20,430	\$ —	\$ 20,430	\$ 82,879	\$ —	\$ 82,879					
Investments in mutual funds and common stocks	Investments in mutual funds and common stocks											
	stocks	—	36,603	36,603	—	39,143	39,143					
		\$ 20,430	\$ 36,603	\$ 57,033	\$ 82,879	\$ 39,143	\$ 122,022					
Short-term investments	Short-term investments											
	investments	\$ 5,419	\$ 6,294	\$ 11,713	\$ 67,872	\$ 9,821	\$ 77,693					
Long-term investments	Long-term investments											
	investments	15,011	30,309	45,320	15,007	29,322	44,329					
		\$ 20,430	\$ 36,603	\$ 57,033	\$ 82,879	\$ 39,143	\$ 122,022					

**Debt securities.** The Company's short-term debt investments are principally bank certificates of deposit with contractual maturities longer than three months but shorter than one year. The Company's long-term debt investments are bank time deposits with contractual maturities longer than one year. These debt securities are accounted for as held-to-maturity and recorded at amortized cost, which approximated their fair values at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**.

**Equity securities.** The Company holds certain equity investments that have readily determinable fair values from public markets. Substantially all of the Company's remaining short-term and long-term equity investments are held within a trust to fund existing obligations associated with the Company's non-qualified deferred compensation plans.

#### 5. Goodwill

Changes in the carrying value of goodwill by reportable segment were as follows:

	U.S. dialysis	Other — Ancillary services	Consolidated
Balance at December 31, 2022	\$ 6,416,825	\$ 659,785	\$ 7,076,610
Acquisitions	—	25,723	25,723

Impairment charges	—	(26,083)	(26,083)
Foreign currency and other adjustments	—	36,310	36,310
Balance at December 31, 2023	\$ 6,416,825	\$ 695,735	\$ 7,112,560
Acquisitions	102,082	35,208	137,290
Divestitures	(1,687)	—	(1,687)
Foreign currency and other adjustments	—	(18,461)	(18,461)
Balance at March 31, 2024	\$ 6,517,220	\$ 712,482	\$ 7,229,702
Balance at March 31, 2024:			
Goodwill	\$ 6,517,220	\$ 858,977	\$ 7,376,197
Accumulated impairment charges	—	(146,495)	(146,495)
	\$ 6,517,220	\$ 712,482	\$ 7,229,702

The Company did not recognize any goodwill impairment charges during the three months ended March 31, 2024 or the three months ended March 31, 2023. None of the Company's various reporting units were considered at risk of significant goodwill impairment as of March 31, 2024.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

## 5. Goodwill

Changes in the carrying value of goodwill by reportable segment were as follows:

	U.S. dialysis	Other — Ancillary services	Consolidated
Balance at December 31, 2021	\$ 6,400,162	\$ 646,079	\$ 7,046,241
Acquisitions	16,750	32,297	49,047
Divestitures	(87)	(3,263)	(3,350)
Foreign currency and other adjustments	—	(15,328)	(15,328)
Balance at December 31, 2022	\$ 6,416,825	\$ 659,785	\$ 7,076,610
Acquisitions	—	4,688	4,688
Foreign currency and other adjustments	—	6,925	6,925
Balance at September 30, 2023	\$ 6,416,825	\$ 671,398	\$ 7,088,223
Balance at September 30, 2023:			
Goodwill	\$ 6,416,825	\$ 789,338	\$ 7,206,163
Accumulated impairment charges	—	(117,940)	(117,940)
	\$ 6,416,825	\$ 671,398	\$ 7,088,223

The Company did not recognize any goodwill impairment charges during the nine months ended September 30, 2023 and 2022.

The Company's business continues to be impacted by the effects of the coronavirus (COVID-19). While the Company does not currently expect a material adverse impact to its business as a result of COVID-19, there can be no assurance that the magnitude of the cumulative impacts from COVID-19 will not have a material adverse impact on one or more of the Company's businesses. These cumulative impacts from COVID-19 may include, among other things, the cumulative impact on mortality rates for the kidney patient population and the cumulative impact on certain conditions and developments in the U.S. and global economies, labor market conditions, inflation and monetary policies.

Developments, events, changes in operating performance and other changes in key circumstances since the dates of the Company's last annual goodwill impairment assessments have not caused management to believe it is more likely than not that the fair values of any of the Company's reporting units would be less than their respective carrying amounts as of September 30, 2023. Except for the Company's Germany kidney care reporting unit as described further in Note 10 to the Company's consolidated financial statements included in the 2022 10-K, none of the Company's various other reporting units were considered at risk of significant goodwill impairment as of September 30, 2023.

## 6. Equity method and other investments

The Company maintains equity method and other minor investments in the private securities of certain other healthcare and healthcare-related businesses as follows:

	September 30, 2023	December 31, 2022	March 31, 2024	March 31, 2024	December 31, 2023

Mozarc	Mozarc		
Medical	Medical		
Holdings	Holdings		
LLC	LLC	\$342,315	
APAC joint venture	APAC joint venture	98,215	\$ 99,141
Other equity method partnerships	Other equity method partnerships	112,305	116,403
Adjusted cost method and other investments	Adjusted cost method and other investments	12,559	15,564
		\$565,394	\$231,108
		\$	

During the **nine** three months ended **September 30, 2023** **March 31, 2024** and **2022** **2023** the Company recognized equity investment income of **\$22,502** **\$6,682** and **\$24,696**, **\$6,820**, respectively, from its equity method investments in nonconsolidated dialysis partnerships. The Company also recognized equity investment losses from other equity method investments of **\$38,653** **(\$19,029)** and **\$1,974** **(\$2,478)** in other (loss) income, net during the **nine** three months ended **September 30, 2023** **March 31, 2024** and **2022**, **2023**, respectively.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

On May 25, 2022, the Company entered into an agreement with Medtronic, Inc. and one of its subsidiaries (collectively, Medtronic) to form a new, independent kidney care-focused medical device company (Mozarc Medical Holding LLC, or Mozarc) via a deconsolidating partial interest sale from Medtronic to the Company, which closed effective April 1, 2023. The Company holds a 50% voting equity interest in Mozarc and Medtronic holds the other 50% voting equity interest. The Company does not maintain a controlling financial interest in Mozarc and therefore accounts for this investment on the equity method, with equity method income or loss recognized in Other income (loss), net, on a one-month lag.

At the closing, the Company made an estimated purchase price payment, including certain transaction cost adjustments, to Medtronic of \$44,651, subject to certain customary post-closing adjustments, and contributed certain other non-cash assets to Mozarc with an estimated value of \$14,000. In addition, the Company agreed to pay Medtronic additional consideration of up to \$300,000 if certain regulatory, commercial and financial milestones are achieved between 2024 and 2028. At close, the Company and Medtronic also each contributed an additional \$224,415 in cash to Mozarc to fund its development initiatives.

The Company's investment in Mozarc was recorded at an initial estimated cost of \$375,326, which represents the sum of the cash amounts paid and contributed for the Company's investment in Mozarc, the estimated fair value of the non-cash assets contributed, the estimated fair value of the Company's contingent consideration payable to Medtronic for its interest in Mozarc of \$86,200, and direct costs incurred to complete this transaction. The foregoing cost estimates are based upon the best information available to management but remain subject to change based on finalization of post-closing purchase price adjustments yet to be completed between the parties and finalization of related third-party valuation reports. As of September 30, 2023, the book value of the Company's contingent consideration payable to Medtronic approximates its estimated fair value.

The recorded cost of the Company's equity method investment in Mozarc, and its prospective equity method income (or loss) from that investment, remain subject to finalization of fair value estimates for the following based on third-party valuation reports: the Company's non-cash assets contributed to Mozarc, the Company's contingent consideration payable to Medtronic, and valuation of Mozarc's underlying net assets, including its intangible assets, fixed assets, leases and certain working capital items, some of which are pending final quantification for certain post-closing purchase price adjustments.

See Note **9** **8** to the Company's consolidated financial statements included in the **2022** **2023** 10-K for further description of the Company's other equity method investments.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

## 7. Long-term debt

Long-term debt comprised the following:

	As of March 31, 2024			As of March 31, 2024		
	March 31, 2024	March 31, 2024	December 31, 2023	Maturity date	Interest rate	Estimated fair value <sup>(1)</sup>

Senior  
Secured  
Credit  
Facilities:

Term Loan A-1  
Term Loan A-1  
Term Loan A-1  
Term Loan  
B-1  
Revolving  
line of  
credit

Senior  
Notes:

4.625% Senior  
Notes  
4.625% Senior  
Notes  
4.625% Senior  
Notes  
3.75%  
Senior  
Notes

Acquisition  
obligations  
and other  
notes  
payable<sup>(4)</sup>  
Financing  
lease  
obligations<sup>(5)</sup>

Total debt principal  
outstanding

Total debt principal  
outstanding

Total debt principal  
outstanding

Discount, premium  
and deferred  
financing costs<sup>(6)</sup>

Discount, premium  
and deferred  
financing costs<sup>(6)</sup>

Discount, premium  
and deferred  
financing costs<sup>(6)</sup>

	As of September 30, 2023				
	September 30, 2023	December 31, 2022	Maturity date	Interest rate	Estimated fair value <sup>(1)</sup>
Senior Secured Credit Facilities:					
Term Loan A-1 <sup>(2)</sup>	\$1,242,188		(3)	SOFR+CSA+2.00%	\$1,220,449
Term Loan B-1	2,610,643	\$2,660,831	8/12/2026	SOFR+CSA+1.75%	\$2,578,010
New Revolving line of credit <sup>(2)</sup>	—		(3)	SOFR+CSA+2.00%	\$ —
Prior Term Loan A	—	1,498,438	8/12/2024	(4)	\$ —

Prior Revolving line of credit	—	165,000	8/12/2024	(4)	\$	—
Senior Notes:						
4.625% Senior Notes	2,750,000	2,750,000	6/1/2030	4.625	%	\$2,258,438
3.75% Senior Notes	1,500,000	1,500,000	2/15/2031	3.75	%	\$1,143,750
Acquisition obligations and other notes payable <sup>(5)</sup>						
	97,657	120,562	2036	6.89	%	\$97,657
Financing lease obligations <sup>(6)</sup>	250,695	273,688	2039	4.48	%	
Total debt principal outstanding	8,451,183	8,968,519				
Discount, premium and deferred financing costs <sup>(7)</sup>	(57,479)	(44,498)				
	<u>8,393,704</u>	<u>8,924,021</u>				
Less current portion						
Less current portion						
Less current portion	Less current portion	(108,558)	(231,404)			
	<u>\$8,285,146</u>	<u>\$8,692,617</u>				

(1) For the Company's senior secured credit facilities, and senior notes, fair value estimates are based upon bid and ask quotes, typically a level 2 input. For our senior notes, fair value estimates are based on market level 1 inputs. For acquisition obligations and other notes payable, the carrying values presented here approximate their estimated fair values, based on estimates of their present values typically using level 2 interest rate inputs.

(2) The Company's interest rate in its Term Loan A-1 and new revolving line of credit is subject to adjustment depending upon the Company's leverage ratio under the credit agreement governing its senior secured credit facilities. Based on the Company's leverage ratio as of September 30, 2023, the Company's interest rate effective in the fourth quarter of 2023 will be SOFR plus CSA plus 1.75% for its Term Loan A-1 and new revolving line of credit.

(3) Outstanding Term Loan A-1 and new revolving the Revolving line of credit balances are due on April 28, 2028, unless any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the outstanding Term Loan A-1 and the new revolving Revolving line of credit balances become due at that 91 day date (May 13, 2026).

(4) (3) At March 31, 2023, the interest rate on the The Company's then-existing senior secured credit facilities was LIBOR bear interest at Term SOFR, plus a CSA and an interest rate margin, as detailed in effect of 1.75% for the prior table above. The Term Loan A-1 and prior revolving line of credit credit bear a CSA of 0.10%. As of March 31, 2024, the CSA for all tranches outstanding on the Company's Term Loan B-1 was 0.11%.

(5) (4) The interest rate presented for acquisition obligations and other notes payable is their weighted average interest rate based on the current fixed and variable interest rate components in effect as of September 30, 2023 March 31, 2024.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

(6) (5) Financing lease obligations are measured at their approximate present values at inception. The interest rate presented is the weighted average discount rate embedded in financing leases outstanding.

(7) (6) As of September 30, 2023 March 31, 2024, the carrying amount of the Company's senior secured credit facilities have has been reduced by a discount of \$2,724 \$2,251 and deferred financing costs of \$34,688 \$30,358, and the carrying amount of the Company's senior notes have has been reduced by deferred financing costs of \$32,668 \$30,313 and increased by a debt premium of \$12,601 \$11,656. As of December 31, 2022 December 31, 2023, the carrying amount of the Company's senior secured credit facilities were was reduced by a discount of \$3,497 \$2,487 and deferred financing costs of \$18,816 \$32,498, and the carrying amount of the Company's senior notes were was reduced by deferred financing costs of \$36,203 \$31,491 and increased by a debt premium of \$14,018 \$12,129.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**

**(unaudited)**  
(dollars and shares in thousands, except per share data)

Scheduled maturities of long-term debt at September 30, 2023 were as follows:

2023 (remainder of the year)	\$	29,877
2024	\$	110,271
2025	\$	129,871
2026	\$	2,660,604
2027	\$	113,551
2028	\$	1,014,649
Thereafter	\$	4,392,360

On April 3, 2023, the Company entered into the Second Amendment (the Second Amendment) to its senior secured credit agreement (the Credit Agreement). The Second Amendment modifies the Credit Agreement to, among other things, transition the interest pricing on Term Loan B-1 from LIBOR + 1.75% to a forward-looking term rate (Term SOFR) based on the Secured Overnight Financing Rate (SOFR) + 1.75% plus an additional credit spread adjustment (CSA), provided that this adjusted rate shall never be less than 0.00%, as well as to update the successor interest rate provisions in the Credit Agreement with respect to Term Loan B-1. As of September 30, 2023, the CSA for all tranches outstanding on the Company's Term Loan B-1 was 0.11%. The Company adopted Accounting Standards Update (ASU) No. 2020-04 and ASU No. 2022-06 regarding reference rate reform during the second quarter and applied one of their practical expedients to treat the amendment of Term Loan B-1 as a non-substantial modification.

On April 28, 2023, the Company entered into the Third Amendment (the Third Amendment, and together with the Second Amendment, the Amendments) to the Credit Agreement. The Third Amendment modifies the Credit Agreement to, among other things, refinance its Term Loan A and revolving line of credit with a secured Term Loan A-1 facility in the aggregate principal amount of \$1,250,000 and a secured revolving line of credit in the aggregate principal amount of up to \$1,500,000 (the foregoing referred to as the new Term Loan A-1 and new revolving line of credit, respectively).

The new Term Loan A-1 and new revolving line of credit initially bear interest at Term SOFR, plus a CSA of 0.10% and an interest rate margin of 2.00%, which is subject to adjustment depending upon the Company's leverage ratio under the Credit Agreement, as amended, and which can range from 1.25% to 2.25%, provided that this adjusted rate shall never be less than 0.00%. The new Term Loan A-1 requires amortizing quarterly principal payments beginning on September 30, 2023 of \$7,813 per quarter for During the first four payments, \$15,625 per quarter for the fifth through sixteenth payments, \$23,438 per quarter for the seventeenth through nineteenth payments, with the balance due on April 28, 2028. The new revolving line of credit has a five-year term. However, under the Third Amendment, Term Loan A-1 and the new revolving line of credit become due if any of Term Loan B-1 remains outstanding 91 days prior to the Term Loan B-1 maturity date, in which case the Term Loan A-1 balance and any outstanding balance on the new revolving line of credit become due at that 91 day date (May 13, 2026).

Borrowings under the Company's senior secured credit facilities are guaranteed and secured by substantially all of DaVita Inc.'s and certain of the Company's domestic subsidiaries' assets and rank senior to all unsecured indebtedness. Borrowings under the new Term Loan A-1, Term Loan B-1 and new revolving line of credit rank equal in priority for that security and related subsidiary guarantees under the facility's terms. The Credit Agreement, as amended, contains certain customary affirmative and negative covenants such as various restrictions or limitations on permitted amounts of investments (including acquisitions), share repurchases, payment of dividends, and redemptions and incurrence of other indebtedness. Many of these restrictions and limitations will not apply as long as the Company's leverage ratio calculated in accordance with the Amendments is below 4.00:1.00. In addition, the Amendments require compliance with a maximum leverage ratio covenant, tested quarterly, of 5.00:1.00 through June 30, 2026 and 4.50:1.00 thereafter.

In the second quarter of 2023, the Company used a portion of the proceeds from the new Term Loan A-1 and initial borrowing of \$400,000 on the new revolving line of credit to pay off the remaining principal balance outstanding and accrued interest and fees on its prior Term Loan A and prior revolving line of credit in the amount of \$1,602,199. The remaining borrowings added cash to the balance sheet for general corporate purposes.

In addition to the prepayments described above, during the first nine three months of 2023, 2024, the Company made regularly scheduled and other principal payments under its senior secured credit facilities totaling \$54,011 on its prior Term Loan A, \$7,813 \$7,812 on Term Loan A-1 and \$50,188 \$6,858 on Term Loan B-1.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

As a result of the transactions described above, the Company recognized debt extinguishment and modification costs of \$7,962 in the second quarter of 2023 composed partially of deferred financing costs written off for the portion of debt considered extinguished and reborrowed as a result of the repayment of all principal balances outstanding on the Company's prior Term Loan A and prior revolving line of credit and partially of fees incurred for this transaction. For the portion of the debt that was considered extinguished and reborrowed, the Company recognized constructive financing cash outflows and financing cash inflows on the statement of cash flows of \$434,393 and \$150,000 for the Term Loan A and prior revolving line of credit, respectively, even though no funds were actually paid or received. Another \$715,019 of the debt considered extinguished in this refinancing represented a non-cash financing activity.

After September 30, 2023 March 31, 2024, the Company's 2019 interest rate cap agreements described below have the economic effect of capping the Company's maximum exposure to SOFR variable interest rate changes on equivalent amounts of the Company's floating rate debt, including all of Term Loan B-1 and a portion of new Term Loan A-1. The remaining \$352,831 \$323,491 outstanding principal balance of new Term Loan A-1 is and \$765,000 balance outstanding on the revolving line of credit are subject to SOFR-based interest rate volatility. These cap agreements are designated as cash flow hedges and, as a result, changes in their fair values are reported in other comprehensive income. The original premiums paid for the caps are amortized to debt expense on a straight-line basis over the term of each cap agreement starting from its effective date. These cap agreements do not contain credit risk-contingent features.

In the second and third quarters of 2023 the Company entered into several forward interest rate cap agreements, described below, that have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt (2023 cap agreements). These 2023 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income. These 2023 cap agreements, do not contain credit-risk contingent features, and become effective and expire as described in the table below. Certain of these 2023 cap agreements have notional amounts that amortize downward over time.

On October 18, 2023, the Company entered into several forward interest rate cap agreements with an aggregate notional amount of \$500,000 that become effective on June 28, 2024 and expire on December 31, 2026, and a forward interest rate cap agreement with an aggregate notional amount of \$250,000 that becomes effective on December 31, 2024 and expires on December 31, 2025 (together, the October 2023 cap agreements). These October 2023 cap agreements have the economic effect of capping the Company's exposure to SOFR variable interest rate changes on specific portions of the Company's floating rate debt and do not contain credit-risk contingent features. Additionally, the October 2023 cap agreements are designated as cash flow hedges and, as a result, changes in their fair values will be reported in other comprehensive income.

Finally, during and as of the end of the second quarter, the Company transitioned the variable rate base on its senior secured credit facilities and related hedging interest rate caps from LIBOR to SOFR. This transition involved a SOFR-to-LIBOR rate mismatch between this debt and the 2019 interest rate caps for a portion of the second quarter, but the Company's interest rate hedges remained highly effective throughout the transition and thereafter.

This transition was accomplished through the Amendments to the Credit Agreement for the Company's senior secured credit facility debt and, for the Company's 2019 interest rate caps outstanding, through the International Swaps and Derivatives Association (ISDA)'s Interbank Offered Rate (IBOR)Fallbacks Supplement and IBOR Fallbacks Protocol which were established in anticipation of the cessation of LIBOR. That ISDA protocol incorporated fallbacks for derivatives linked to LIBOR which facilitated their transition to a replacement reference rate. The Company has adhered to this ISDA protocol and as of June 30, 2023 has transitioned all of its LIBOR-based derivative exposure to SOFR.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

The following table summarizes the Company's interest rate cap agreements outstanding as of **September 30, 2023** and **December 31, 2022**, which are classified in other long-term assets on its consolidated balance sheet: **March 31, 2024**:

	Notional amount	SOFR rate maximum	Effective date	Expiration date	Nine months ended		Fair value	
					September 30, 2023		September 30, 2023	2023
					Debt expense (offset)	Recorded OCI gain		
2019 cap agreements	\$ 3,500,000	2.00%	6/30/2020	6/30/2024	\$ (74,475)	\$ 28,901	\$ 90,048	\$ 139,755
2023 cap agreements	\$ 200,000	3.75%	6/28/2024	12/31/2025		\$ 1,047	\$ 2,238	
2023 cap agreements	\$ 1,000,000	4.00% <sup>(1)</sup>	6/28/2024	12/31/2025		\$ 3,142	\$ 12,379	
2023 cap agreements	\$ 1,000,000	4.75% <sup>(2)</sup>	6/28/2024	12/31/2025		\$ 751	\$ 9,056	
2023 cap agreements	\$ 800,000	3.75%	6/30/2024	12/31/2025		\$ 3,871	\$ 8,836	

Year cap agreements executed	Notional amount	SOFR maximum rate	Approximate effective date	Notional reduction or contractual maturity date		
				At December 31 unless noted		
2019	\$ 3,500,000	2.00%	6/30/2020	\$ 3,500,000		
2023	\$ 1,000,000	3.75%	6/30/2024	\$ 500,000	\$ 500,000	
2023	\$ 1,000,000	4.00% <sup>(2)</sup>	6/30/2024	\$ 250,000	\$ 750,000	
2023	\$ 1,000,000	4.75% <sup>(3)</sup>	6/30/2024	\$ 250,000	\$ 750,000	
2023	\$ 500,000	5.00% <sup>(4)</sup>	6/30/2024		\$ 500,000	
2023	\$ 250,000	4.50%	12/31/2024		\$ 250,000	
2023	\$ 750,000	4.00%	12/31/2024		\$ 250,000	\$ 500,000

(1) The Company's 2019 cap agreements mature on June 30, 2024.

(2) Effective January 1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.

(2) (3) Effective January 1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.

(4) Effective January 1, 2025, the maximum rate of 5.00% decreases to 4.50% for these interest rate caps.

The fair value of the Company's interest rate cap agreements, which are classified in other long-term assets on its consolidated balance sheet, was \$67,356 and \$79,805 as of March 31, 2024 and December 31, 2023, respectively.

See Note 10 for further details on amounts reclassified from accumulated other comprehensive loss and recorded as debt expense (offset) related to the Company's interest rate cap agreements for the three and nine months ended **September 30, 2023** **March 31, 2024** and **2022, 2023**.

As a result of the variable rate cap from the Company's 2019 interest rate cap agreements, the Company's weighted average effective interest rate on its senior secured credit facilities at the end of the **third** **first** quarter of **2023** **2024** was **4.70%** **4.88%**, based on the current margins in effect for its senior secured credit facilities as of **September 30, 2023** **March 31, 2024**, as detailed in the table above.

The Company's weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, for the three and nine months ended **September 30, 2023** **March 31, 2024** was **4.61%** **4.51%** and as of **September 30, 2023** **March 31, 2024** was **4.56%** **4.69%**.

As of **September 30, 2023** **March 31, 2024**, the Company's interest rates were fixed and economically fixed on approximately **54%** **50%** and **95%** **88%** of its total debt, respectively.

As of **September 30, 2023** **March 31, 2024**, the Company had **an undrawn** \$735,000 available and \$765,000 drawn on its \$1,500,000 revolving line of credit under its senior secured credit facilities of \$1,500,000. Credit available under this revolving line of credit is reduced by the amount of

**DAVITA INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**

**(unaudited)**

(dollars and shares in thousands, except per share data)

any letters of credit outstanding under the facility, of which there were none as of **September 30, 2023** **March 31, 2024**. The Company also had letters of credit of approximately **\$151,387** **\$154,373** outstanding under a separate bilateral secured letter of credit facility as of **September 30, 2023** **March 31, 2024**.

**8. Commitments and contingencies**

The majority of the Company's revenues are from government programs and may be subject to adjustment as a result of: (i) examination by government agencies or contractors, for which the resolution of any matters raised may take extended periods of time to finalize; (ii) differing interpretations of government regulations by different Medicare contractors or regulatory authorities; (iii) differing opinions regarding a patient's medical diagnosis or the medical necessity of services provided; and (iv) retroactive applications or interpretations of governmental requirements. In addition, the Company's revenues from commercial payors may be subject to adjustment as a result of potential claims for refunds, as a result of government actions or as a result of other claims by commercial payors.

The Company operates in a highly regulated industry and is a party to various lawsuits, demands, claims, *qui tam* suits, governmental investigations (which frequently arise from *qui tam* suits) and audits (including, without limitation, investigations or other actions resulting from its obligation to self-report suspected violations of law) and other legal proceedings, including, without limitation, those described below. The Company records accruals for certain legal proceedings and regulatory matters to the extent that the Company determines an unfavorable outcome is probable and the amount of the loss can be reasonably estimated. As of **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023**, the Company's total recorded accruals with respect to legal proceedings and regulatory matters, net of anticipated third party recoveries, were immaterial. While these accruals reflect the Company's best estimate of the probable loss for those matters as of the dates of those accruals, the recorded amounts may differ materially from the actual amount of the losses for those matters, and any anticipated third party recoveries for any such losses may not ultimately be recoverable. Additionally, in some cases, no estimate of the possible loss or range of loss in excess

**DAVITA INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**

**(unaudited)**

(dollars and shares in thousands, except per share data)

of amounts accrued, if any, can be made because of the inherently unpredictable nature of legal proceedings and regulatory matters, which also may be impacted by various factors, including, without limitation, that they may involve indeterminate claims for monetary damages or may involve fines, penalties or non-monetary remedies; present novel legal theories or legal uncertainties; involve disputed facts; represent a shift in regulatory policy; are in the early stages of the proceedings; or may result in a change of business practices. Further, there may be various levels of judicial review available to the Company in connection with any such proceeding.

The following is a description of certain lawsuits, claims, governmental investigations and audits and other legal proceedings to which the Company is subject.

**Certain Governmental Inquiries and Related Proceedings**

**2017 U.S. Attorney Colorado Investigation:** In November 2017, the U.S. Attorney's Office, District of Colorado informed the Company of an investigation it was conducting into possible federal healthcare offenses involving DaVita Kidney Care, as well as several of the Company's wholly-owned subsidiaries. In addition to DaVita Kidney Care, the matter currently includes an investigation into DaVita Rx, DaVita Laboratory Services, Inc. (DaVita Labs), and RMS Lifeline Inc. (Lifeline). In each of August 2018, May 2019, and July 2021, the Company received a **CID Civil Investigative Demand (CID)** pursuant to the FCA from the U.S. Attorney's Office relating to this investigation. In May 2020, the Company sold its interest in Lifeline, but the Company retained certain liabilities of the Lifeline business, including those related to this investigation. The Company is **continuing to cooperate** **engaged in discussions with the government in U.S. Attorney's Office and the Civil Division of the United States Department of Justice to resolve this investigation.** matter. The Company can make no assurance as to the final outcome. The Company has reserved \$40,000 for this matter, which includes any potential payment of attorneys' fees.

**2020 U.S. Attorney New Jersey Investigation:** In March 2020, the U.S. Attorney's Office, District of New Jersey served the Company with a subpoena and a CID relating to an investigation being conducted by that office and the U.S. Attorney's Office, Eastern District of Pennsylvania. The subpoena and CID request information on several topics, including certain of the Company's joint venture arrangements with physicians and physician groups, medical director agreements, and compliance with its five-year Corporate Integrity

Agreement, the term of which expired October 22, 2019. In November 2022, the Company learned that, on April 1, 2022, the U.S. Attorney's Office for the District of New Jersey notified the U.S. District Court for the District of New Jersey of its decision not to elect to intervene in the matter of *U.S. ex rel. Doe v. DaVita Inc.* and filed a Stipulation of Dismissal. On April 13, 2022, the U.S. District Court for the District of New Jersey dismissed the case without prejudice. On October 12, 2022, the U.S. Attorney's Office for the Eastern District of Pennsylvania notified the U.S.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

District Court, Eastern District of Pennsylvania, of its decision not to elect to intervene at this time in the matter of *U.S. ex rel. Bayne v. DaVita Inc., et al.* The court then unsealed an amended complaint, which alleges violations of federal and state False Claims Acts, by order dated October 14, 2022. In May 2023, On November 8, 2023, the private party relator served the Company with filed a second fourth amended complaint. On July 14, 2023 November 29, 2023, the Company filed a motion to dismiss the second amended complaint. On August 4, 2023, the private party relator filed a third amended complaint. On October 18, 2023, the Company filed a motion to dismiss the third fourth amended complaint.

2020 California Department of Insurance Investigation: In April 2020, the California Department of Insurance (CDI) sent the Company an Investigative Subpoena relating to an investigation being conducted by that office. CDI issued a superseding subpoena in September 2020 and an additional subpoena in September 2021. Those subpoenas request information on a number of topics, including but not limited to the Company's communications with patients about insurance plans and financial assistance from the American Kidney Fund (AKF), analyses of the potential impact of patients' decisions to change insurance providers, and documents relating to donations or contributions to the AKF. The Company is continuing to cooperate with CDI in this investigation.

2023 District of Columbia Office of Attorney General Investigation: In January 2023, the Office of the Attorney General for the District of Columbia issued a CID to the Company in connection with an antitrust investigation into the AKF. The CID covers the period from January 1, 2016 to the present. The CID requests information on a number of topics, including but not limited to the Company's communications with AKF, documents relating to donations to the AKF, and communications with patients, providers, and insurers regarding the AKF. The Company is cooperating with the government in this investigation.

2024 Federal Trade Commission Investigation: In April 2024, the Company received from the Federal Trade Commission (FTC) two CIDs in connection with an industry investigation under Section 5 of the Federal Trade Commission Act regarding the acquisition of Medical Director services and provision of dialysis services. The CIDs cover the period from January 1, 2016 to the present and generally seek information relating to restrictive covenants, such as non-competes, with physicians. The Company is cooperating with the government in this investigation.

\* \* \*

Although the Company cannot predict whether or when proceedings might be initiated or when these matters may be resolved (other than as may be described above), it is not unusual for inquiries such as these to continue for a considerable period of time through the various phases of document and witness requests and ongoing discussions with regulators and to

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

develop over the course of time. In addition to the inquiries and proceedings specifically identified above, the Company frequently is subject to other inquiries by state or federal government agencies, many of which relate to *qui tam* complaints filed by relators. Negative findings or terms and conditions that the Company might agree to accept as part of a negotiated resolution of pending or future government inquiries or relator proceedings could result in, among other things, substantial financial penalties or awards against the Company, substantial payments made by the Company, harm to the Company's reputation, required changes to the Company's business practices, an impact on the Company's various relationships and/or contracts related to the Company's business, exclusion from future participation in the Medicare, Medicaid and other federal health care programs and, if criminal proceedings were initiated against the Company, members of its board of directors or management, possible criminal penalties, any of which could have a material adverse effect on the Company.

**Other Proceedings**

2021 Antitrust Indictment and Putative Class Action Suit: On July 14, 2021, an indictment was returned by a grand jury in the U.S. District Court, District of Colorado against the Company and its former chief executive officer in the matter of *U.S. v. DaVita Inc., et al.* alleging that purported agreements entered into by DaVita's former chief executive officer not to solicit senior-level employees violated Section 1 of the Sherman Act. On April 15, 2022, a jury returned a verdict in the Company's favor, acquitting both the Company and its former chief executive officer on all counts. On April 20, 2022, the court entered judgments of acquittal and closed the case. On August 9, 2021, DaVita Inc. and its former chief executive officer were added as defendants in a consolidated putative class action complaint in the matter of *In re Outpatient Medical Center Employee Antitrust Litigation* in the U.S. District Court, Northern District of Illinois. This class action complaint asserts that the defendants violated Section 1 of the Sherman Act and seeks to bring an action on behalf of certain groups of individuals employed by the Company between February 1, 2012 and January 5, 2021. On September 26, 2022, the court denied the

**DAVITA INC.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

Company's motion to dismiss. The Company disputes the allegations in the class action complaint, as well as the asserted violations of the Sherman Act, and intends to defend this action accordingly.

Additionally, from time to time the Company is subject to other lawsuits, demands, claims, governmental investigations and audits and legal proceedings that arise due to the nature of its business, including, without limitation, contractual disputes, such as with payors, suppliers and others, employee-related matters and professional and general liability claims. From time to time, the Company also initiates litigation or other legal proceedings as a plaintiff arising out of contracts or other matters.

\* \* \*

Other than as may be described above, the Company cannot predict the ultimate outcomes of the various legal proceedings and regulatory matters to which the Company is or may be subject from time to time, including those described in this Note 8, or the timing of their resolution or the ultimate losses or impact of developments in those matters, which could have a material adverse effect on the Company's revenues, earnings and cash flows. Further, any legal proceedings or regulatory matters involving the Company, whether meritorious or not, are time consuming, and often require management's attention and result in significant legal expense, and may result in the diversion of significant operational resources, may impact the Company's various relationships and/or contracts related to the Company's business or otherwise harm the Company's business, results of operations, financial condition, cash flows or reputation.

**Resolved Matters**

**2016 U.S. Attorney Texas Investigation:** In February 2016, DaVita Rx, LLC (DaVita Rx), a wholly-owned subsidiary of the Company, received a Civil Investigative Demand (CID) from the U.S. Attorney's Office, Northern District of Texas. The government conducted a federal False Claims Act (FCA) investigation concerning allegations that DaVita Rx presented or caused to be presented false claims for payment to the government for prescription medications, as well as an investigation into the Company's relationships with pharmaceutical manufacturers. After its investigation, the government and the named states declined to intervene in the matter, and on April 5, 2023, the U.S. District Court, Northern District of Texas, entered an order unsealing the complaint in the matter of *U.S. ex rel. Grenon v. DaVita Rx, LLC et al.* The complaint was not served on the Company. On May 31, 2023, the private party relator filed a notice of voluntary dismissal of all claims. On June 1, 2023, the U.S. District Court for the Northern District of Texas dismissed the matter without prejudice.

\* \* \*

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

**Other Commitments**

The Company also has certain potential commitments to provide working capital funding, if necessary, to certain nonconsolidated dialysis businesses that the Company manages and in which the Company owns a noncontrolling equity interest or which are wholly-owned by third parties of approximately \$9,279, \$8,423.

**9. Shareholders' equity**

*Stock-based compensation*

During the **nine** **three** months ended **September 30, 2023** **March 31, 2024**, the Company granted **1,343,696** stock-settled restricted and performance stock units with an aggregate grant-date fair value of **\$103,599** **\$96,222** and a weighted average expected life of approximately 3.4 years.

As of **September 30, 2023** **March 31, 2024**, the Company had **\$149,839** **\$189,601** in total estimated but unrecognized stock-based compensation expense under the Company's equity compensation and employee stock purchase plans. The Company expects to recognize this expense over a weighted average remaining period of **1.4** **1.5** years.

*Share repurchases*

The following table summarizes the Company's common stock repurchases during the three months ended March 31, 2024:

	Three months ended March 31, 2024		
	Shares repurchased	Amount paid <sup>(1)</sup>	Average price paid per share <sup>(2)</sup>
Open market repurchases:	2,119	\$ 240,117	\$ 112.76

(1) Includes commissions and the 1% excise tax imposed on certain stock repurchases made after December 31, 2022 by the Inflation Reduction Act of 2022. The excise tax is recorded as part of the cost basis of treasury stock repurchased and, as such, is included in stockholders' equity.

(2) Excludes commissions and the excise tax described above.

The Company **has** **not** **repurchased** **repurchase** any shares during the three months ended March 31, 2023. Furthermore, the Company **did** **not** **repurchase** any shares subsequent to **December 31, 2022** **March 31, 2024** through May 2, 2024.

**10. Accumulated other comprehensive loss**

	Three months ended September 30, 2023			Nine months ended September 30, 2023		
	Interest	Foreign currency	Accumulated other comprehensive loss	Interest	Foreign currency	Accumulated other comprehensive loss
	rate cap agreements	translation adjustments	comprehensive loss	rate cap agreements	translation adjustments	comprehensive loss
Beginning balance	\$ 85,297	\$ (92,349)	\$ (7,052)	\$ 98,685	\$ (167,871)	\$ (69,186)
Unrealized gains (losses)	9,319	(47,644)	(38,325)	37,712	27,878	65,590
Related income tax	(2,323)	—	(2,323)	(9,407)	—	(9,407)
	6,996	(47,644)	(40,648)	28,305	27,878	56,183
Reclassification into net income	(28,244)	—	(28,244)	(74,475)	—	(74,475)
Related income tax	7,046	—	7,046	18,580	—	18,580
	(21,198)	—	(21,198)	(55,895)	—	(55,895)
Ending balance	\$ 71,095	\$ (139,993)	\$ (68,898)	\$ 71,095	\$ (139,993)	\$ (68,898)

	Three months ended September 30, 2022			Nine months ended September 30, 2022		
	Interest	Foreign currency	Accumulated other	Interest	Foreign currency	Accumulated other
	rate cap agreements	translation adjustments	comprehensive loss	rate cap agreements	translation adjustments	comprehensive loss
Beginning balance	\$ 55,237	\$ (167,033)	\$ (111,796)	\$ (1,178)	\$ (138,069)	\$ (139,247)
Unrealized gains (losses)	55,045	(66,100)	(11,055)	127,460	(95,064)	32,396
Related income tax	(13,733)	—	(13,733)	(31,800)	—	(31,800)
	41,312	(66,100)	(24,788)	95,660	(95,064)	596
Reclassification into net income	1,377	—	1,377	4,132	—	4,132
Related income tax	(344)	—	(344)	(1,032)	—	(1,032)
	1,033	—	1,033	3,100	—	3,100
Ending balance	\$ 97,582	\$ (233,133)	\$ (135,551)	\$ 97,582	\$ (233,133)	\$ (135,551)

The interest rate cap agreement net realized losses reclassified into net income are recorded as debt expense. As of December 31, 2023, the Company is authorized to make share repurchases pursuant to a December 17, 2021 Board authorized repurchase plan of \$2,000,000. This authorization allows the Company to make purchases from time to time in the corresponding consolidated statements of income. See Note 7 for further details.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

open market or in privately negotiated transactions, including without limitation, through accelerated share repurchase transactions, derivative transactions, tender offers, Rule 10b5-1 plans or any combination of the foregoing, depending upon market conditions and other considerations.

As of May 2, 2024, the Company has a total of \$1,072,904, excluding excise taxes, available under the current authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, the Company remains subject to share repurchase limitations, including under the terms of its senior secured credit facilities.

**10. Accumulated other comprehensive loss**

	Three months ended March 31, 2024			Three months ended March 31, 2023		
	Interest	Foreign currency	Accumulated other	Interest	Foreign currency	Accumulated other
	rate cap agreements	translation adjustments	comprehensive loss	rate cap agreements	translation adjustments	comprehensive loss
Beginning balance	\$ 27,853	\$ (79,937)	\$ (52,084)	\$ 98,685	\$ (167,871)	\$ (69,186)
Unrealized gains (losses)	17,745	(39,720)	(21,975)	(4,716)	33,561	28,845
Related income tax	(4,428)	—	(4,428)	1,177	—	1,177
	13,317	(39,720)	(26,403)	(3,539)	33,561	30,022
Reclassification into net income	(28,818)	—	(28,818)	(20,975)	—	(20,975)

Related income tax	7,190	—	7,190	5,233	—	5,233
	(21,628)	—	(21,628)	(15,742)	—	(15,742)
Ending balance	\$ 19,542	\$ (119,657)	\$ (100,115)	\$ 79,404	\$ (134,310)	\$ (54,906)

The interest rate cap agreement net realized gains reclassified into net income are recorded as debt expense in the corresponding consolidated statements of income. See Note 7 for further details.

## 11. Acquisitions and divestitures

During three months ended March 31, 2024 the Company acquired dialysis businesses, as follows:

	Three months ended
	March 31, 2024
Cash paid, net of cash acquired	\$ 105,163
Liabilities assumed	\$ 357
Fair value of previously held equity method investments	\$ 67,526
Number of dialysis centers acquired — U.S.	9
Number of dialysis centers acquired — International	67

In these transactions, the Company acquired a controlling interest in a previously nonconsolidated U.S. dialysis partnership for which it recognized a non-cash gain of \$35,147 on our prior investment upon consolidation. The Company estimated the fair value of its previously held equity interests using appraisals developed with independent third party valuation firms.

The assets and liabilities for these acquisitions were recorded at their estimated fair values at the dates of the acquisitions and are included in the Company's consolidated financial statements, as are their operating results, from the designated effective dates of the acquisitions.

The initial purchase price allocations for these acquisitions have been recorded at estimated fair values based on information that was available to management and will be finalized when certain information arranged to be obtained is received. In particular, certain income tax amounts are pending final evaluation and quantification of any pre-acquisition tax contingencies. In addition, valuation of intangibles, contingent earn-outs, leases, and certain other working capital items relating to these acquisitions are pending final quantification.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

The following table summarizes the assets acquired and liabilities assumed in these transactions and recognized at their acquisition dates at estimated fair values, as well as the estimated fair value of noncontrolling interests assumed in these transactions:

	Three months ended
	March 31, 2024
Current assets	\$ 33,732
Property and equipment	32,274
Right-of-use lease assets and other long-term assets	29,703
Indefinite-lived licenses	3,329
Goodwill	137,290
Liabilities assumed	(43,024)
Noncontrolling interests assumed	(20,258)
	<hr/>
	\$ 173,046

The amount of goodwill related to these acquisitions recognized or adjusted during the three months ended March 31, 2024 that is deductible for tax purposes was \$59,521.

## 12. Variable interest entities (VIEs)

At September 30, 2023 March 31, 2024, these condensed consolidated financial statements include total assets of VIEs of \$284,761 \$293,733 and total liabilities and noncontrolling interests of VIEs to third parties of \$160,526 \$139,024. There have been no material changes in the nature of the Company's arrangements with VIEs or its judgments concerning them from those described in Note 23 22 to the Company's consolidated financial statements included in the 2022 2023 10-K.

## 12.13. Fair values of financial instruments

The Company measures the fair value of certain assets, liabilities and noncontrolling interests subject to put provisions (redeemable equity interests classified as temporary equity) based upon certain valuation techniques that include observable or unobservable inputs and assumptions that market participants would use in pricing these assets.

liabilities, temporary equity and commitments. The Company has also classified assets, liabilities and temporary equities that are measured at fair value on a recurring basis into the appropriate fair value hierarchy levels as defined by the Financial Accounting Standards Board (FASB).

The following table summarizes the Company's assets, liabilities and temporary equities measured at fair value on a recurring basis as of **September 30, 2023** **March 31, 2024**:

	Quoted prices in active markets for identical assets				Significant other observable inputs	Significant unobservable inputs
	Total	(Level 1)		(Level 2)	(Level 3)	
<b>Assets</b>						
Investments in equity securities	\$ 36,603	\$ 36,603		—	\$ —	—
Interest rate cap agreements	\$ 122,557	\$ —		\$ 122,557	\$ —	—
<b>Liabilities</b>						
Contingent earn-out obligations for acquisitions	\$ 19,377	\$ —		—	\$ —	19,377
<b>Temporary equity</b>						
Noncontrolling interests subject to put provisions	\$ 1,445,403	\$ —		—	\$ —	1,445,403

For a reconciliation of changes in noncontrolling interests subject to put provisions during the three and nine months ended September 30, 2023, see the consolidated statement of equity.

	Quoted prices in active markets for identical assets				Significant other observable inputs	Significant unobservable inputs
	Total	(Level 1)		(Level 2)	(Level 3)	
<b>Assets</b>						
Investments in equity securities	\$ 36,326	\$ 36,326				
Interest rate cap agreements	\$ 67,356			\$ 67,356		
<b>Liabilities</b>						
Contingent earn-out obligations for acquisitions	\$ 20,951				\$ 20,951	
<b>Temporary equity</b>						
Noncontrolling interests subject to put provisions	\$ 1,503,474				\$ 1,503,474	

Investments in equity securities represent investments in various open-ended registered investment companies (mutual funds) and common stocks and are recorded at fair value estimated based on reported market prices or redemption prices, as applicable. See Note 4 for further discussion.

Interest rate cap agreements are recorded at fair value estimated from valuation models utilizing the income approach and commonly accepted valuation techniques that use inputs from closing prices for similar assets and liabilities in active markets as well as other relevant observable market inputs at quoted intervals such as current interest rates, forward yield

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

curves, implied volatility and credit default swap pricing. The Company does not believe the ultimate amount that could be realized upon settlement of these interest rate cap agreements would be materially different from the fair value estimates currently reported. See Note 7 for further discussion.

As of **September 30, 2023** **March 31, 2024**, the Company had contingent earn-out obligations associated with business acquisitions that could result in the Company paying the former owners a total of up to approximately ~~\$54,387~~ **\$63,862** if certain performance targets or quality margins are met over the next one year to ~~five~~ **four** years. The estimated fair value measurements of these contingent earn-out obligations are primarily based on unobservable inputs, including key financial metrics such as projected earnings before interest, taxes, depreciation, and amortization (EBITDA), revenue and other key performance indicators. The estimated fair values of these contingent earn-out obligations are remeasured as of each reporting date and could fluctuate based upon any significant changes in key assumptions, such as changes in the Company's credit risk adjusted rate that is used to discount obligations to present value.

The estimated fair value of noncontrolling interests subject to put provisions is based principally on the higher of either estimated liquidation value of net assets or a multiple of earnings for each subject dialysis partnership, based on historical earnings, revenue mix, and other performance indicators that can affect future results. The multiples used for these valuations are derived from observed ownership transactions for dialysis businesses between unrelated parties in the U.S. in recent years.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

and the specific valuation multiple applied to each dialysis partnership is principally determined by its recent and expected revenue mix and contribution margin. As of **September 30, 2023** **March 31, 2024**, an increase or decrease in the weighted average multiple used in these valuations of one times EBITDA would change the estimated fair value of these noncontrolling interests by approximately **\$185,000**, **\$195,000**. See Notes **17** **16** and **24** **23** to the Company's consolidated financial statements included in the **2022** **2023** 10-K for further discussion of the Company's methodology for estimating the fair value of noncontrolling interests subject to put obligations. For a reconciliation of changes in noncontrolling interests subject to put provisions during the three months ended March 31, 2024, see the consolidated statement of equity.

The Company's fair value estimates for its senior secured credit facilities and senior notes are based upon quoted bid and ask prices for these instruments, typically a level 2 input. See Note 7 for further discussion of the Company's debt.

The book value of the Company's contingent consideration payable to Medtronic, Inc. for its interest in Mozarc Medical Holdings LLC approximates its estimated fair value, which is based on level 3 inputs.

Other financial instruments consist primarily of cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable, other accrued liabilities, lease liabilities and debt. The balances of financial instruments other than debt and lease liabilities are presented in these condensed consolidated financial statements at **September 30, 2023** **March 31, 2024** at their approximate fair values due to the short-term nature of their settlements.

#### **13.14. Segment reporting**

The Company's operating divisions **comprises** are composed of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. **IKC** **integrated kidney care** business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.

The Company's separate operating segments include its U.S. dialysis and related lab services business, its U.S. **IKC** **integrated kidney care** business, its U.S. other ancillary services, its **kidney care** operations in each foreign sovereign jurisdiction, and its equity method **investments** **investment** in each of the Asia Pacific joint venture (APAC JV) and **Mozarc**. The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category. See Note **25** **24** to the Company's consolidated financial statements included in the **2022** **2023** 10-K for further description of how the Company determines and measures results for its operating segments.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

The following is a summary of segment revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

		Three months ended March 31,		Nine months ended September 30,			
				2023	2022	2023	2022
<b>Segment revenues:</b>	<b>Segment revenues:</b>						
Segment revenues:							
Segment revenues:							
U.S. dialysis							
U.S. dialysis							
U.S. dialysis	<b>U.S. dialysis</b>						
Dialysis patient service revenues:	Dialysis patient service revenues:						
Dialysis patient service revenues:							
Dialysis patient service revenues:							
External sources	External sources	\$ 2,754,778	\$ 2,674,240	\$ 8,042,561	\$ 7,858,939		
External sources							
External sources							
Intersegment revenues							
Intersegment revenues							
Intersegment revenues	Intersegment revenues	24,289	22,957	66,698	64,526		
U.S. dialysis patient service revenues	U.S. dialysis patient service revenues	2,779,067	2,697,197	8,109,259	7,923,465		

U.S. dialysis patient service revenues					
U.S. dialysis patient service revenues					
Other revenues:					
Other revenues:					
Other revenues:	External sources	6,239	6,056	18,822	18,134
External sources					
External sources					
Intersegment revenues					
Intersegment revenues					
Intersegment revenues	Intersegment revenues	—	—	—	(10)
Total U.S. dialysis revenues	Total U.S. dialysis revenues	2,785,306	2,703,253	8,128,081	7,941,589
Total U.S. dialysis revenues					
Total U.S. dialysis revenues					
<b>Other—Ancillary services</b>					
<b>Other—Ancillary services</b>					
Other—Ancillary services	Other—Ancillary services				
Dialysis patient service revenues	Dialysis patient service revenues	197,172	172,254	560,108	513,935
Dialysis patient service revenues					
Dialysis patient service revenues					
Other external sources					
Other external sources					
Other external sources	Other external sources	163,143	96,144	372,909	301,998
Intersegment revenues	Intersegment revenues	2,232	—	5,007	—
Intersegment revenues					
Intersegment revenues					
Total ancillary services revenues					
Total ancillary services revenues					
Total ancillary services revenues	Total ancillary services revenues	362,547	268,398	938,024	815,933
Total net segment revenues	Total net segment revenues	3,147,853	2,971,651	9,066,105	8,757,522
Total net segment revenues					
Total net segment revenues					
Elimination of intersegment revenues					
Elimination of intersegment revenues					
Elimination of intersegment revenues	Elimination of intersegment revenues	(26,521)	(22,957)	(71,705)	(64,516)
Consolidated revenues	Consolidated revenues	\$ 3,121,332	\$ 2,948,694	\$ 8,994,400	\$ 8,693,006
Consolidated revenues					
Consolidated revenues					
<b>Segment operating margin (loss):</b>					
<b>Segment operating margin (loss):</b>					
Segment operating margin (loss):	Segment operating margin (loss):				
U.S. dialysis	U.S. dialysis	\$ 509,135	\$ 351,474	\$ 1,330,992	\$ 1,230,715
U.S. dialysis					
U.S. dialysis					
Other—Ancillary services					

<b>Other—Ancillary services</b>					
Other—Ancillary services	Other—Ancillary services	28,098	(15,271)	(18,372)	(56,689)
Total segment operating margin	Total segment operating margin	537,233	336,203	1,312,620	1,174,026
Total segment operating margin	Total segment operating margin				
<b>Reconciliation of segment operating income to consolidated income before income taxes:</b>	<b>Reconciliation of segment operating income to consolidated income before income taxes:</b>				
Corporate administrative support	Corporate administrative support	(41,294)	(24,417)	(99,745)	(91,217)
Corporate administrative support	Corporate administrative support				
Consolidated operating income	Consolidated operating income				
Consolidated operating income	Consolidated operating income	495,939	311,787	1,212,875	1,082,810
Debt expense	Debt expense	(98,080)	(99,680)	(302,361)	(256,057)
Debt extinguishment and modification costs	Debt extinguishment and modification costs	—	—	(7,962)	—
Other loss, net	Other loss, net	(19,650)	(4,898)	(14,525)	(7,968)
Debt expense	Debt expense				
Other (loss) income, net	Other (loss) income, net				
Other (loss) income, net	Other (loss) income, net				
Consolidated income before income taxes	Consolidated income before income taxes	\$ 378,209	\$ 207,209	\$ 888,027	\$ 818,785
Consolidated income before income taxes	Consolidated income before income taxes				

Depreciation and amortization expense by reportable segment was as follows:

			Three months ended March 31,		
			Three months ended March 31,		
			Three months ended March 31,		
			Three months ended September 30,		Nine months ended September 30,
			2023	2022	2023
U.S. dialysis	U.S. dialysis	\$ 175,908	\$ 184,688	\$ 514,710	\$ 507,320
U.S. dialysis	U.S. dialysis				
U.S. dialysis	U.S. dialysis				
Other—Ancillary services	Other—Ancillary services				
Other—Ancillary services	Other—Ancillary services				
Other—Ancillary services	Other—Ancillary services	12,515	9,726	35,456	31,214
Other—Ancillary services	Other—Ancillary services	\$ 188,423	\$ 194,414	\$ 550,166	\$ 538,534

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**  
(dollars and shares in thousands, except per share data)

Expenditures for property and equipment by reportable segment were as follows:

		Nine months ended September 30,		Three months ended March 31,		Three months ended March 31,		Three months ended March 31,			
U.S. dialysis	U.S. dialysis	\$	363,895	\$	363,046					2024	
Other—Ancillary services	Other—Ancillary services		45,116		46,345						2023
		\$	409,011	\$	409,391						

A summary of assets by reportable segment were as follows:

	September 30, 2023	December 31, 2022
U.S. dialysis	\$ 14,574,707	\$ 15,084,454
Other—Ancillary services	2,354,033	1,843,798
Consolidated assets	\$ 16,928,740	\$ 16,928,252

#### 14.15. New accounting standards

New standards *recently not yet adopted*

In March 2020, the FASB issued Accounting Standards Update (ASU) No. 2020-04, *Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting*. ASU No. 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships, subject to certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in this ASU were effective beginning on March 12, 2020, and the Company could elect to apply the amendments prospectively through December 31, 2022. In December 2022, November 2023, the FASB issued ASU No. 2022-06, 2023-07, *Reference Rate Reform Segment Reporting (Topic 848) 280: Deferral of the Sunset Date of Topic 848 Improvements to Reportable Segment Disclosures (ASU 2023-07)*, which extended improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance also requires disclosure of the election date chief operating decision maker's (CODM) position for each segment and detail of how the CODM uses financial reporting to December 31, 2024. Effective January 1, 2022 certain LIBOR tenors that do not affect assess their segment's performance. ASU 2023-07 is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company has completed its initial assessment of the Company, including the one-week and two-month U.S. dollar LIBOR rate, ceased or became non-representative. The remaining U.S. dollar LIBOR tenors ceased or became non-representative effective July 1, 2023. This change will have no impact on the Company's ability to borrow. The application of this ASU did new guidance and does not expect it to have a material impact on the Company's consolidated financial statements.

In December 2023, the Financial Accounting Standards Board issued ASU 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures*, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both U.S. and foreign jurisdictions. The amendments in the ASU also remove disclosures related to certain unrecognized tax benefits and deferred taxes. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024. The amendments may be applied prospectively or retrospectively, and early adoption is permitted. The Company is currently assessing the effect this guidance may have on its consolidated financial statements. *See Note 7*

#### 16. Subsequent Events

*Change Healthcare Funding Agreement*

On February 21, 2024, we received notice from Change Healthcare (CHC), a subsidiary of UnitedHealth Group (United) of a cybersecurity breach affecting some of CHC's information technology systems. At the time, CHC acted as an intermediary for further discussion processing the vast majority of our payment claims for domestic commercial and government payors. In response to the cybersecurity breach, both the Company and CHC severed those business service connections between our systems and CHC's. As a result of the outage, the Company was unable to submit payment claims through CHC's platform. The Company was able to submit Medicare claims outside of CHC's platform, but experienced a significant reduction in cash flow during this period of time due to the CHC outage. On March 1, 2024, CHC launched a temporary assistance funding program to help bridge the gap in short-term cash flow needs for providers impacted by the disruption of CHC's services. Under the program, CHC provides funding to providers for amounts that would otherwise have been received (with certain limitations), but for the disruption in processing electronic claims as a result of the outage. Amounts provided under this program are subject to repayment within 45 business days of receiving notice from CHC that claims processing and payment processing services have been restored and payments impacted during the service disruption period are being processed. Such notice has not been received as of the date of this filing. As of April 30, 2024, DaVita had received approximately \$472,000 of funds related to this program, which were utilized along with cash on hand to pay off the \$765,000 previously outstanding on the Company's debt, revolving line of credit under its senior secured credit facilities.

CHC began to restore claims submission functionality on March 28, 2024 and the Company has resumed submission of most of its commercial claims through CHC's platform, although the Company continues to experience payment collection delays. As of March 31, 2024, because the outage impacted the Company's ability to submit claims, our patient accounts receivable balances and days sales outstanding (DSO) increased, which ultimately negatively impacted our cash flows for the first quarter of 2024, and resulted in an increase in outstanding borrowings under our revolving credit facility. Subsequent to March 31, 2024, accounts receivable balances and DSO have declined and are expected to continue to decline over the next few months as we continue claims submissions and cash collections.

**DAVITA INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS—(continued)**  
**(unaudited)**

(dollars and shares in thousands, except per share data)

**Fourth Amendment to Credit Agreement**

The Company plans to enter into a fourth amendment to its existing credit agreement which is expected to extend the maturity date for approximately \$1,640,300 of our senior secured term loan B-1 facility to 2031, among other things. The transaction is expected to close in May 2024, subject to agreement on and delivery of definitive documentation.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

**Forward-looking statements**

This Quarterly Report on Form 10-Q, including this Management's Discussion and Analysis of Financial Condition and Results of Operations, contains statements that are forward-looking statements within the meaning of the federal securities laws and as such are intended to be covered by the safe harbor for "forward-looking statements" provided by the Private Securities Litigation Reform Act of 1995. These forward-looking statements could include, among other things, statements about our balance sheet and liquidity, our expenses, and expense offsets, revenues, billings and collections, patient census, availability or cost of supplies, treatment volumes, mix expectation, such as the percentage or number of patients under commercial insurance, DaVita's response to and the continuing impact effects of the coronavirus (COVID-19) pandemic, the continuing impact of the COVID-19 pandemic recent Change Healthcare (CHC) cybersecurity outage on the U.S. us or our operations, current macroeconomic, marketplace and global economies, labor market conditions, and overall impact on our patients and teammates, as well as other statements regarding our future operations, financial condition and prospects, capital allocation plans, expenses, cost saving initiatives, other strategic initiatives, use of contract labor, government and commercial payment rates, expectations related to value-based care (VBC), integrated kidney care and (IKC), Medicare Advantage (MA) plan enrollment and our international operations, expectations regarding increased competition and marketplace changes, including those related to new or potential entrants in the dialysis and pre-dialysis marketplace and the potential impact of innovative technologies, drugs, or other treatments on the dialysis industry, expectations regarding the impact of our continuing cost-savings initiatives and our ongoing stock repurchase program. All statements in this report, other than statements of historical fact, are forward-looking statements. Without limiting the foregoing, statements including the words "expect," "intend," "will," "could," "could," "plan," "anticipate," "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on DaVita's current expectations and are based solely on information available as of the date of this report. DaVita undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may be required by law. Actual future events and results could differ materially from any forward-looking statements due to numerous factors that involve substantial known and unknown risks and uncertainties. These risks and uncertainties include, among other things:

- the current macroeconomic and marketplace conditions, and global events and domestic political or governmental volatility, many of which are interrelated and which relate to, among other things, inflation, rising potential interest rates, rate volatility, labor market conditions, wage pressure, evolving monetary policies, and the continuing impact of the COVID-19 pandemic on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition and results of operations; further spread or resurgence of the virus, including as a result of the emergence of new strains of the virus; the continuing impact of the pandemic on our revenues and non-acquired growth due to lower treatment volumes; COVID-19's impact on the chronic kidney disease (CKD) population and our patient population including on the mortality of these patients; any potential negative impact on our commercial mix or the number of our patients covered by commercial insurance plans; the potential impact of new or potential entrants in the dialysis and pre-dialysis marketplace and potential impact of innovative technologies, drugs, or other treatments on our patients and industry; our ability to successfully implement cost savings initiatives; supply chain challenges and disruptions; and elevated teammate turnover and training costs and higher salary and wage expense, driven in part by persisting labor market conditions and a high demand for our clinical personnel, any of which may also have the effect of heightening many of the other risks and uncertainties discussed below, and in many cases, the impact of the pandemic and the aforementioned global economic conditions on our business may persist even as the pandemic continues to subside;
- the concentration of profits generated by higher-paying commercial payor plans for which there is continued downward pressure on average realized payment rates; a reduction in the number or percentage of our patients under such plans, including, without limitation, as a result of restrictions continuing legislative efforts to restrict or prohibitions on prohibit the use and/or availability of charitable premium assistance, such as AB 290, which may result in the loss of revenues or patients, as a result of our making incorrect assumptions about how our patients will respond to any change in financial assistance from charitable organizations, or as a result of payors' implementing restrictive plan designs, including, without limitation, actions taken in response to the U.S. Supreme Court's decision in Marietta Memorial Hospital Employee Health Benefit Plan, et al. v. DaVita Inc. et al. (Marietta); how and whether regulators and legislators will respond to the Marietta decision including, without limitation, whether they will issue regulatory guidance or adopt new legislation; how courts will interpret other anti-discriminatory provisions that may apply to restrictive plan designs; whether there could be other potential negative impacts of the Marietta decision; and the timing of each of these items;
- the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or guidance, enforcement thereof or related litigation result in a reduction in coverage or reimbursement rates for our services, a reduction in the number of patients enrolled in or that select higher-paying commercial plans, including for example MA plans or other material impacts to our business or operations; or our making incorrect assumptions about how our patients will respond to any such developments;
- risks arising from potential changes in laws, regulations or requirements applicable to us, such as potential and proposed federal and/or state legislation, regulation, ballot, executive action or other initiatives, including, without limitation, those related to healthcare, antitrust matters, including, among others, non-competes and other restrictive

covenants, and acquisition, merger, joint venture or similar transactions and/or labor matters;

- our ability to attract, retain and motivate teammates and our ability to manage operating cost increases or productivity decreases whether due to union organizing activities, which continue to increase for us and in the dialysis industry overall, legislative or other changes, demand for labor, volatility and uncertainty in the labor market, the current challenging and highly competitive labor market conditions, or other reasons;
- our ability to respond to challenging U.S. and global economic and marketplace conditions, including, among other things, our ability to successfully identify cost savings opportunities and to invest in and implement cost savings initiatives such as ongoing initiatives that increase our use of third-party service providers to perform certain activities, initiatives that relate to clinic optimization and capacity utilization improvement, and procurement opportunities, among other things;
- our ability to successfully implement our strategies with respect to integrated kidney care IKC and value-based care VBC initiatives and home based dialysis in the desired time frame and in a complex, dynamic and highly regulated environment, including, among other things, maintaining our existing business; meeting growth expectations; recovering our investments; entering into or renewing agreements with payors, third party vendors and others on terms that are competitive and, as appropriate, prove actuarially sound; structuring operations, agreements and arrangements to comply with evolving rules and regulations; finding, training and retaining appropriate staff; and further developing our integrated care and other capabilities to provide competitive programs at scale;
- a reduction in government payment rates under the Medicare End Stage Renal Disease program, state Medicaid or other government-based programs and the impact of the MA benchmark structure;
- noncompliance by us or our business associates with any privacy or security laws or any security breach by us or a third party, such as the recent cyber attack on CHC, including any such non-compliance or breach involving the misappropriation, loss or other unauthorized use or disclosure of confidential information;
- legal and compliance risks, such as our continued compliance with complex, and at times, evolving government regulations and requirements; requirements, and with additional laws that may apply to our operations as we expand geographically or enter into new lines of business, including through acquisitions or joint ventures;
- the impact of the political environment and related developments on the current healthcare marketplace and on our business, including with respect to the Affordable Care Act, the exchanges and many other core aspects of the current healthcare marketplace, as well as the composition of the U.S. Supreme Court, and the current presidential administration president and congressional majority;
- changes in pharmaceutical practice patterns, reimbursement and payment policies and processes, or pharmaceutical pricing, including with respect to hypoxia inducible factors, oral phosphate binders, among other things;
- our ability to develop and maintain relationships with physicians and hospitals, changing affiliation models for physicians, and the emergence of new models of care or other initiatives introduced by the government or private sector that, among other things, may erode our patient base and impact reimbursement rates;
- our ability to complete acquisitions, mergers, dispositions, joint ventures or other strategic transactions that we might announce or be considering, on terms favorable to us or at all, to successfully integrate any acquired businesses, to successfully operate any acquired businesses, joint ventures or other strategic transactions, or to successfully expand our operations and services in markets outside the United States, or to businesses or products outside of dialysis services;
- continued increased competition from dialysis providers and others, and other potential marketplace changes, including without limitation increased investment in and availability of funding to new entrants in the dialysis and pre-dialysis marketplace;
- the variability of our cash flows, including, without limitation, any extended billing or collections cycles; cycles including, without limitation, due to defects or operational issues in our billing systems or in the billing systems or services of third parties on which we rely, such as the operational issues at CHC resulting from a recent cyber attack; the risk that we may not be able to generate or access sufficient cash in the future to service our indebtedness or to fund our other liquidity needs; and the risk that we may not be able to refinance our indebtedness as it becomes due, on terms favorable to us or at all;
- factors that may impact our ability to repurchase stock under our stock repurchase program and the timing of any such stock repurchases, as well as our any use by us of a considerable amount of available funds to repurchase stock;
- risks arising from the use of accounting estimates, judgments and interpretations in our financial statements;
- impairment of our goodwill, investments or other assets;
- our aspirations, goals and disclosures related to environmental, social and governance (ESG) matters, including, among other things, evolving regulatory requirements affecting ESG standards, measurements and reporting requirements; the availability of suppliers that can meet our sustainability standards; and our ability to recruit, develop and retain diverse talent in our labor markets; and
- the other risk factors, trends and uncertainties set forth in our Annual Report on Form 10-K for the year ended December 31, 2022 (2022 December 31, 2023 (2023 10-K)), our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023, and the risks and uncertainties discussed in any subsequent reports that we file or furnish with the Securities and Exchange Commission (SEC) from time to time.

The following should be read in conjunction with our condensed consolidated financial statements.

## Company Overview

Our principal business is to provide dialysis and related lab services to patients in the United States, which we refer to as our U.S. dialysis business. We also operate our U.S. integrated kidney care (IKC) business, our U.S. other ancillary services, and our international operations, which we collectively refer to as our ancillary services, as well as our corporate administrative support. Our U.S. dialysis business is a leading provider of kidney dialysis services in the U.S. for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD) or end stage kidney disease (ESKD).

## Recent Developments

### Change Healthcare

On February 21, 2024, we received notice from Change Healthcare (CHC), a subsidiary of UnitedHealth Group (United), of a cybersecurity breach affecting some of CHC's information technology systems. At the time, CHC acted as an intermediary for processing the vast majority of our payment claims for domestic commercial and government payors. CHC reported that it had isolated the impacted systems from other connecting systems upon detection of the cybersecurity breach, and had shut down its systems (CHC Outage). We suspended all claims processing activity with CHC promptly following receipt of notice from CHC and pending resolution of the cybersecurity breach. As a result of the CHC Outage, we were unable to submit payment claims through CHC's platform, and therefore, we experienced a significant reduction in cash flow during this period of time. As a result of the suspension of claims processing activity with CHC, we set up alternative methods to submit Medicare claims for processing and worked to establish additional alternative methods for claim processing. In addition, we worked to mitigate the impact of the outage through other means, including, for example, by securing certain interest-free funding from United and its affiliates (CHC Funding Arrangement).

Based on information provided by CHC and officials investigating the CHC Outage, we have no indication that our systems were infiltrated by the same threat actor that caused the CHC Outage. CHC began to restore claims submission functionality on March 28, 2024, and CHC subsequently presented us with security protocols that had been put in place following the cybersecurity breach. Following an evaluation of these protocols, and in reliance thereon, we resumed claims submissions and billing processes through CHC's information technology systems. As of the date of this filing, through a combination of CHC's platform and the aforementioned alternate billing processes, we are current on our primary claims submissions. However, the CHC Outage, and the resultant delay in claims submissions, led to an increase in our days sales outstanding (DSOs), adversely impacted cash flows for the first quarter of 2024, and resulted in an increase in outstanding borrowings under our revolving credit facility. While we have started to receive cash collections from the claims submitted through CHC after March 28, 2024, we continue to experience payment collection delays, and it is too early to know whether we will receive the full expected value for the claims submitted through CHC that were delayed in their original submission as a result of the outage. We expect that the DSO increase related to the CHC Outage will decline over the next few months as we continue claims submissions and cash collections in the ordinary course. As of the date of this report, we have fully paid down our revolver balance through cash on hand and the interest-free funding from United discussed above.

CHC recently reported that it identified protected health information (PHI), or personally identifiable information (PII), from users of the CHC systems that was potentially impacted by the CHC Outage. We have not been informed whether any of our data, including any PHI or PII from our patients, was potentially impacted by the CHC Outage despite several inquiries regarding the same. We understand that the CHC investigation and data forensics is still ongoing and that there is a potential that our data and PHI or PII from our patients may have been impacted by the CHC Outage.

Since receiving notice from CHC, we have been reviewing and monitoring our information technology infrastructure and network environment, including specifically for the indicators of compromise identified by CHC and its agents. While there can be no assurances, we do not believe our information technology systems have been affected based on the information available to date. We have dedicated and expect to continue to dedicate resources to help resolve the impact of this temporary outage, including, among other things, administrative processes related to collections for services rendered and resolution of disputes

such as retractions from and refunds to commercial and government payors, and the CHC Outage may continue to increase the risks associated with billing and collections. While the CHC Outage has not impacted our ability to provide care to our patients in the ordinary course and we do not currently expect the outage to have a material impact on our operations, financial condition or results of operation, the ultimate impact of the CHC Outage remains subject to future developments and risks that are difficult to predict. These risks may include, among other things, a recurrence of system outages or service suspensions or the risk that our information technology systems or our proprietary information and sensitive or confidential data, including PHI or PII, may have been compromised through the CHC Outage, any of which may have a material adverse effect on our business, results of operations, financial condition, cash flows or reputation. For a further discussion of the risks associated with outages, disruptions or incidents at third parties on which we rely, see the risk factors in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023 (2023 10-K) under the headings, "Failing to effectively maintain, operate or upgrade our information systems or those of third-party service providers upon which we rely..." and "Privacy and information security laws are complex..."

### General Economic and Marketplace Conditions Conditions; Legal and Regulatory Developments

Developments in general economic and market conditions have directly and indirectly impacted the Company and in the future could have a material adverse impact on our patients, teammates, physician partners, suppliers, business, operations, reputation, financial condition, results of operations, share price, cash flows and/or liquidity. Many of these external factors and conditions are interrelated, including, among other things, inflation, rising potential interest rates, rate volatility and other economic conditions, labor market conditions, wage pressure, the continuing impact of COVID-19 on the mortality rates of our patients and other ESKD or CKD patients, supply chain challenges and the potential impact and application of innovative technologies, drugs or other treatments. Certain of these impacts could be further intensified by concurrent global events such as the ongoing conflict between Russia and Ukraine and armed conflict in Israel, Gaza and the surrounding areas, which has have continued to drive sociopolitical and economic uncertainty across the globe.

### Operational and Financial Impacts

In the third first quarter of 2023, treatment per day volumes were approximately flat slightly lower compared to the second quarter, fourth quarter of 2023. We continued to experience improvements with respect to the negative impact of COVID-19 on the mortality rates of our patients. On a full year over full year basis, we continue to experience a negative impact on revenue and treatment volume due to the cumulative and compounding negative impact of COVID-19 on the mortality rates of our patients and the associated adverse impact on our patient census. We expect that this impact would likely continue. However, we have continued to negatively impact our revenue experience improvements with respect to these negative impacts with treatment volumes remaining relatively flat year over year and non-acquired growth new-to-dialysis admissions increasing year over year for a period of time after mortality rates normalize due to the compounding impact of mortalities, among other things. New five consecutive quarters. Despite these improvements, new-to-dialysis admission rates, treatment volumes, future revenues and non-acquired growth, among other things, could also continue to be negatively impacted over time to the extent that the ESKD and CKD populations experience sustained elevated mortality levels. The magnitude of these cumulative impacts could have a material adverse impact on our results of operations, financial condition and cash flows.

Ongoing global economic conditions and political and regulatory developments, such as general labor, supply chain and inflationary pressures have also increased, and will likely continue to increase, our expenses, including, among others, staffing and labor costs. We continue to experience elevated increased levels of compensation year to date compared to the prior year though we have experienced slight wage improvement with contract labor improvements offset by investments in the third quarter compared to the prior quarter. our teammate compensation. We expect certain of these increased staffing and labor costs to continue, due to, among other factors, recent legislative changes, such as our

implementation the continuation of the provisions of Senate Bill 525 in California, and increased training costs. a challenging healthcare labor market. The cumulative impact of these increased costs could be material. In addition, our industry has experienced increased union organizing activities, including the filing of petitions by unions at certain of our competitors' clinics with a number of those clinics voting to unionize. Potential potential staffing shortages or other potential developments or disruptions related to our teammates, if material, could ultimately lead to the unplanned closures of certain centers or adversely impact clinical operations, or may otherwise have a material adverse impact on our ability to provide dialysis services or the cost of providing those services, among other things. Our industry has also experienced increased union organizing activities, including the filing of petitions by a union at certain of our clinics in California and at certain of our competitors' clinics, with certain of our competitors' clinics ultimately voting to unionize. We are engaging with our teammates at clinics where union petitions have been filed to respond to these petitions and future elections. Regardless of the outcome of these discussions, other teammates at other clinics may file similar petitions in the future, and these petitions, if filed, may lead to additional elections. If a significant portion of our teammates were to become unionized, we could experience, among other things, an upward trend in wages and benefits and labor and employment claims, including, without limitation, the filing of class action suits, or adverse outcomes of such claims; face work stoppages or other business disruptions; or experience negative impacts on our employee culture. In addition, we are and may continue to be subject to targeted corporate campaigns by union organizers in response to which we have been and expect to continue to be required to expend substantial resources, both time and financial. Any of these events or circumstances, including our responses to such events or circumstances, could have a material adverse effect on our employee relations, treatment growth, productivity, business, results of operations, financial condition, cash flows and reputation. For further discussion of the risks related to rising labor costs and union organizing activities, see the discussion in the risk factors in Part I, Item 1A Risk Factors of our 2023 10-K under the heading, "Our business is labor intensive..."

The impact of the pandemic on our patient population combined with the cost inflation trends described above have put pressure on our existing cost structure, and as noted above, we expect that certain of those increased costs will persist as inflationary and supply chain pressures and challenging labor market conditions continue. During the third quarter of 2024, we continued to invest in and implement cost savings opportunities and invest in other initiatives designed to help mitigate these cost and volume pressures. These opportunities include anticipated identified cost savings related to the achievement of general and administrative cost efficiencies through ongoing initiatives that increase our use of third party service providers to perform certain activities, including, among others, finance and accounting functions and related information technology functions. These opportunities and investments also include, among others, initiatives relating to clinic optimization, capacity utilization improvement and procurement opportunities, as well as investments in revenue cycle management. We have incurred, and expect to continue to incur, charges in connection with the continued implementation of certain of these initiatives. There can be no assurance that we will be able to successfully execute these initiatives or that they will achieve expectations or succeed in helping offset the impact of these challenging conditions.

#### Other Legal and Regulatory Developments

Developments On April 23, 2024, the FTC published a final rule that would generally ban all non-compete clauses with employees and prohibit employers from enforcing existing non-compete clauses in contracts with workers, with limited exceptions. Specifically, employers may continue to enforce an existing non-compete with a "senior executive" as defined in the healthcare marketplace related final rule as an officer with "policy-making authority" who earns total annual compensation in excess of \$151,164. In addition, individuals may enter into a non-compete "pursuant to new or innovative technologies, drugs and other treatments have the potential to impact the rate a bona fide sale of growth a business entity, of the ESKD patient population person's ownership interest in a business entity, or of all or substantially all of a business entity's operating assets", which may lead apply in several circumstances for the Company. The rule is scheduled to reductions in demand for dialysis treatments, and uncertainty surrounding the development of such new technologies, drugs and other treatments may drive volatility in our stock price. For example, in October 2023, a clinical study for Novo Nordisk's Ozempic®, a glucagon-like peptide 1 (GLP-1) receptor agonist was stopped early for efficacy. This development generated uncertainty become effective 120 days after it is published in the marketplace with respect Federal Register. However, several parties have filed legal challenges to the rule, including challenges that seek to enjoin implementation of the rule pending a determination of its constitutional validity. We are continuing to assess the potential impact of these or other similar classes of drugs or new classes of drugs or treatments the rule on our business, but if the rate of growth of the ESKD patient population. We expect that further information on GLP-1s and their potential application to kidney care will be released by third parties later this year and in the first half of 2024, and the release of such information then or in the future, or the release of any other information regarding current or future new or innovative technologies, drugs and other treatments may drive volatility in our stock price. Any sustained or significant decline in the rate of growth of the ESKD patient population or demand for our services, whether final rule is implemented as a result of developments related to new or innovative technologies, drugs, treatments or otherwise, may currently contemplated, it would have a material an adverse impact on, among other things, our agreements with teammates, our arrangements with medical directors, or the terms of our existing agreements with physicians. There are also other legislative efforts, including in more than half of the states' legislatures, that seek to place restrictions on non-compete agreements between employers and workers. While few of these states passed legislation during 2023 that impacted our business, results of operation, financial condition, cash flows and stock price.

it is possible that similar legislation could be introduced in 2024. Any failure on our part to adequately adjust our business to this rule, any state follow-on regulations and operations to address these developments or other marketplace dynamics, or any failure to appropriately implement these cost savings initiatives in accordance with applicable legal, regulatory or compliance requirements the potential impact thereof could adversely impact our ability to provide dialysis services or the cost of providing those services, among other things. If this adverse impact is significant or sustained, it may ultimately have a material adverse effect on our business, reputation, results of operations, financial condition, cash flows and stock price. reputation.

We believe that the aforementioned recent developments and general economic and marketplace conditions will continue to impact the Company in the future. We believe that their ultimate impact will depend depends on future developments that are highly uncertain and difficult to predict.

#### Financial Results

The discussion below includes analysis of our financial condition and results of operations for the three months ended September 30, 2023 March 31, 2024 compared to the three months ended June 30, 2023 December 31, 2023, and the year-to-date periods for the nine three months ended September 30, 2023 March 31, 2024 compared to the nine three months ended September 30, 2022 March 31, 2023.

#### Consolidated results of operations

The following tables summarize our revenues, operating income (loss) and adjusted operating income (loss) by line of business. See the discussion of our results for each line of business following the tables. When multiple drivers are identified in the following discussion of results, they are listed in order of magnitude:

Three months ended Q3 2023 vs. Q2 2023

		September									
		30, 2023	June 30, 2023	Amount	Percent						
		(dollars in millions)									
		Three months ended		Three months ended		Three months ended					
		March 31, 2024		March 31, 2024		December 31, 2023					
		(dollars in millions)									
<b>Revenues:</b>	<b>Revenues:</b>										
U.S. dialysis	U.S. dialysis										
U.S. dialysis	U.S. dialysis	\$ 2,785	\$ 2,731	\$ 54	2.0 %	\$ 2,756	\$ 2,809				
Other — Ancillary services	Other — Ancillary services	363	292	71	24.3 %	Other — Ancillary services	342				
Elimination of intersegment revenues	Elimination of intersegment revenues	(27)	(22)	(5)	(22.7)%	Elimination of intersegment revenues	(27)				
Total consolidated revenues	Total consolidated revenues	\$ 3,121	\$ 3,000	\$ 121	4.0 %	Total consolidated revenues	\$ 3,071				
<b>Operating income (loss):</b>	<b>Operating income (loss):</b>										
Operating income (loss):	Operating income (loss):										
U.S. dialysis	U.S. dialysis	\$ 509	\$ 461	\$ 48	10.4 %	\$ 526	\$ 444				
Other — Ancillary services	Other — Ancillary services	28	(22)	50	227.3 %	Other — Ancillary services	(12)				
Corporate administrative support	Corporate administrative support	(41)	(34)	(7)	(20.6)%	Corporate administrative support	(30)				
Operating income	Operating income	\$ 496	\$ 405	\$ 91	22.5 %	Operating income	\$ 484				
<b>Adjusted operating income (loss):</b>	<b>Adjusted operating income (loss):</b>										
(1):	(1):										
<b>Adjusted operating income (loss):</b>	<b>Adjusted operating income (loss):</b>										
U.S. dialysis	U.S. dialysis	\$ 537	\$ 487	\$ 50	10.3 %	\$ 505	\$ 476				
Other — Ancillary services	Other — Ancillary services	28	(22)	50	227.3 %	Other — Ancillary services	(12)				
Corporate administrative support	Corporate administrative support	(41)	(33)	(8)	(24.2)%	Corporate administrative support	(30)				

Adjusted operating income	Adjusted operating income	\$ 525	\$ 432	\$ 93	21.5 %	Adjusted operating income	\$ 463	\$ 415	\$ 48	11.6	11.6	%
---------------------------	---------------------------	--------	--------	-------	--------	---------------------------	--------	--------	-------	------	------	---

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

(1) For a reconciliation of adjusted operating income (loss) by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

YTD Q3 2023 vs.																											
Nine months ended				YTD Q3 2022																							
September		September							March		March																
30,		30,							2024		2023																
(dollars in millions)																											
Three months ended																											
March 31,				March				YTD Q1 2024 vs. YTD Q1 2023																			
2024				2023				(dollars in millions)																			
<b>Revenues:</b>	<b>Revenues:</b>																										
U.S. dialysis	U.S. dialysis																										
U.S. dialysis	U.S. dialysis			\$ 8,128	\$ 7,942	\$ 186	2.3 %	\$ 2,756	\$ 2,612	\$ 144	5.5	5.5 %															
Other — Ancillary services	Other — Ancillary services			938	816	122	15.0 %	342	284	58	58	20.4 %															
Elimination of intersegment revenues	Elimination of intersegment revenues			(72)	(65)	(7)	(10.8) %	(27)	(23)	(4)	(4)	(17.4) %															
Total consolidated revenues	Total consolidated revenues			\$ 8,994	\$ 8,693	\$ 301	3.5 %	\$ 3,071	\$ 2,873	\$ 198	6.9	6.9 %															
<b>Operating income (loss):</b>	<b>Operating income (loss):</b>																										
Operating income (loss):	Operating income (loss):																										
U.S. dialysis	U.S. dialysis																										
U.S. dialysis	U.S. dialysis			\$ 1,331	\$ 1,231	\$ 100	8.1 %	\$ 526	\$ 361	\$ 165	45.7	45.7 %															
Other — Ancillary services	Other — Ancillary services			(18)	(57)	39	68.4 %	(12)	(25)	(25)	13	52.0 %															
Corporate administrative support	Corporate administrative support			(100)	(91)	(9)	(9.9) %	(30)	(25)	(25)	(5)	(20.0) %															
Operating income	Operating income			\$ 1,213	\$ 1,083	\$ 130	12.0 %	Operating income	\$ 484	\$ 312	\$ 172	55.1 %															
<b>Adjusted operating income (loss):</b>	<b>Adjusted operating income (loss):</b>																										
(1):	(1):																										
<b>Adjusted operating income (loss):</b>	<b>Adjusted operating income (loss):</b>																										
(1):	(1):																										

U.S. dialysis	U.S. dialysis	\$ 1,425	\$ 1,281	\$ 144	11.2 %	\$ 505	\$ 400	\$ 105	26.3	26.3	%
U.S. dialysis	U.S. dialysis	\$ 1,425	\$ 1,281	\$ 144	11.2 %	\$ 505	\$ 400	\$ 105	26.3	26.3	%
Other — Ancillary services	Other — Ancillary services	(18)	(57)	39	68.4 %	Other — Ancillary services	(12)	(24)	(24)	12	50.0 %
Corporate administrative support	Corporate administrative support	(98)	(91)	(7)	(7.7)%	Corporate administrative support	(30)	(24)	(24)	(6)	(25.0) %
Adjusted operating income	Adjusted operating income	\$ 1,308	\$ 1,133	\$ 175	15.4 %	Adjusted operating income	\$ 463	\$ 352	\$ 111	31.5	31.5 %

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

(1) For a reconciliation of adjusted operating income (loss) by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

#### U.S. dialysis results of operations

Treatment volume:

	Three months ended		Q3 2023 vs. Q2 2023			
	September 30, 2023		June 30, 2023			
	Amount	Percent	Amount	Percent		
<b>Three months ended</b>						
	March 31, 2024		March 31, 2024	December 31, 2023	Q1 2024 vs. Q4 2023	
Dialysis treatments	Dialysis treatments	7,306,948	7,231,242	75,706	1.0 %	
Average treatments per day	Average treatments per day	92,493	92,708	(215)	(0.2)%	
Treatment days	Treatment days	79.0	78.0	1.0	1.3 %	
Normalized non-acquired treatment growth <sup>(1)</sup>	Normalized non-acquired treatment growth <sup>(1)</sup>	0.5 %	(0.2)%			

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

(1) Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given quarter versus the prior year quarter.

	YTD Q3 2023 vs. YTD Q3 2022					
	Nine months ended		Q3 2022			
	September 30, 2023	September 30, 2022	Amount	Percent		
<b>Three months ended</b>						
	March 31, 2024		March 31, 2024	March 31, 2023	YTD Q1 2024 vs. YTD Q1 2023	
Dialysis treatments	Dialysis treatments	21,655,618	21,714,773	(59,155)	(0.3)%	
Average treatments per day	Average treatments per day	92,545	92,798	(253)	(0.3)%	
Treatment days	Treatment days	234.0	234.0	—	— %	

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

Our U.S. dialysis treatment volume is directly correlated with our operating revenues and expenses. The **increase** in our U.S. dialysis treatments for the **third** quarter of **2023** from the **second** quarter of 2023 was primarily driven by one **additional** treatment day and **non-acquired growth**. This increase was partially offset by decreased average treatments per day due to mix of treatment **days**. This decrease was partially offset by increased patient count from **acquired** and a **decrease** in hospital **inpatient treatments**.

non-acquired treatment growth.

The **decrease** in our U.S. dialysis treatments for the **nine** months ended **September 30, 2023** from the **nine** months ended **September 30, 2022** March 31, 2023 was primarily driven by one additional treatment day and increased patient count from non-acquired growth partially offset by decreased average treatments per day and decreased hospital inpatient treatments, partially offset by an increase in patient count.

Revenues:

Q3 2023 vs. Q2										
Three months ended		2023								
September		June 30,								
30,	2023	2023	Amount	Percent						
(dollars in millions, except per treatment data)										
<b>Total</b>	<b>Total</b>									
revenues	revenues	\$ 2,785	\$ 2,731	\$ 54	2.0 %	Total revenues	\$ 2,756	\$ 2,809	\$ (53)	
Average	Average									
patient	patient									
service	service									
revenue	revenue									
per	per									
treatment	treatment	\$380.33	\$376.73	\$3.60	1.0 %	Average patient service revenue per treatment	\$384.54	\$386.31	\$ (1.77)	

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

YTD Q3 2023 vs.											
Nine months ended		YTD Q3 2022									
September		September									
30,	2023	30,	2022	Amount	Percent						
(dollars in millions, except per treatment data)											
<b>Total</b>	<b>Total</b>										
revenues	revenues	\$ 8,128	\$ 7,942	\$ 186	2.3 %	Total revenues	\$ 2,756	\$ 2,612	\$ 144		
Average	Average										
patient	patient										
service	service										
revenue	revenue										
per	per										
treatment	treatment	\$374.46	\$364.89	\$ 9.57	2.6 %	Average patient service revenue per treatment	\$384.54	\$366.14	\$ 18.40		

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

U.S. dialysis average patient service revenue per treatment for the **third** quarter of 2024 compared to the **fourth** quarter of 2023 compared to decreased driven by a seasonal decline from co-insurance and deductibles, partially offset by an increase in the **second** quarter of 2023 increased, primarily due to Medicare base rate and other annual

rate increases, favorable changes in commercial mix and Medicare Advantage mix, a net seasonal increase in average reimbursement rates and other normal fluctuations. Our U.S. dialysis average patient service revenue per treatment was negatively impacted by a decrease in hospital inpatient revenues, dialysis treatments.

U.S. dialysis average patient service revenue per treatment for the nine three months ended September 30, 2023 March 31, 2024 increased compared to the nine three months ended September 30, 2022 March 31, 2023 primarily driven by the increase in average reimbursement rates from revenue cycle improvements and normal annual rate increases including Medicare rate increases, favorable changes in commercial and Medicare Advantage mix, and a net increase in Medicare rate due to a base rate increase in 2023, partially offset by the phased-in increase of sequestration of 1% in April 2022 and full 2% beginning July 1, 2022 and thereafter. Other drivers of this change include improved cash collections on previously reserved balances assumed to be uncollectible.

On October 27, 2023, Centers for Medicare & Medicaid Services (CMS) issued a final rule to update the Medicare ESRD Prospective Payment System payment rate and policies for calendar year 2024. Among other things, the final rule updates the Acute Kidney Injury hospital inpatient dialysis payment rate for renal dialysis services furnished by ESRD facilities and requirements for the ESRD Quality Incentive Program. CMS estimates that the overall impact of the rule will increase ESRD facilities' average reimbursement by 2.1% in 2024, rates.

*Operating expenses:*

Q3 2023 vs. Q2														
Three months ended		2023												
September														
30,	June 30,	2023	2023	Amount	Percent									
(dollars in millions, except per treatment data)														
Three months ended														
March 31,		2024		March		December		Q1 2024 vs. Q4 2023						
		31,		2024		31,		2023						
(dollars in millions, except per treatment data)														
Patient care costs	Patient care costs	\$ 1,827	\$ 1,826	\$ 1	0.1 %	Patient care costs	\$ 1,825	\$ (84)	(4.4) %					
General and administrative	General and administrative	281	279	2	0.7 %	General and administrative	275	283	(8) (2.8) %					
Depreciation and amortization	Depreciation and amortization	176	172	4	2.3 %	Depreciation and amortization	173	181	(8) (4.4) %					
Equity investment income	Equity investment income	(8)	(8)	—	— %	Equity investment income	(6)	(8)	2 25.0 %					
Gain on changes in ownership interest						Gain on changes in ownership interest	(35)		(100.0) %					
Total operating expenses and charges	Total operating expenses and charges	\$ 2,276	\$ 2,270	\$ 6	0.3 %	Total operating expenses and charges	\$ 2,230	\$ (135)	(5.7) %					
Patient care costs per treatment	Patient care costs per treatment	\$250.08	\$252.57	\$ (2.49)	(1.0) %	Patient care costs per treatment	\$255.13	\$ (8.06)	(3.1) (3.1) %					

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

YTD Q3 2023 vs.				
Nine months ended		YTD Q3 2022		
September		September		
30,	30,	2023	2022	Amount Percent
(dollars in millions, except per treatment data)				

Three months ended										YTD Q1 2024 vs. YTD Q1 2023						
March 31, 2024					March 31, 2023					2023						
										Amount	Percent					
(dollars in millions, except per treatment data)																
Patient care costs	Patient care costs	\$ 5,485	\$ 5,469	\$ 16	0.3 %	Patient care costs	\$ 1,825	\$ 1,832	\$ (7)	(0.4)	(0.4) %					
General and administrative <sup>(1)</sup>	General and administrative	819	755	64	8.5 %	General and administrative	275	259	16	6.2 %						
Depreciation and amortization	Depreciation and amortization	515	507	8	1.6 %	Depreciation and amortization	173	167	6	3.6	3.6 %					
Equity investment income	Equity investment income	(22)	(21)	(1)	(4.8) %	Equity investment income	(6)	(6)	(6)	—	— %					
Gain on changes in ownership interest	Gain on changes in ownership interest					Gain on changes in ownership interest	(35)	(35)	(35)	(100.0)	%					
Total operating expenses and charges	Total operating expenses and charges	\$ 6,797	\$ 6,711	\$ 86	1.3 %	Total operating expenses and charges	\$ 2,230	\$ 2,251	\$ (21)	(0.9)	(0.9) %					
Patient care costs per treatment	Patient care costs per treatment	\$253.30	\$251.88	\$ 1.42	0.6 %	Patient care costs per treatment	\$255.13	\$257.34	\$ (2.21)	(0.9)	(0.9) %					

Certain columns, rows or percentages may not sum or recalculate due to the presentation of rounded numbers.

(1) General and administrative expenses for the nine months ended September 30, 2022 include advocacy costs of approximately \$51 million to counter union policy efforts, including a California ballot initiative.

#### Charges impacting operating income

**Closure costs.** During the third quarter of 2023, we continued the strategic review of our outpatient clinic capacity requirements and utilization, which have been impacted both by declines in our patient census in some markets due to the COVID-19 pandemic, as well as by our initiatives toward, and advances in, increasing the proportion of our home dialysis patients. This continuing review, begun in the third quarter of 2022, has resulted in higher than normal charges for center capacity closures over the last number of quarters. These capacity closure costs include net losses on assets retired, lease costs, asset impairments and accelerated depreciation and amortization.

During the **third first quarter of 2023, 2024**, we incurred charges for U.S. dialysis center closures of approximately **\$24.0 \$14.6** million, which increased our patient care costs by **\$4.4 \$3.3** million, our general and administrative expenses by **\$3.4 \$7.1** million and our depreciation and amortization expense by **\$16.2 \$4.2** million. By comparison, during the **second fourth quarter of 2023**, U.S. dialysis center closures were approximately **\$21.1 \$31.8** million, which increased our patient care costs by **\$5.7 \$5.3** million, our general and administrative expenses by **\$7.8 \$4.6** million and our depreciation and amortization expense by **\$7.6 \$21.9** million.

During the **nine months ended September 30, 2023, first quarter of 2023**, U.S. dialysis center closures were approximately **\$67.3 \$22.2** million, which increased our patient care costs by **\$22.7 \$12.6** million, our general and administrative expenses by **\$16.0 \$4.8** million and our depreciation and amortization expense by **\$28.6 \$4.8** million. By comparison, during the **nine months ended September 30, 2022, U.S. dialysis center** These capacity closures were approximately **\$50.3** million, which increased our patient care costs by **\$14.7** million, our general included net losses on assets retired, lease costs, asset impairments and administrative expenses by **\$13.9** million and our accelerated depreciation and amortization expense by **\$21.7** million. amortization.

We will continue to optimize our U.S. dialysis center footprint through center mergers and/or closures and expect our center closure rates to remain at elevated levels over the next several quarters. current fiscal year.

**Severance costs.** During the fourth quarter of 2022, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions. As a result of this plan, we recognized expenses related to termination and

other benefit commitments in our U.S. dialysis business. This plan included additional charges of **\$4.3 \$0.4** million and **\$5.0 \$16.9** million during the **third quarters ended December 31, 2023** and **second quarter of 2023**, respectively and **\$26.3** million during the **nine months ended September 30, 2023, March 31, 2023**, respectively.

**Patient care costs.** U.S. dialysis patient care costs per treatment for the **third** first quarter of **2023** **2024** decreased from the **second** fourth quarter of 2023 primarily due to decreases in health benefit expense, other direct operating expenses associated with our dialysis centers, contributions to charitable organizations and pharmaceutical unit costs. These decreases were partially offset by increased compensation expenses including increased wage rates. Additionally, our fixed other direct operating expenses negatively impacted patient care costs per treatment due to decreased **minor equipment expense** treatments in the first quarter of 2024, as well as increases in travel costs and **utilities expense** driven by professional fees.

U.S. dialysis patient care costs per treatment for the three months ended March 31, 2024 decreased from the three months ended March 31, 2023 primarily due to decreased other direct operating expenses associated with our **virtual power purchase arrangements**. Other drivers of this change include decreased pharmaceutical dialysis centers, center closure costs, **professional fees**, **medical supplies expense**, as described above, contract wages, contributions to charitable organizations and **travel pharmaceutical unit costs**. In addition, our fixed other direct operating expenses **positively favorably impacted** patient care costs per treatment due to increased treatments in the third quarter of 2023. Our patient costs per treatment **2024**. These decreases were **negatively impacted** partially offset by increased compensation expenses including increased wages and headcount, health benefit expense due to higher claims volume, as well as increased insurance costs.

U.S. dialysis patient care costs per treatment for the nine months ended September 30, 2023 increased from the nine months ended September 30, 2022 primarily due to increased compensation expenses including increased wage rates, **and headcount**, as well as increases in **professional fees**, **medical supplies expense**, **repairs and maintenance expense** and **travel costs**. Other drivers of this change include increased **utilities expense** driven by our **virtual power purchase arrangements** and increased center closure costs, as described above. In addition, our fixed other direct operating expenses **unfavorably impacted** patient care costs per treatment due to decreased treatments in 2023. These increases were partially offset by decreased pharmaceutical costs and contract wages.

expense.

**General and administrative expenses.** U.S. dialysis general and administrative expenses in the **third** first quarter of **2023 increased** **2024 decreased** from the **second** fourth quarter of 2023 primarily due to **increases** **seasonal decreases** in purchased services and health benefit expense, as well as **decreases** in contributions to our charitable foundation, **professional fees** and **travel costs** related to **management meeting costs** and **IT-related costs**. **meetings**. These **increases** **decreases** were partially offset by **decreased** **increased** compensation expenses and center closure costs, as described above, and long-term incentive compensation, above.

U.S. dialysis general and administrative expenses for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** increased from the **nine** **three** months ended **September 30, 2022** primarily **March 31, 2023** due to **increases** in compensation expenses including increased wage rates and severance costs, as described above. Other drivers of this change include gains recognized on the sale of our self-developed properties in the second quarter of 2022, increased **IT-related costs** and **travel costs**, and increased contributions to our charitable foundation. These increases were partially offset by decreased advocacy costs, including primarily related to a refund received in 2023 related to 2022 advocacy costs, as well as increases in compensation expenses including increased wage rates. Other drivers of this change include increased **IT-related costs** and **decreased** **professional fees**. These increases were partially offset by decreased severance costs, as described above.

**Depreciation and amortization.** U.S. dialysis depreciation and amortization expenses for the quarter ended **September 30, 2023** increased **March 31, 2024** decreased compared to the quarter ended **June 30, 2023** **December 31, 2023** primarily due to **decreased** **accelerated depreciation** related to center closures, as described above, partially offset by **decreased** depreciation related to corporate IT projects.

U.S. dialysis depreciation and amortization expenses for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** compared to the **nine** **three** months ended **September 30, 2022** **March 31, 2023** increased primarily due to **accelerated depreciation** related to center closures, as described above as well as a full year of depreciation from the rollout of our new clinical system which was placed in service in May of 2022. These increases were partially offset by a decrease in depreciation related to leasehold improvements due to the reduction in number of centers operated, corporate IT projects.

**Equity investment income.** U.S. dialysis equity investment income remained relatively flat for the **third** first quarter of **2023** **2024** compared to the **second** fourth quarter of 2023 and for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** compared to the **nine** **three** months ended **September 30, 2022** **March 31, 2023**.

**Gain on changes in ownership interests.** During the first quarter of 2024, we acquired a controlling interest in a previously nonconsolidated dialysis partnership for which we recognized a non-cash gain of \$35.1 million on our prior investment upon consolidation.

**Operating income and adjusted operating income:**

Three months ended			Q3 2023 vs. Q2		Three months ended			Q1 2024 vs. Q4 2023	
September 30, 2023	June 30, 2023	2023	Amount	Percent	March 31, 2024	December 31, 2023	Amount	Percent	
(dollars in millions)									
Operating income	Operating income	\$ 509	\$ 461	\$ 48 10.4 %	Operating income	\$ 526	\$ 444	\$ 82	18.5 %
Adjusted operating income <sup>(1)</sup>	Adjusted operating income <sup>(1)</sup>	\$ 537	\$ 487	\$ 50 10.3 %	Adjusted operating income <sup>(1)</sup>	\$ 505	\$ 476	\$ 29	6.1 %

(1) For a reconciliation of adjusted operating income by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

		YTD Q3 2023 vs.			
Nine months ended		YTD Q3 2022			
September	September	2023	2022	Amount	Percent
(dollars in millions)					
Three months ended		Three months ended		YTD Q1 2024 vs. YTD Q1 2023	
March 31,		March 31,		Amount	
2024		2023		(dollars in millions)	
(dollars in millions)					
Operating income	Operating income	\$ 1,331	\$ 1,231	\$ 100	8.1 %
Adjusted operating income <sup>(1)</sup>	Adjusted operating income <sup>(1)</sup>	\$ 1,425	\$ 1,281	\$ 144	11.2 %
Operating income		Operating income		Operating income	
		\$ 526	\$ 361	\$ 165	45.7 %
		\$ 505	\$ 400	\$ 105	26.3 %
Adjusted operating income <sup>(1)</sup>		Adjusted operating income <sup>(1)</sup>		Adjusted operating income <sup>(1)</sup>	

(1) For a reconciliation of adjusted operating income by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

U.S. dialysis operating income for the **third** **first** quarter of **2023** **2024** compared to the **second** **fourth** quarter of 2023 and for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** compared to the **nine** **three** months ended **September 30, 2022** **March 31, 2023**, was impacted by center **closure** **costs**, and **severance costs**, **gain on changes in ownership interest**, as described above.

U.S. dialysis operating income and adjusted operating income for the **third** **first** quarter of 2024 compared to the **fourth** quarter of 2023 were positively impacted by **decreases** in charitable contributions, health benefit expense, other direct operating expenses associated with our dialysis centers, seasonal decreases in purchased services, as well as decreased pharmaceutical unit costs. Operating income and adjusted operating income were negatively impacted by increased compensation expenses and additional depreciation related to corporate IT projects. Operating income and adjusted operating income for the **first** quarter of 2024 were also negatively impacted by decreased average patient service revenue per treatment and dialysis treatments, as described above.

U.S. dialysis operating income and adjusted operating income for the **three** months ended **March 31, 2024** compared to the **three** months ended **March 31, 2023** were positively impacted by an increase in average patient service revenue per treatment and dialysis treatments, as described above. Operating income and adjusted operating income for the **three** months ended **March 31, 2024** were also positively impacted by decreases in **minor equipment expense**, **utilities expense**, as described above, **pharmaceutical costs**, **contract wages**, **depreciation expense related to IT projects**, as well as **decreased professional fees** and **long-term incentive compensation**. Operating income and adjusted **other direct** operating income were negatively impacted by **increased compensation expenses** **health benefit expenses**, **insurance costs**, associated with our dialysis centers, contributions to our **charitable foundation organizations** and **IT-related costs**.

U.S. dialysis operating income and adjusted operating income for the **nine** **months** ended **September 30, 2023** were positively impacted by **increased average patient service revenue per treatment**, as described above. U.S. dialysis operating income and adjusted operating income were also positively impacted by **decreases in pharmaceutical costs**, **contract wages** and **advocacy costs**, as described above. **wages**. Operating income and adjusted operating income were negatively impacted by **increases in compensation expenses**, **decreased gains on sale** and **decreased dialysis treatments**, **each advocacy costs**, including the **refund** described above. U.S. dialysis operating income and adjusted operating income were also impacted by **increases in travel costs**, **above**, **additional depreciation related to corporate IT projects**, as well as **increased IT-related costs**, **repairs and maintenance expense**, **medical supplies expense**, **utilities expense**, as described above. **professional fees** and **contributions to our charitable foundation**, **medical supplies expense**.

#### Other—Ancillary services

Our other operations include ancillary services that are primarily aligned with our core business of providing dialysis services to our network of patients. As of **September 30, 2023** **March 31, 2024**, these consisted principally of our U.S. IKC business, certain U.S. other ancillary businesses (including our clinical research programs, transplant software business, and venture investment group), and our international operations.

These ancillary services generated revenues of approximately **\$363** million and **\$938** million **\$342** million in the **third** **first** quarter of **2023** and **nine** **months** ended **September 30, 2023**, **respectively**, **2024**, representing approximately **12%** and **10%** **11%** of our consolidated **revenues**, **respectively**, **revenues**.

As of **September 30, 2023** **March 31, 2024**, DaVita IKC provided integrated care and disease management services to approximately **59,000** **68,600** patients in risk-based integrated care arrangements and to an additional **16,000** **14,200** patients in other integrated care arrangements. We also expect to add additional service offerings to our business and pursue additional strategic initiatives in the future as circumstances warrant, which could include, among other things, healthcare services not related to **dialysis**, **kidney disease**.

For a discussion of the risks related to IKC and our ancillary services, see the discussion in the risk factors in Part I, Item 1A Risk Factors of our **2022** **2023** 10-K under the headings, **"The U.S. integrated kidney care, U.S. other ancillary services and international operations that we operate or invest in now or in the future..."** and **"If we are not able to successfully implement our strategy with respect to our integrated kidney care and value-based care initiatives..."**

As of **September 30, 2023** **March 31, 2024**, our international dialysis operations provided dialysis and administrative services through a total of **359** **427** outpatient dialysis centers located in **11** **12** countries outside of the United States.

#### Ancillary services results of operations

		Three months ended		Q3 2023 vs. Q2 2023							
		September 30, 2023	June 30, 2023	Amount	Percent						
		(dollars in millions)									
Three months ended						Three months ended	Q1 2024 vs. Q4 2023				
						March 31, 2024	December 31, 2023				
						Amount	Percent				
						(dollars in millions)					
Revenues:	Revenues:										
U.S. IKC											
U.S. IKC	U.S. IKC	\$ 158	\$ 94	\$ 64	68.1 %	\$ 116	\$ 160	\$ (44)	(27.5)	(27.5)	%
U.S. other ancillary	U.S. other ancillary	4	7	(3)	(42.9)%	6	7	(1)	(1)	(14.3)	(14.3)%
International	International	200	190	10	5.3 %	219	194	25	25	12.9	12.9 %
Total ancillary services revenues	Total ancillary services revenues	\$ 363	\$ 292	\$ 71	24.3 %	\$ 342	\$ 361	\$ (19)	(5.3)	(5.3)	(5.3) %
Operating (loss) income:	Operating (loss) income:										
Operating (loss) income:											
U.S. IKC											
U.S. IKC	U.S. IKC	\$ 11	\$ (39)	\$ 50	128.2 %	\$ (26)	\$ 27	\$ (53)	(196.3)	(196.3)	%
U.S. other ancillary	U.S. other ancillary	(2)	(2)	—	— %	(2)	(19)	(19)	17	17	89.5 %
International <sup>(1)</sup>	International <sup>(1)</sup>	19	20	(1)	(5.0)%	16	1	1	15	15	1,500.0 %
Total ancillary services operating income (loss)		\$ 28	\$ (22)	\$ 50	227.3 %						
Total ancillary services operating (loss) income	Total ancillary services operating (loss) income					\$ (12)	\$ 10	\$ (22)			(220.0) %
Adjusted operating (loss) income <sup>(2)</sup> :	Adjusted operating (loss) income <sup>(2)</sup> :										
Adjusted operating (loss) income <sup>(2)</sup> :											
Adjusted operating (loss) income <sup>(2)</sup> :											
U.S. IKC											
U.S. IKC	U.S. IKC	\$ 11	\$ (40)	\$ 51	127.5 %	\$ (26)	\$ (28)	\$ 2	7.1	7.1	%
U.S. other ancillary	U.S. other ancillary	(2)	(2)	—	— %	(2)	—	(2)	(2)	—	— %
International <sup>(1)</sup>	International <sup>(1)</sup>	19	20	(1)	(5.0)%	16	1	1	15	15	1,500.0 %

Total ancillary services adjusted operating income (loss)	Total ancillary services adjusted operating income (loss)	Total ancillary services adjusted operating income (loss)	\$ 28	\$ (22)	\$ 50	227.3 %	\$ (12)	\$	\$ (27)	\$	\$ 15	55.6	55.6	%
---	---	---	-------	---------	-------	---------	---------	----	---------	----	-------	------	------	---

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

(1) The reported operating income and adjusted operating income for the three months ended **September 30, 2023** **March 31, 2024** and **June 30, 2023** **December 31, 2023** includes foreign currency gains (**losses**) embedded in equity method income recognized from our APAC JV of approximately **\$0.4 million** **\$1.5 million** and **\$1.2 million**, **(\$2.5) million**, respectively.

(2) For a reconciliation of adjusted operating (loss) income by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

YTD Q3 2023 vs.																											
		Nine months ended		YTD Q3 2022																							
		September	September																								
		30,	30,																								
		2023	2022	Amount																							
(dollars in millions)																											
Three months ended																											
March 31,																											
2024																											
(dollars in millions)																											
Revenues:	Revenues:																										
U.S. IKC	U.S. IKC																										
U.S. IKC	U.S. IKC																										
U.S. IKC	U.S. IKC	\$ 351	\$ 276	\$ 75	27.2 %	\$ 116	\$ 98	\$ 18	18.4	\$ 18.4	\$ 18.4	%															
U.S. other ancillary	U.S. other ancillary	18	17	1	5.9 %	U.S. other ancillary	6	7	7	(1)	(1)	(14.3)	(14.3)	(14.3)	%												
International	International	569	523	46	8.8 %	International	219	179	179	40	40	22.3	22.3	22.3	%												
Total ancillary services revenues	Total ancillary services revenues	\$ 938	\$ 816	\$ 122	15.0 %	Total ancillary services revenues	\$ 342	\$ 284	\$ 58	20.4	20.4	20.4	20.4	20.4	%												
Operating (loss) income:	Operating (loss) income:																										
Operating (loss) income:	Operating (loss) income:																										
U.S. IKC	U.S. IKC																										
U.S. IKC	U.S. IKC	\$ (66)	\$ (90)	\$ 24	26.7 %	(26)	\$ (37)	\$ 11	29.7	29.7	29.7	%															
U.S. other ancillary	U.S. other ancillary	(7)	(8)	1	12.5 %	U.S. other ancillary	(2)	(3)	(3)	1	1	33.3	33.3	33.3	%												
International <sup>(1)</sup>	International <sup>(1)</sup>	54	41	13	31.7 %	International <sup>(1)</sup>	16	15	15	1	1	6.7	6.7	6.7	%												
Total ancillary services operating loss	Total ancillary services operating loss	\$ (18)	\$ (57)	\$ 39	68.4 %	Total ancillary services operating loss	\$ (12)	\$ (25)	\$ 13	52.0	52.0	52.0	52.0	52.0	%												
Adjusted operating (loss) income <sup>(2)</sup> :	Adjusted operating (loss) income <sup>(2)</sup> :																										
Adjusted operating (loss) income <sup>(2)</sup> :	Adjusted operating (loss) income <sup>(2)</sup> :																										

Adjusted operating (loss) income <sup>(2)</sup> :	U.S. IKC	U.S. IKC	\$ (65)	\$ (90)	\$ 25	27.8 %	\$	(26)	\$	\$ (37)	\$	\$ 11	29.7	29.7	%
U.S. IKC	U.S. IKC	U.S. IKC													
U.S. other ancillary	U.S. other ancillary	U.S. other ancillary	(7)	(8)	1	12.5 %	U.S. other ancillary	(2)	(3)	(3)	1	1	1	33.3	33.3 %
International <sup>(1)</sup>	International <sup>(1)</sup>	International <sup>(1)</sup>	54	41	13	31.7 %	International <sup>(1)</sup>	16	15	15	1	1	1	6.7	6.7 %
Total ancillary services adjusted operating loss	Total ancillary services adjusted operating loss	Total ancillary services adjusted operating loss	\$ (18)	\$ (57)	\$ 39	68.4 %	Total ancillary services adjusted operating loss	\$ (12)	\$ (24)	\$ 12	50.0	50.0	50.0	%	%

Certain columns, rows or percentages may not sum due to the presentation of rounded numbers.

(1) The reported operating income and adjusted operating income for the **nine** three months ended **September 30, 2023** **March 31, 2024** and **September 30, 2022** **March 31, 2023** includes foreign currency gains (**losses**) embedded in equity method income recognized from our Asia Pacific joint venture (APAC JV) of approximately **\$1.0 million** **\$1.5 million** and **\$4.7 million**, **\$(0.7) million**, respectively.

(2) For a reconciliation of adjusted operating (loss) income by reportable segment, see "Reconciliations of Non-GAAP measures" section below.

#### Revenues

IKC revenues for the **third** first quarter of **2023** **increased** **2024 decreased** compared to the **second** fourth quarter of 2023 due to a net **increase** **decrease** in shared savings and from our value-based care (VBC) contracts, partially offset by increased revenues from our special needs plans. Other U.S. other ancillary revenues for the **third** first quarter of 2023 **decreased** **2024 remained relatively flat** compared to the **second** fourth quarter of 2023. International revenues for the first quarter of 2024 increased compared to the fourth quarter of 2023 due to a **decrease** **acquired and non-acquired treatment growth, average reimbursement rate increases** in revenues certain countries, and additional reserves in our clinical research programs. International revenues for the **third** fourth quarter of 2023 **increased** compared to the second quarter of 2023 due to increased treatments primarily from one additional treatment day, as well as acquisition-related growth, for amounts deemed uncollectible.

IKC revenues for the **nine** three months ended **September 30, 2023** **March 31, 2024** increased compared to the **nine** three months ended **September 30, 2022** **March 31, 2023** due to a net increase in shared savings and revenues related to our special needs programs. Other savings. U.S. other ancillary services revenues for the **nine** three months ended **September 30, 2023** **March 31, 2024** remained relatively flat compared to the **nine** three months ended **September 30, 2022** **March 31, 2023**. Our international revenues for the **nine** three months ended **September 30, 2023** **March 31, 2024** increased from the **nine** three months ended **September 30, 2022** **March 31, 2023** due to acquisition-related acquired and non-acquired treatment growth as well as and average reimbursement rate increases in certain countries.

#### Charges impacting operating income - severance

**IKC adjustment.** During the fourth quarter of 2023, IKC revenues were affected by the lifting of certain revenue recognition constraints for some of our VBC contracts with health plans, allowing us to recognize approximately \$55 million in incremental shared savings revenues compared to what we would have recognized under prior year constraints.

#### Severance and other costs

During the fourth quarter of 2022, similar to U.S. dialysis, we committed to a plan to increase efficiencies and cost savings in certain general and administrative support functions and other overhead costs. As a result of this plan, we recognized expenses related to termination and other benefit commitments in our IKC business of **\$0.4 million** **\$0.4 million** during the **nine** three months ended **September 30, 2023** **March 31, 2023**.

**Goodwill impairment charge and related items.** During the fourth quarter of 2023, we recognized a goodwill impairment charge of \$26.1 million in our transplant software business as part of its annual goodwill impairment assessment. We also recognized a gain of \$7.7 million due to a reduction in the estimated value of earn-out obligations from our original acquisition of this business. This impairment charge and related gain resulted from a reduction in estimated fair value for the business driven primarily from the business not achieving its revenue targets, with reduced revenue expectations for future years, as well as an increase in the risk-free rate.

#### Operating income (loss) and adjusted operating income (loss)

##### IKC operating income and adjusted operating (loss) income

Our IKC operating results were impacted by the IKC adjustment, as described above. IKC operating results and adjusted operating loss for the **third** first quarter of **2023** **2024** compared to the **second** fourth quarter of 2023 were also impacted by increased revenues as described above, from our special needs plans partially offset by increased medical costs expenses for our special needs plans and continued investments in our integrated care support functions. Other plans. Our U.S. other ancillary services operating loss was impacted by a goodwill impairment charge and

related gain, as described above. U.S. other ancillary services operating loss and adjusted operating loss for the **third** first quarter of 2023 remained **2024 were otherwise relatively flat** compared to the **second** fourth quarter of 2023. International operating income and adjusted operating income for the **third** first quarter of 2023 decreased **2024 increased** from the **second** fourth quarter of 2023 primarily due to favorable changes in the second quarter related to fair value of contingent consideration associated with prior acquisitions, partially

offset by increased revenues, as described above, and decreases increases in equity income resulting from fluctuations in foreign currency at our APAC JV, JV, partially offset by acquisition-related costs.

IKC operating loss and adjusted operating loss for the nine three months ended September 30, 2023 March 31, 2024 compared to the nine three months ended September 30, 2022 March 31, 2023 decreased, primarily due to increases in revenue, as described above, partially offset by continued investments in our integrated care support functions. Other U.S. ancillary services operating loss and adjusted operating loss for the nine three months ended September 30, 2023 March 31, 2024 remained relatively flat compared to the nine three months ended September 30, 2022 March 31, 2023. International operating income and adjusted operating income for the nine three months ended September 30, 2023 increased March 31, 2024 remained relatively flat compared to the nine three months ended September 30, 2022 March 31, 2023 primarily driven by increases in revenue, as described above, partially offset by decreases and increases in equity income resulting from fluctuations in foreign currency at our APAC JV, offset by acquisition-related costs, as well as increases in professional fees and other direct operating expenses associated with our international dialysis centers, compensation expenses.

#### Corporate administrative support

	Three months ended		Q3 2023 vs. Q2 2023	
	September 30, 2023	June 30, 2023	Amount	Percent
Corporate administrative support	\$ (41)	\$ (34)	\$ (7)	(20.6)%

	Three months ended		Q1 2024 vs. Q4 2023	
	March 31, 2024	December 31, 2023	Amount	Percent
Corporate administrative support	\$ (30)	\$ (63)	\$ 33	52.4 %

	Nine months ended		YTD Q3 2023 vs. YTD Q3 2022	
	September 30, 2023	September 30, 2022	Amount	Percent
Corporate administrative support	\$ (100)	\$ (91)	\$ (9)	(9.9)%

	Three months ended		YTD Q1 2024 vs. YTD Q1 2023	
	March 31, 2024	March 31, 2023	Amount	Percent
Corporate administrative support	\$ (30)	\$ (25)	\$ (5)	(20.0)%

*Accruals for legal matters.* During the quarter ended December 31, 2023, we recorded a charge of \$29 million for a legal matter within corporate administrative support.

Corporate administrative support expenses for the quarter ended September 30, 2023 March 31, 2024 compared to the quarter ended June 30, 2023 and December 31, 2023 decreased primarily due to an accrual for a legal matter recorded in the fourth quarter of 2023, as described above, as well as decreased long-term incentive compensation. Corporate administrative support expenses for the nine three months ended September 30, 2023 March 31, 2024 compared to the nine three months ended September 30, 2022 March 31, 2023 increased primarily due to increased legal fees, compensation expenses and professional fees, partially offset by decreased long-term incentive compensation.

#### Corporate-level charges

	Three months ended		Three months ended		Q1 2024 vs. Q4 2023	
	March 31, 2024		March	December	Amount	Percent
			31, 2024	31, 2023		
Debt expense		Debt expense	\$ 99	\$ 96	\$ 3	3.1 %
<b>Three months ended Q3 2023 vs. Q2 2023</b>						
	September					
	30, 2023	June 30, 2023				
	Amount	Amount	Percent			

Debt expense	\$ 98	\$104	\$ (6)	(5.8)%									
Debt extinguishment and modification costs	\$ —	\$ 8	\$ (8)	(100.0)%									
Other (loss) income, net													
Other (loss) income, net													
Other (loss) income, net	Other (loss) income, net	\$ (20)	\$ 1	\$ (21) (2,100.0)%	\$ (13)	\$	\$ (5)	\$	\$ (8)	(160.0)	(160.0)	%	
Effective income tax rate	Effective income tax rate	18.2 %	16.5 %	1.7 %	Effective income tax rate	17.7 %	20.2 %						(2.5) %
Effective income tax rate	Effective income tax rate				Effective income tax rate								
attributable to	attributable to				attributable to								
DaVita Inc. <sup>(1)</sup>	DaVita Inc. <sup>(1)</sup>	21.8 %	21.3 %	0.5 % <sup>(1)</sup>		21.5 %	29.0 %						(7.5) %
Net income attributable to	Net income attributable to												
noncontrolling interests	noncontrolling interests	\$ 63	\$ 68	\$ (5) (7.4)%	noncontrolling interests	\$ 66	\$	\$ 80	\$	\$ (14)	(17.5)	(17.5)	%

(1) For a reconciliation of our effective income tax rate attributable to DaVita Inc., see "Reconciliations of Non-GAAP measures" section below.

Three months ended				Three months ended				YTD Q1 2024 vs. YTD Q1 2023		
March 31, 2024				March 31, 2024		March 31, 2023				
(dollars in millions)								(dollars in millions)		
Debt expense		Debt expense		\$ 99	\$101	\$ (2)	(2.0)	%		
YTD Q3 2023 vs.										
Nine months ended		YTD Q3 2022								
September		September								
30,		30,								
2023		2022		Amount		Percent				
(dollars in millions)										
Debt expense	\$302	\$256	\$ 46	18.0	%					
Debt extinguishment and modification costs	\$ 8	\$ —	\$ 8	100.0	%					
Other loss, net	\$ (15)	\$ (8)	\$ (7)	(87.5)	%					
Other (loss) income, net										
Other (loss) income, net										
Other (loss) income, net						\$ (13)	\$ 4	\$ (17)	(425.0)	%
Effective income tax rate	Effective income tax rate	18.2 %	20.0 %	(1.8)%	Effective income tax rate	17.7 %	20.5 %		(2.8)	%
Effective income tax rate attributable to DaVita Inc. <sup>(1)</sup>	Effective income tax rate attributable to DaVita Inc. <sup>(1)</sup>	22.9 %	24.9 %	(2.0)%	Effective income tax rate attributable to DaVita Inc. <sup>(1)</sup>	21.5 %	27.5 %		(6.0)	%
Net income attributable to noncontrolling interests	Net income attributable to noncontrolling interests	\$186	\$163	\$ 23	14.1 %	\$ 66	\$ 55	\$ 11	20.0	20.0 %

(1) For a reconciliation of our effective income tax rate attributable to DaVita Inc., see "Reconciliations of Non-GAAP measures" section below.

#### Debt expense

Debt expense for the **third** first quarter of 2024 compared to the **fourth** quarter of 2023 **compared to the second quarter of 2023 decreased** increased primarily due to **decreases** **increases** in our weighted average outstanding credit facility balance and our weighted average effective interest rate. Debt expense for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** compared to the **nine** **three** months ended **September 30, 2022** **increased** **March 31, 2023 decreased** primarily due to an increase in our weighted average effective interest rate, partially offset by a decrease in our weighted average outstanding credit facility balance.

Our overall weighted average effective interest rate for the three months ended **September 30, 2023** **March 31, 2024** was **4.61%** **4.51%** compared to **4.67%** **4.45%** for the three months ended **June 30, 2023** **December 31, 2023**. See Note 7 to the condensed consolidated financial statements for further information on the components of our debt.

#### Debt extinguishment and modification costs

The **nine** months ended **September 30, 2023** included debt extinguishment and modification costs of \$8 million related to the refinancing of our prior Term Loan A and prior revolving line of credit. These costs were composed partially of deferred financing costs written off for the portion of this debt considered extinguished and reborrowed and partially of fees incurred as part of this debt refinancing.

#### Other (loss) income, net

Other loss for the **third** first quarter of 2024 increased compared to the **fourth** quarter of 2023 primarily due to **decreases** in interest income and an increase in equity investment losses at Mozarc Medical Holdings LLC (Mozarc). Other loss for the three months ended March 31, 2024 compared to other income for the **second** quarter of 2023 was driven by net losses in Mozarc due to the \$14.0 million gain recognized in the second quarter on the non-cash assets contributed to Mozarc (Mozarc gain). Other loss for the **nine** **three** months ended **September 30, 2023** compared to the **nine** months ended **September 30, 2022** **increased**, **March 31, 2023 was** primarily driven by increased **net equity** investment losses in Mozarc including the Mozarc gain, partially offset by an increase a decrease in interest income, net losses on investments.

#### Effective income tax rate

The effective income tax rate and the effective income tax rate attributable to DaVita Inc. **increased** **decreased** for the **third** first quarter of **2023** **2024** compared to the **second** fourth quarter of 2023 primarily due to a **decrease** **an increase** in benefits recognized **tax benefits** in the first quarter of 2024 from stock-based compensation, a **nontaxable** **non-cash gain on changes in ownership and one-time benefits** **unfavorable adjustment** recognized in connection with the closure of our federal IRS exam **fourth quarter for tax years 2016-2017 in the second quarter**, **nondeductible costs related to a legal matter**. The **increase** **was** partially offset by benefits recognized in the **third** **fourth quarter for finalized tax returns**, in connection with the release of reserves that expired under the statute of limitations.

The effective income tax rate and the effective income tax rate attributable to DaVita Inc. for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** decreased compared to the **nine** **three** months ended **September 30, 2022** **March 31, 2023** primarily due to a **decrease** **an increase** in **forecasted non-deductible advocacy spend** **benefits** **recognized in the first quarter of 2024 from stock-based compensation and a larger benefit recognized for tax returns finalized** **nontaxable non-cash gain on changes in the third quarter of 2023**, **ownership interest**.

#### Net income attributable to noncontrolling interests

The decrease in net income attributable to noncontrolling interests for the **third** first quarter of **2023** **2024** from the **second** fourth quarter of 2023 was due to reduced earnings at certain U.S. dialysis partnerships. The increase in net income attributable to noncontrolling interests for the **nine** **three** months ended **September 30, 2023** **March 31, 2024** from the **nine** **three** months ended **September 30, 2022** **March 31, 2023** was due to increased profitability at certain U.S. dialysis partnerships.

#### Accounts **U.S. dialysis accounts receivable**

Our U.S. dialysis accounts receivable balances at **September 30, 2023** **March 31, 2024** and **December 31, 2022** **December 31, 2023** were **\$1.708 billion** **\$2.180 billion** and **\$1.899 billion** **\$1.632 billion**, respectively, representing approximately **57** **73** and **66** **54** days of revenue outstanding (DSO), respectively. The **decrease** **increase** in DSO is primarily due to **improved collections from certain payers**, **payment collection delays related to the CHC Outage**, described above. Our DSO calculation is based on the current quarter's average revenues per day. There were no significant changes from the **second** **fourth quarter of 2023** to the **third** **first quarter of 2023** **2024** in the carrying amount of accounts receivable outstanding over one year old.

#### Liquidity and capital resources

The following table shows the summary of **summarizes** our major sources and uses of cash, cash equivalents and restricted cash:

		Nine months ended		YTD Q3 2023 vs. YTD	
		September 30,		Q3 2022	
		2023	2022	Amount	Percent
(dollars in millions and shares in thousands)					
		Three months ended March 31,		Three months ended March 31,	
		2024		2023	
(dollars in millions and shares in thousands)					
Net cash provided by operating activities:	Net cash provided by operating activities:				YTD Q1 2024 vs. 1
Net income	Net income				Amount
Net income	Net income				(dollars in millions and shares)

Net income	Net income	\$ 726	\$ 655	\$ 71	10.8 %	\$ 306	\$	\$ 171	\$	\$ 135	\$ 78.9	\$ 78.9	%
Non-cash items in net income	Non-cash items in net income	664	596	68	11.4 %	Non-cash items in net income	199	209	209	(10)	(10)	(4.8)	
Other working capital changes	Other working capital changes	191	32	159	496.9 %	Other working capital changes	(634)	89	89	(723)	(723)	(812.4)	(
Other	Other	(7)	(63)	56	88.9 %	Other	(6)	(6)	(6)	—	—	—	
		\$1,574	\$1,221	\$ 353	28.9 %		\$ (135)	\$ 463		\$ (598)			(
<b>Net cash used in investing activities:</b>	<b>Net cash used in investing activities:</b>												
Capital expenditures:													
Routine maintenance/information technology/other		\$ (287)	\$ (284)	\$ (3)	(1.1)%								
Development and relocations		(122)	(125)	3	2.4 %								
<b>Net cash used in investing activities:</b>	<b>Net cash used in investing activities:</b>												
<b>Net cash used in investing activities:</b>	<b>Net cash used in investing activities:</b>												
Maintenance capital expenditures <sup>(1)</sup>													
Maintenance capital expenditures <sup>(1)</sup>													
Maintenance capital expenditures <sup>(1)</sup>						\$ (85)		\$ (109)		\$ 24		22.0 %	
Development capital expenditures <sup>(2)</sup>						Development capital expenditures <sup>(2)</sup>	(36)	(39)		3		7.7 %	
Acquisition expenditures	Acquisition expenditures	(8)	(44)	36	81.8 %	Acquisition expenditures	(105)	—	—	(105)	(105)	(100.0)	(
Proceeds from sale of self-developed properties	Proceeds from sale of self-developed properties	5	107	(102)	(95.3)%	Proceeds from sale of self-developed properties	3	—	—	3	3	100.0	
Other	Other	(192)	(71)	(121)	(170.4)%		\$ (604)	\$ (417)	\$ (187)	(44.8)%			
Other							8	\$ (215)	31	\$ (117)	(23)	\$ (98)	(74.2) %
<b>Net cash used in financing activities:</b>	<b>Net cash used in financing activities:</b>												
Debt (payments) net of issuances		\$ (521)	\$ 149	\$ (670)	(449.7)%								
Deferred and debt related financing costs		(53)	—	(53)	(100.0)%								
<b>Net cash used in financing activities:</b>	<b>Net cash used in financing activities:</b>												
<b>Net cash used in financing activities:</b>	<b>Net cash used in financing activities:</b>												

Certain columns or rows may not sum due to the presentation of rounded numbers.

(1) Maintenance capital expenditures represent capital expenditures to maintain the productive capacity of the business and include those made for investments in information technology, dialysis center renovations, capital asset replacements, and any other capital expenditures that are not development or acquisition expenditures.

(2) Development capital expenditures represent capital expenditures (other than acquisition expenditures) made to expand the productive capacity of the business and include those for new U.S. and international dialysis center developments, dialysis center expansions, and new or expanded contracted hospital operations.

(3) For a reconciliation of our free cash flow, see "Reconciliations of Non-GAAP measures" section below.

### *Consolidated cash flows*

Consolidated cash flows from operating activities during the nine three months ended September 30, 2023 increased March 31, 2024 decreased compared to the nine three months ended September 30, 2022 March 31, 2023 primarily due to a decrease in cash collections from the CHC Outage, as described above, as well as decreased other working capital items, partially offset by improvements in operating results, results.

CHC began to restore claims submission functionality on March 28, 2024 and we have resumed submission of most of our commercial claims through CHC's platform, although we continue to experience payment collection delays. As of March 31, 2024, the CHC Outage, described above, affected our ability to bill providers and resulted in an increase in our patient accounts receivable balances and DSO, which ultimately negatively impacted our net cash collections, decreases provided by operating activities for the first quarter of 2024, and resulted in an increase in outstanding borrowings under our revolving credit facility. Subsequent to March 31, 2024, accounts receivable balances and DSO have declined and are expected to continue to decline over the next few months as we continue claims submissions and cash taxes and other collections. As needed, we expect to fund any increase in working capital items.

resulting from the billing and payment disruption through the temporary assistance funding program, cash on hand and draws on our revolving credit facility.

Free cash flow during the **nine** three months ended **September 30, 2023** increased from **March 31, 2024** was negative as compared to the **nine** three months ended **September 30, 2022** **March 31, 2023** which was positive primarily due to **an increase** **a decrease** in net cash provided by operating activities, as described above, partially offset by **an increase** **a decrease** in **distributions of noncontrolling interest and decreases in proceeds from sale of self-developed properties, capital expenditures.**

Significant uses of cash during the period included **regularly scheduled principal payments under our senior secured credit facilities totaling approximately \$8 million on Term Loan A-1 and \$7 million on Term Loan B-1**, as well as additional required payments under other debt arrangements. Significant sources of cash during the period included net draws on our revolving line of credit of \$765 million. As of the date of this filing, we have utilized funds related to the CHC Funding Arrangement, described above, along with cash on hand to pay off the \$765 million previously outstanding on our revolving line of credit.

By comparison, the same period in 2023 included net debt payments which consisted of the **pay-off** **repayment of the remaining principal balance outstanding \$165 million** on our prior **Term Loan A** and prior **revolving line of credit** in the amount of \$1,444 million and \$150 million, respectively. Other uses of cash included **regularly scheduled and other mandatory principal payments under our senior secured credit facilities totaling approximately \$54 million on our prior Term Loan A** \$8 million on our new **Term Loan A-1**, described below, \$50 million on **Term Loan B-1**, additional net repayments of \$15 million on our revolving line of credit, as well as additional required payments under other debt arrangements. Additionally, we recognized financing cash outflows of \$30 million in deferred financing costs related to the Amendments to the Senior Secured Credit Agreement and \$23 million in cap premium fees for our 2023 forward interest cap agreements. Significant sources of cash during the period included the refinancing of the **Term Loan A** and **revolving line of credit** with a secured **Term Loan A-1** facility in the aggregate principal amount of \$1,250 million.

By comparison, the same period in 2022 included a net draw of \$275 million on our prior revolving line of credit, net debt payments which consisted of regularly scheduled mandatory principal payments under our senior secured credit facilities totaling approximately \$66 million on our prior **Term Loan A** and \$21 million \$36 million on **Term Loan B-1**, as well as additional required payments under other debt arrangements. **In addition, during the nine months ended September 30, 2022 we used cash to repurchase 8,094,661 shares of our common stock.**

#### Dialysis center footprint

The table below shows the footprint of our dialysis operations by number of dialysis centers owned or operated:

		U.S.		International									
				Three months		Nine months							
				ended	ended	ended	ended						
		September 30,											
		2023	2022	2023	2022	2023	2022						
		U.S.											
		U.S.											
		U.S.											
Three months ended				International									
March 31,													
2024													
2024													
2024													
Number of centers operated at beginning of period													
Number of centers operated at beginning of period													
Number of centers operated at beginning of period	Number of centers operated at beginning of period	2,703	2,810	2,724	2,815	353	349						
Acquired centers	Acquired centers	—	5	—	5	2	3						
Acquired centers	Acquired centers	—	5	—	5	2	3						
Developed centers	Developed centers	5	6	18	33	3	1						
Developed centers	Developed centers	5	6	18	33	3	1						

Net change in non-owned managed or administered centers <sup>(1)</sup>	Net change in non-owned managed or administered centers <sup>(1)</sup>	1	(1)	3	(1)	1	2	1	5
Net change in non-owned managed or administered centers <sup>(1)</sup>									
Net change in non-owned managed or administered centers <sup>(1)</sup>									
Sold and closed centers <sup>(2)</sup>									
Sold and closed centers <sup>(2)</sup>									
Sold and closed centers <sup>(2)</sup>	Sold and closed centers <sup>(2)</sup>	—	(9)	(3)	(16)	—	(2)	(2)	(2)
Closed centers <sup>(3)</sup>	Closed centers <sup>(3)</sup>	(15)	(35)	(48)	(60)	—	(1)	(2)	(1)
Closed centers <sup>(3)</sup>									
Closed centers <sup>(3)</sup>									
Number of centers operated at end of period	Number of centers operated at end of period	2,694	2,776	2,694	2,776	359	352	359	352
Number of centers operated at end of period									
Number of centers operated at end of period									

(1) Represents dialysis centers which we manage or provide administrative services to but in which we own a noncontrolling equity interest or which are wholly-owned by third parties, including our APAC JV centers.

(2) Represents dialysis centers that were sold and/or closed for which the majority of patients were not retained.

(3) Represents dialysis centers that were closed for which the majority of patients were retained and transferred to one of our other existing outpatient dialysis centers.

#### Stock repurchases

The following table summarizes our common stock repurchases during the three months ended March 31, 2024:

	Three months ended March 31, 2024		
	Shares repurchased	Amount paid (in millions)	Average paid per share
Open market repurchases:	2,119,415	\$ 240	\$ 112.76

The Company did not repurchase any shares during the three months ended March 31, 2023.

#### Available liquidity

As of September 30, 2023 March 31, 2024, we had an undrawn \$735 million available and \$765 million drawn on our \$1.5 billion revolving line of credit under our senior secured credit facilities of \$1.5 billion facilities. Credit available under this new revolving line of credit is reduced by the amount of any letters of credit outstanding thereunder, of which there were none as of September 30, 2023 March 31, 2024. We separately had approximately \$151 million \$154 million in letters of credit outstanding under a separate bilateral secured letter of credit facility.

See Note 7 to the condensed consolidated financial statements for components of our long-term debt and their interest rates. We may from time to time seek to obtain funds or refinance existing debt through additional debt financings or other capital alternatives.

We believe that our cash flow from operations and other sources of liquidity, including from amounts available under our senior secured credit facilities and our access to the capital markets, will be sufficient to fund our scheduled debt service under the terms of our debt agreements and other obligations for the foreseeable future, including the next 12 months. From time to time, depending on market conditions, our capital requirements and the availability of financing, among other things, we may seek to refinance our existing debt and may incur additional indebtedness. Our primary recurrent sources of liquidity are cash from operations and cash from borrowings, which are subject to general, economic,

financial, competitive, regulatory and other factors that are beyond our control, as described in Part I, Item 1A Risk Factors of our 2022 2023 10-K.

## Reconciliations of Non-GAAP measures

The following tables provide reconciliations of adjusted operating income (loss) to operating income (loss) as presented on a U.S. generally accepted accounting principles (GAAP) basis for our U.S. dialysis reportable segment as well as for our U.S. IKC business, our U.S. other ancillary services, our international business, and for our total ancillary services which combines them and is disclosed as our other segments category, in addition to our corporate administrative support. These non-GAAP or "adjusted" measures are presented because management believes these measures are useful adjuncts to, but not alternatives for, our GAAP results.

Specifically, management uses adjusted operating income (loss) to compare and evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe this non-GAAP measure is also useful to investors and analysts in evaluating our performance over time and relative to competitors, as well as in analyzing the underlying trends in our business. We also believe this presentation enhances a user's understanding of our normal operating income by excluding certain items which we do not believe are indicative of our ordinary results of operations.

In addition, our effective income tax rate on income attributable to DaVita Inc. excludes noncontrolling owners' income, which primarily relates to non-tax paying entities. We believe this adjusted effective income tax rate is useful to management, investors and analysts in evaluating our performance and establishing expectations for income taxes incurred on our ordinary results attributable to DaVita Inc.

Finally, our free cash flow represents net cash provided by operating activities less distributions to noncontrolling interests and all capital expenditures (including development capital expenditures **routine and maintenance and information technology capital expenditures**), plus contributions from noncontrolling interests and proceeds from the sale of self-developed properties. Management uses this measure to assess our ability to fund acquisitions and meet our debt service obligations and we believe this measure is equally useful to investors and analysts as an adjunct to cash flows from operating activities and other measures under GAAP.

It is important to bear in mind that these non-GAAP "adjusted" measures are not measures of financial performance under GAAP and should not be considered in isolation from, nor as substitutes for, their most comparable GAAP measures.

Three months ended September 30, 2023									
Ancillary services									
U.S.	U.S.	U.S.			Corporate				
dialysis	IKC	Other	International	Total	administration	Consolidated			
(dollars in millions)									
Three months ended March 31, 2024									
Ancillary services									
U.S.					U.S. dialysis				
U.S. dialysis	IKC					Corporate administration			Consolidated
(dollars in millions)									
(dollars in millions)									
(dollars in millions)									
Operating income	Operating income								
(loss)	(loss)	\$509	\$ 11	\$(2)	\$19	\$28	\$ (41)	\$ 496	
Center closure charges	Center closure charges								
		24						24	
Severance and other costs									
		4					—	5	
Gain on changes in ownership interest									
Adjusted operating income	Adjusted operating income								
(loss)	(loss)	\$537	\$ 11	\$(2)	\$19	\$28	\$ (41)	\$ 525	
Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.									

Three months ended June 30, 2023									
Ancillary services									
U.S.	U.S.	U.S.			Corporate				
dialysis	IKC	Other	International	Total	administration	Consolidated			
(dollars in millions)									
Three months ended December 31, 2023									
Three months ended December 31, 2023									
U.S. dialysis					Ancillary services				
					Corporate administration				Consolidated

		U.S.		IKC													
(dollars in millions)																	
(dollars in millions)																	
(dollars in millions)																	
Operating income (loss)	Operating income (loss)	\$461	\$ (39)	\$ (2)	\$20	\$ (22)	\$ (34)	\$ 405									
Center closure charges	Center closure charges	21					21										
Severance and other costs	Severance and other costs	5	—		—	—	5										
Legal matter																	
IKC adjustment																	
Earn-out revaluation																	
Goodwill impairment																	
Adjusted operating income (loss)	Adjusted operating income (loss)	\$487	\$ (40)	\$ (2)	\$20	\$ (22)	\$ (33)	\$ 432									

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Three months ended March 31, 2023									
		Ancillary services				Corporate			
		U.S. dialysis	U.S. IKC	U.S. Other	International	Total	administration	Consolidated	
(dollars in millions)									
Operating income (loss)	\$ 361	\$ (37)	\$ (3)	\$ 15	\$ (25)	\$ (25)	\$ (25)	\$ 312	
Center closure charges	22								22
Severance and other costs	17	—					1		18
Adjusted operating income (loss)	\$ 400	\$ (37)	\$ (3)	\$ 15	\$ (24)	\$ (24)	\$ (24)	\$ 352	

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Three months ended									
		March 31, 2024				December 31, 2023			
(dollars in millions)									
Income before income taxes		\$ 372	\$ 289	\$ 215					
Less: Noncontrolling owners' income primarily attributable to non-tax paying entities		(66)	(77)	(55)					
Income before income taxes attributable to DaVita Inc.		\$ 305	\$ 212	\$ 159					
Income tax expense		\$ 66	\$ 58	\$ 44					
Less: Income tax attributable to noncontrolling interests		—	3	—					
Income tax expense attributable to DaVita Inc.		\$ 66	\$ 61	\$ 44					
Effective income tax rate on income attributable to DaVita Inc.		21.5 %	29.0 %	27.5 %					

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Nine months ended September 30, 2023									
--------------------------------------	--	--	--	--	--	--	--	--	--

	Ancillary services					Corporate	
	U.S. dialysis	U.S. IKC	U.S. Other	International	Total	administration	Consolidated
(dollars in millions)							
Operating income (loss)	\$ 1,331	\$ (66)	\$ (7)	\$ 54	\$ (18)	\$ (100)	\$ 1,213
Center closure charges	67	—	—	—	—	—	67
Severance and other costs	26	—	—	—	—	1	28
Adjusted operating income (loss)	\$ 1,425	\$ (65)	\$ (7)	\$ 54	\$ (18)	\$ (98)	\$ 1,308

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

	Nine months ended September 30, 2022						
	U.S. dialysis	U.S. IKC	U.S. Other	International	Total	Corporate administration	Consolidated
(dollars in millions)							
Operating income (loss)	\$ 1,231	\$ (90)	\$ (8)	\$ 41	\$ (57)	\$ (91)	\$ 1,083
Center closure charges	50	—	—	—	—	—	50
Adjusted operating income (loss)	\$ 1,281	\$ (90)	\$ (8)	\$ 41	\$ (57)	\$ (91)	\$ 1,133

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

	Three months ended				Nine months ended	
	September 30,		June 30,		September 30,	September 30,
	2023	2023	2023	2022	2023	2022
(dollars in millions)						
Income before income taxes	\$ 378	\$ 295	\$ 888	\$ 819		
Less: Noncontrolling owners' income primarily attributable to non-tax paying entities	(63)	(68)	(186)	(163)		
Income before income taxes attributable to DaVita Inc.	\$ 315	\$ 227	\$ 702	\$ 655		
Income tax expense	\$ 69	\$ 49	\$ 162	\$ 164		
Less: Income tax attributable to noncontrolling interests	—	—	(1)	(1)		
Income tax expense attributable to DaVita Inc.	\$ 69	\$ 48	\$ 161	\$ 163		
Effective income tax rate on income attributable to DaVita Inc.	21.8 %	21.3 %	22.9 %	24.9 %		

Certain columns or rows may not sum or recalculate due to the presentation of rounded numbers.

Nine months ended		Three months ended		Three months ended	
September	September	March 31,	March 31,	March 31,	2023
30,	30,	2024	2024	2023	2023
(dollars in millions)					
Net cash provided by operating activities	Net cash provided by operating activities	\$ 1,574	\$ 1,221		
Adjustments to reconcile net cash provided by operating activities to free cash flow:	Adjustments to reconcile net cash provided by operating activities to free cash flow:				

Distributions to noncontrolling interests	Distributions to noncontrolling interests	(203)	(189)
Distributions to noncontrolling interests			
Distributions to noncontrolling interests			
Contributions from noncontrolling interests	Contributions from noncontrolling interests	12	11
Expenditures for routine maintenance and information technology			
Expenditures for development and relocations		(287)	(284)
Maintenance capital expenditures		(122)	(125)
Development capital expenditures			
Proceeds from sale of self-developed properties	Proceeds from sale of self-developed properties	5	107
Free cash flow	Free cash flow	\$ 979	\$ 742

Certain columns or rows may not sum due to the presentation of rounded numbers.

#### Off-balance sheet arrangements and aggregate contractual obligations

In addition to the debt obligations and operating lease liabilities reflected on our balance sheet, we have commitments associated with letters of credit, as well as certain working capital funding obligations associated with our equity investments in nonconsolidated dialysis ventures that we manage and some that we manage which are wholly-owned by third parties. For additional information see Note 8 to the condensed consolidated financial statements.

We also have potential obligations to purchase the noncontrolling interests held by third parties in many of our majority-owned dialysis partnerships and other nonconsolidated entities. These obligations are in the form of put provisions that are exercisable at the third-party owners' discretion within specified periods as outlined in each specific put provision. For additional information on these obligations and how we measure and report them, see Note 12 13 to the condensed consolidated financial statements included in this report and Notes 17 16 and 24 23 to the consolidated financial statements included in our 2022 2023 10-K.

For information on the maturities and other terms of our long-term debt, see Note 7 to the condensed consolidated financial statements.

As of September 30, 2023 March 31, 2024, we have outstanding letters of credit in the aggregate amount of approximately \$151 million \$154 million under a bilateral secured letter of credit facility separate from our senior secured credit facilities.

As of September 30, 2023 March 31, 2024, we have outstanding purchase agreements with various suppliers to purchase set amounts of dialysis equipment, parts, pharmaceuticals and supplies. If we fail to meet the minimum purchase commitments under these contracts during any year, we are required to pay the difference to the supplier, as described further in Note 17 16 to the Company's consolidated financial statements included in the 2022 our 2023 10-K.

On March 5, 2024, we entered into an agreement with Fresenius Medical Care to acquire their dialysis service operations in Chile, Ecuador, Columbia and Brazil. This agreement involves four separate acquisitions, with Chile completed in March 2024 and Ecuador, Columbia and Brazil expected to close at various times throughout 2024. These three remaining acquisitions are subject to customary closing conditions and regulatory approvals as of March 31, 2024. In total, we will make cash payments of approximately \$237 million, subject to certain customary adjustments prior to the closing.

#### New Accounting Standards

See discussion of new accounting standards in Note 14 15 to the condensed consolidated financial statements.

#### Item 3. Quantitative and Qualitative Disclosures about Market Risk

##### Interest rate and foreign currency sensitivity

There has been no material change in the nature of the Company's interest rate risks or foreign currency exchange risks from those described in Part II Item 7A of our Annual Report on Form 10-K for the year ended **December 31, 2022** **December 31, 2023**.

The **tables** table below provides information about our financial instruments that are sensitive to changes in interest rates as of **September 30, 2023** **March 31, 2024**. For further information on the components of the Company's long-term debt and their interest rates, see Note 7 to the condensed consolidated interim financial statements included in this Quarterly Report on Form 10-Q at Part I Item 1.

		Expected maturity date								Expected maturity date	Average interest rate	Fair value <sup>(1)</sup>
		2023	2024	2025	2026	2027	2028	Thereafter	Total	Average interest rate	Fair value <sup>(1)</sup>	
		(dollars in millions)										
		(dollars in millions)										
Long-term debt:	Long-term debt:											
Fixed rate	Fixed rate	\$ 4	\$ 30	\$ 34	\$ 44	\$ 31	\$ 29	\$ 4,391	\$ 4,563	4.42 %	\$ 3,465	
Variable rate	Variable rate	\$ 26	\$ 80	\$ 96	\$ 2,617	\$ 82	\$ 986	\$ 1	\$ 3,888	4.73 %	\$ 3,833	

(1) Represents the fair value of the Company's long-term debt excluding financing leases. See Note 7 to the condensed consolidated financial statements for further details.

During and as of the end of the second quarter, the Company transitioned the variable rate base on its senior secured credit facilities and related hedging interest rate caps from LIBOR to SOFR. This transition involved a SOFR-to-LIBOR rate mismatch between this debt and the 2019 interest rate caps for a portion of the second quarter, but the Company's interest rate hedges remained highly effective throughout the transition and thereafter.

The scheduled principal payments for all debt that bears a variable rate by its terms, including all of Term Loan B-1 and Term Loan A-1, have been included on the variable rate line of the schedule of expected maturities above. Additionally, the principal amounts of Term Loan B-1 and Term Loan A-1 have been included in the calculation of the average variable interest rate presented.

However, principal amounts of **\$2,611 million** **\$2,597 million** for Term Loan B-1 and **\$889 million** **\$903 million** of Term Loan A-1 (the capped debt) are subject to SOFR effectively hedged by our 2019 interest rate cap agreements through June 30, 2024, with additional caps of 2.00% through June 30, 2024, from our 2023 interest rate cap agreements extending for further periods. As of **September 30, 2023** **March 31, 2024**, applicable SOFR rates were above **this the** 2.00%, threshold of our cap agreements making the interest rates on this capped debt "economically fixed", unless or until applicable SOFR rates were to fall back below 2.00% during the remaining term of the caps.

As a result, as of **September 30, 2023** **March 31, 2024**, total fixed and economically fixed debt was **\$8,064 million** **\$8,066 million**, with an average interest rate of 4.30%, while total variable rate debt not subject to caps was **\$388 million** **\$1,113 million** with an average rate of **10.30%** **7.49%**.

See Note 7 for further details on the Company's interest rate cap agreements.

	Notional amount	Contract maturity date							Thereafter	Receive variable	Fair value
		2023	2024	2025	2026	2027	2028				
(dollars in millions)											
2019 cap agreements	\$ 3,500	\$ —	\$ 3,500	\$ —	\$ —	\$ —	\$ —	\$ —	SOFR above 2.00%(1)		\$ 90.0
2023 cap agreements	\$ 200	\$ —	\$ 100	\$ 100	\$ —	\$ —	\$ —	\$ —	SOFR above 3.75%		\$ 2.2
2023 cap agreements	\$ 1,000	\$ —	\$ 250	\$ 750	\$ —	\$ —	\$ —	\$ —	SOFR above 4.00%(2)		\$ 12.4
2023 cap agreements	\$ 1,000	\$ —	\$ 250	\$ 750	\$ —	\$ —	\$ —	\$ —	SOFR above 4.75%(3)		\$ 9.1
2023 cap agreements	\$ 800	\$ —	\$ 400	\$ 400	\$ —	\$ —	\$ —	\$ —	SOFR above 3.75%		\$ 8.8

(1) As defined in the ISDA IBOR Fallbacks Protocol, LIBOR contracts that qualify as derivative instruments transitioned to a SOFR rate plus credit spread adjustment upon LIBOR cessation on June 30, 2023.

(2) Effective January 1, 2025, the maximum rate of 4.00% decreases to 3.75% for these interest rate caps.

(3) Effective January 1, 2025, the maximum rate of 4.75% decreases to 4.00% for these interest rate caps.

#### Item 4. Controls and Procedures

Management has established and maintains disclosure controls and procedures designed to ensure that information required to be disclosed in the reports that it files or submits pursuant to the Securities Exchange Act of 1934 (Exchange Act) as amended is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer (CEO) and Chief Financial Officer (CFO) as appropriate to allow for timely decisions regarding required disclosures.

At the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of the Company's CEO and CFO, of the effectiveness of the design and operation of our disclosure controls and procedures in accordance with the Exchange Act requirements as of **September 30, 2023** **March 31, 2024**. Based upon that evaluation, the CEO and CFO concluded that the Company's disclosure controls and procedures were effective as required by the Exchange Act as of such date for our Exchange Act reports, including this report. Management recognizes that these controls and procedures can provide only reasonable assurance of desired outcomes, and that estimates and judgments are still inherent in the process of maintaining effective controls and procedures.

There was no change in the Company's internal control over financial reporting that was identified during the evaluation that occurred during the fiscal quarter covered by this report that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

## PART II.

### OTHER INFORMATION

#### Item 1. Legal Proceedings

The information required by this Part II, Item 1 is incorporated herein by reference to the information set forth under the caption "**Commitments**" "**Commitments and contingencies**" "**contingencies**" in Note 8 to the condensed consolidated financial statements included in this report.

#### Item 1A. Risk Factors

*There have been no material changes to the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K (2022 (2023 10-K) for the year ended December 31, 2022 December 31, 2023 filed with Securities and Exchange Commission. You should carefully consider the risks included in our 2022 2023 10-K, together with all the other information in this Quarterly Report on Form 10-Q, including the forward-looking statements in Part I, Item 2 of this Quarterly Report on Form 10-Q under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations."*

#### Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

##### Share repurchases

The Company did not repurchase any shares from January 1, 2023 through September 30, 2023. following table summarizes our repurchases of our common stock during the first quarter of 2024.

Period	Total number of shares purchased	Average price paid per share <sup>(1)</sup>	Total number of shares purchased as part of publicly announced plans or programs	Approximate dollar value of shares that may yet be purchased under the plans or programs
(dollars and shares in thousands, except per share data)				
January 1-31, 2024	1,107	\$ 106.73	1,107	\$ 1,193,759
February 1-29, 2024	952	118.91	952	\$ 1,080,479
March 1-31, 2024	60	126.23	60	\$ 1,072,904
	<b>2,119</b>	<b>\$ 112.76</b>	<b>2,119</b>	

(1) Excludes commissions and the 1% excise tax imposed by the Inflation Reduction Act of 2022.

As of **November 7, 2023** **May 2, 2024**, we had approximately **\$1.596 billion** **\$1.073 billion**, excluding excise taxes, available under the current repurchase authorization for additional share repurchases. Although this share repurchase authorization does not have an expiration date, we remain subject to share repurchase limitations including under our current senior secured credit facilities.

#### Item 3. Defaults Upon Senior Securities

None.

#### Item 4. Mine Safety Disclosures

Not applicable.

#### Item 5. Other Information

None. None of our directors or executive officers adopted or terminated a Rule 10b5-1 trading arrangement or adopted or terminated a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the quarter ended March 31, 2024.

#### Item 6. Exhibits

Exhibit
Number

<a href="#">10.1</a>	Form of Performance-Based Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).*ü
<a href="#">10.2</a>	Form of Restricted Stock Unit Agreement (DaVita Inc. 2020 Incentive Award Plan).*ü
<a href="#">10.3</a>	Form of Stock Appreciation Rights Agreement (DaVita Inc. 2020 Incentive Award Plan).*ü
<a href="#">10.4</a>	Share Repurchase Agreement, dated as of April 30, 2024, by and between DaVita Inc. and Berkshire Hathaway Inc.(1)
<a href="#">31.1</a>	Certification of the Chief Executive Officer, dated <a href="#">November 7, 2023</a> <a href="#">May 2, 2024</a> , pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü
<a href="#">31.2</a>	Certification of the Chief Financial Officer, dated <a href="#">November 7, 2023</a> <a href="#">May 2, 2024</a> , pursuant to Rule 13a-14(a) or 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ü
<a href="#">32.1</a>	Certification of the Chief Executive Officer, dated <a href="#">November 7, 2023</a> <a href="#">May 2, 2024</a> , pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü
<a href="#">32.2</a>	Certification of the Chief Financial Officer, dated <a href="#">November 7, 2023</a> <a href="#">May 2, 2024</a> , pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. ü
101.INS	XBRL Instance Document - The Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. ü
101.SCH	Inline XBRL Taxonomy Extension Schema Document. ü
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document. ü
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document. ü
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document. ü
101.PRE	Inline XBRL Taxonomy Extension Presentation, Linkbase Document. ü
104	Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). ü

ü Included in this filing.

\* Management contract or executive compensation plan or arrangement.

(1) Filed on May 1, 2024 as an exhibit to the Company's Current Report on Form 8-K.

#### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

DAVITA INC.

BY: \_\_\_\_\_ /s/ CHRISTOPHER M. BERRY  
Christopher M. Berry  
Chief Accounting Officer\*

Date: November 7, 2023 May 2, 2024

\* Mr. Berry has signed both on behalf of the Registrant as a duly authorized officer and as the Registrant's principal accounting officer.

4442

Exhibit 10.1

**DaVita Inc.**

**Performance-Based Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan**

This **Performance-Based Restricted Stock Unit Agreement** (this "Agreement") is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the "Company"), and the Grantee indicated below pursuant to the **DaVita Inc. 2020 Incentive Award Plan** (the "Plan").

**Primary Terms**

<b>Grantee:</b>	«Grantee»
<b>Address:</b>	«Address_1» «City», «State» «Zip»
<b>Grant Date:</b>	«Grant Date»
<b>Performance Conditions:</b>	As indicated on <u>Exhibit B</u>
<b>Performance Period:</b>	As indicated on <u>Exhibit B</u>
<b>Vesting Conditions:</b>	As indicated on <u>Exhibit B</u>
<b>Vesting Date:</b>	«Vesting_Date»
<b>Target Number of Units:</b>	«PSU_Award»
<b>Plan Name:</b>	2020 Incentive Award Plan
<b>Plan ID#:</b>	2020

This Agreement includes this cover page and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

Exhibit A – General Terms and Conditions Exhibit B – Performance and Vesting Conditions  
Exhibit C – [Performance Conditions Intentionally Omitted]

Grantee hereby expressly acknowledges and agrees that he/she/they is an employee at will and may be terminated by the Company or its applicable Affiliate at any time, with or without cause. By accepting this Award, Grantee hereby acknowledges he/she/they has a copy of the Plan, and accepts and agrees to the terms and provisions of this Agreement and the Plan. Capitalized terms that are used but not defined in this Agreement shall have the meanings set forth in the Plan.

IN WITNESS WHEREOF, the Company and the Grantee have accepted this Agreement effective as of the Grant Date.

\_\_\_\_\_  
DaVita Inc.

\_\_\_\_\_  
Grantee\*

\*If permitted by the Company, this Agreement  
may be accepted electronically by the Grantee  
pursuant to the Company's third-party stock plan administrator's procedures.

**DaVita Inc.**

**Performance-Based Restricted Stock Unit Agreement**

**Exhibit A – General Terms and Conditions**

For valuable consideration, the receipt of which is acknowledged, the parties hereto agree as follows:

- 1. Grant of Performance Stock Units.** The Company hereby grants to Grantee this award (the "Award") of the target number of performance-based restricted stock units indicated on the front page ("Performance Stock Units") under the Plan, subject to adjustment, forfeiture and the other terms and conditions set forth below and in the Plan. This Award represents Grantee's right to receive shares of common stock of the Company ("Common Stock"), subject to Grantee's fulfillment of the performance, vesting and other conditions set forth in this Agreement.
- 2. Performance and Vesting Conditions.** The number of Performance Stock Units that may be earned by and for which shares of Common Stock ("Shares") become issuable to Grantee (the "Earned Units") shall be based upon the achievement of the Performance Criteria as reviewed and approved by the Administrator and reflected in Exhibit B (the "Performance Goals") over the Performance Period or periods reflected in Exhibit B (the "Performance Period") and the remaining terms of this Agreement (the "Vesting Conditions"). The determination by the Administrator with respect to the achievement of the Performance Goals shall be made as soon as administratively practicable following the end of the applicable Performance Period after all necessary Company information is available.
- 3. Conversion of Performance Stock Units and Stock Issuance.** To the extent that the Administrator determines that some or all of the Performance Goals and the Vesting Conditions have been achieved, then as of the applicable Vesting Date or as soon as administratively practicable thereafter (but in any event no later than 60 days following the applicable Vesting Date or the vesting event, subject to Section 12 below and Exhibit B), the Company shall issue the number of Shares issuable to Grantee (the "Shares"), for the Earned Units determined pursuant to the Administrator's determination of the level of achievement of the Performance Goals, subject to Section 6 below. Notwithstanding the foregoing, in the event Grantee's employment is transferred to a non-U.S. Affiliate, then immediately prior to such transfer this Award shall be cancelled and the Grantee shall have no further rights with respect to the Performance Stock Units or any Shares with respect to such Performance Stock Units.
- 4. Termination of Employment.** Except as set forth in Exhibit B or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, Performance Stock Units will cease vesting upon the date Grantee's employment with the Company or any Affiliate is terminated for any reason. Upon the date that Grantee ceases being an Employee for any reason other than as expressly contemplated in Exhibit B or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, Grantee will forfeit his/her/their right to any unvested Performance Stock Units.
- 5. Rights to Shares.** Grantee shall not have any rights to the Shares subject to the Award, including without limitation, voting rights and rights to dividends, unless and until the Shares shall have been issued by the Company and held of record by or for the benefit of Grantee. The Performance Stock Units shall include a right to Dividend Equivalents equal to the value of any dividends paid on the Common Stock for which the dividend record date occurs between the Grant Date and the date the Performance Stock

<sup>1</sup> For the avoidance of doubt, with respect to Awards granted to individuals who are "officers" under Section 16 of the Exchange Act, the Administrator shall be the Committee (except in the case of the Chief Executive Officer, for whom the independent members of the Board shall make the applicable determination).

Units are settled or forfeited. Subject to vesting, each Dividend Equivalent entitles Grantee to receive the equivalent cash value of any such dividends paid on the number of Shares underlying the Performance Stock Units that are outstanding during such period. Dividend Equivalents will be accrued (without interest)

and will be subject to the same conditions as the Performance Stock Units to which they are attributable, including, without limitation, the vesting conditions and the provisions governing the time and form of settlement of the Performance Stock Units.

## 6. Taxes

(a) **Generally.** Grantee is ultimately liable and responsible for all taxes under all applicable federal, state, local or other laws or regulations (the "Required Tax Payments") owed in connection with the Award, regardless of any action the Company or any of its Affiliates takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any of its Affiliates makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the Award or the subsequent sale of Shares issuable pursuant to the Award. The Company and its Affiliates do not commit and are under no obligation to structure the Award to reduce or eliminate Grantee's tax liability.

(b) **Payment of Withholding Taxes.** As a condition precedent to the delivery to the Grantee of any Shares upon vesting of the Award, the Grantee shall satisfy the Required Tax Payments by the Company withholding from the Shares otherwise to be delivered to the Grantee pursuant to the Award a whole number of Shares having a Fair Market Value, determined as of the date the obligation to withhold or pay taxes first arises in connection with the Award (the "Tax Date"), equal to the Required Tax Payments, with the number of Shares withheld rounded up to the nearest whole Share to satisfy the Required Tax Payments; provided that the number of Shares to be withheld shall be based on the minimum statutory withholding rate or, at the election of Grantee in accordance with such procedures as may be established by the Administrator from time to time, such other withholding rates for federal, state, local and foreign income tax and payroll/employment tax purposes that are applicable to such taxable income and that have been determined by the Administrator to avoid adverse accounting consequences. For the avoidance of doubt, in no instance shall the withholding rate for any Grantee exceed the applicable maximum withholding rate. Notwithstanding the foregoing, the Company (or, in the case of a Grantee subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Committee) may, in its sole discretion, establish alternative methods for the Grantee to satisfy the Required Tax Payments, which may include, without limitation, a cash payment, proceeds from the sale of Shares otherwise issuable to Grantee, or delivery (either actual delivery or by attestation procedures established by the Company) to the Company of previously owned whole Shares, in each case, having an aggregate value, determined as of the Tax Date, equal to the amount necessary to satisfy the Required Tax Payments.

7. **Assignment.** Grantee's interest in this Award may not be assigned or alienated, whether voluntarily or involuntarily.

8. **Clawback Provision.** Notwithstanding any other provision in this Agreement to the contrary, Grantee and this Award shall be subject to the Company's Dodd-Frank Policy on Recoupment of Incentive Compensation, Amended and Restated Incentive Compensation Clawback Policy, and any other clawback policy adopted by the Company, each as may be amended from time to time (each, a "Clawback Policy"), in each case, to the extent applicable to the Grantee and this Award. The provisions of this Section 8 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies (as defined herein below), or any laws or regulations.

---

9. **Amendments.** The Company may amend the provisions of this Agreement at any time; provided that, an amendment that would adversely affect the Grantee's rights under this Agreement in a material manner shall be subject to the written consent of the Grantee.

10. **Change of Control of the Company.** In the event of a Change of Control (as defined in Exhibit B below), the number of Earned Units that are assigned to each Performance Goal issuable shall be determined as specified in the Relative Total Shareholder Return Performance Condition, as set forth in Exhibit B, in the event the Performance Period has not concluded as of the date of such Change of Control. For the avoidance of doubt, in the event the Performance Period has concluded on or prior to the date of the Change of Control, then the Earned Units shall vest and be determined based on the achievement of the applicable Performance Goal during the completed Performance Period.

## 11. [Non-Competition]/Non-Solicitation/Non-Disclosure.

(a) **[Non-Competition].** Grantee acknowledges and recognizes the highly competitive nature of the business of the Company and the unique access to the confidential business, goodwill, personnel, and customer and patient information of the Company, or any of its subsidiaries or affiliates, including trade secret information, that Grantee receives solely as a result of Grantee's employment with the Company, or any of its subsidiaries or affiliates, and accordingly agrees that while Grantee is an Employee, and for the one-year period following termination of such relationship for any reason (whether voluntary or involuntary) (the "Restricted Period"), Grantee shall not, directly or indirectly, as an employee, independent contractor, consultant, or in any other capacity, prepare to provide or provide any of the same or similar services that Grantee performed during his/her/their employment with or service to the Company, or

any of its subsidiaries or affiliates, for any other individual, partnership, limited liability company, corporation, independent practice association, management services organization, or any other entity (collectively, "Person") anywhere in the Restricted Territory that competes in any way with the area of business of the Company, or any of its subsidiaries or affiliates, in which Grantee worked and/or performed services during the last five years of Grantee's employment with the Company, or any of its subsidiaries or affiliates. For purposes of the above, preparing to provide any of the same or similar services includes, but is not limited to, planning with any Person on how best to compete with the Company, or any of its subsidiaries or affiliates, or discussing the Company's, or any of its subsidiaries' or affiliates' business plans or strategies with any Person.

Grantee further agrees that during the Restricted Period, Grantee shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any Person (other than the Company and its subsidiaries and affiliates) engaged in any activity that Grantee was responsible for during the last five years of Grantee's employment with or engagement by the Company, or any of its subsidiaries or affiliates, in the Restricted Territory where such activity is competitive with the activities carried on by the Company, or any of its subsidiaries or affiliates.

Grantee acknowledges that during the Restricted Period, Grantee may be exposed to confidential information and/or trade secrets relating to business areas of the Company, or any of its subsidiaries or affiliates, that are different from and in addition to the areas in which Grantee primarily works for the Company, or any of its subsidiaries or affiliates, (the "Additional Protected Areas of Business"). As a result, Grantee agrees, that during the Restricted Period, he/she/they shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise act for, act on behalf, or provide the

<sup>2</sup> Applicability/inclusion in award agreement based on teammate jurisdiction and status.

---

same or similar services to, any Person (other than the Company and its subsidiaries and affiliates) that engages in the Additional Protected Areas of Business.

Notwithstanding the foregoing, nothing in this Section 11(a) prohibits Grantee from passively owning not in excess of 2% in the aggregate of any company's stock or other ownership interests that are publicly traded on any national or regional stock exchange.

For purposes of this Section 11(a), "Restricted Territory" means the territory or territories or other geographic areas in which the Company and its subsidiaries and affiliates does business and as to which Grantee provided services or had a material presence or influence, and/or about which Grantee learned confidential information and/or trade secrets. Grantee acknowledges and agrees that, given Grantee's role at the Company, or any of its subsidiaries or affiliates, the geographical limitations and duration of this covenant not to compete are reasonable and appropriate, it being understood that the business of the Company and any of its subsidiaries and affiliates can be, and is, practiced throughout the United States, and that the restrictions set forth herein will not impose any undue hardship on Grantee.

To the extent that the provisions of this Section 11(a) conflict with any other agreement signed by Grantee relating to non-competition, the provisions that are most protective of the Company's, and any of its subsidiaries' or affiliates', interests shall govern.

This Section 11(a) (Non-competition) and the rights and obligations of Company hereunder may be assigned by Company and shall inure to the benefit of and shall be enforceable by any such assignee, as well as any of Company's successors in interest. This Section 11(a) (Non-competition) and the rights and obligations of Grantee hereunder may not be assigned by Grantee, but are binding upon Grantee's heirs, administrators, executors, and personal representatives.]

(b) Non-Solicitation. Grantee agrees that during the term of his/her/their employment and/or service to the Company or any of its subsidiaries or affiliates and for the one-year period following the termination of his/her/their employment and/or service by either party for any or no reason (whether voluntary or involuntary), Grantee shall not (i) solicit any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, to work for any Person (other than the Company or any of its subsidiaries or affiliates); (ii) hire any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates); or (iii) take any action that may reasonably result in any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, going to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates).

(c) **Non-Disclosure.** In exchange for Grantee's agreement not to disclose or use Information (as defined below) except as permitted in this Agreement and Grantee's agreement to comply with the restrictive covenants in this Section 11, the Company (or its subsidiaries or affiliates) will provide

---

Grantee access to Information. Grantee agrees not to disclose or use for his/her/their own benefit or purposes or for the benefit or purposes of any Person other than the Company and any of its subsidiaries or affiliates, any trade secrets or other confidential information or data relating to or provided by the Company, or any of its subsidiaries or affiliates, or any of their respective customers including (without limitation) any information relating to development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company, or any of its subsidiaries or affiliates ("Information"); provided, however, the foregoing shall not apply to (i) Information which is generally known to the industry or the public other than as a result of Grantee's breach of any obligation to the Company, or any of its subsidiaries or affiliates; (ii) disclosure that is required by any applicable law, rule or regulation; or (iii) as otherwise provided in Section 11(d). If Grantee receives such a court order or subpoena to produce Information in his/her/their possession, Grantee shall provide the Company reasonable advance notice, in writing, prior to producing said Information, so as to give the Company reasonable time to object to Grantee producing said Information. Grantee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made (a) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (b) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Disclosures to attorneys, made under seal, or pursuant to court order are also protected in certain circumstances under 18 U.S.C. § 1833.

(d) **Protected Rights.** Nothing contained in this Agreement prohibits or limits Grantee's ability to file a charge or complaint with any federal, state or local governmental agency or commission, including but not limited to the U.S. Securities and Exchange Commission. This Agreement also does not prohibit or limit Grantee's ability to communicate with any federal, state or local governmental agency or commission (including but not limited to the U.S. Securities and Exchange Commission), or to otherwise participate in any investigation or proceeding that may be conducted by such an agency or commission (including but not limited to the U.S. Securities and Exchange Commission), including providing documents or other information. Moreover, nothing in this agreement prevents Grantee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Grantee has reason to believe is unlawful.

(e) **Remedies.** Grantee agrees that any breach of Section [11(a)] 11(b), or 11(c) will result in immediate and irreparable harm to the Company and its affiliates for which damages alone are an inadequate remedy and cannot readily be calculated. Accordingly, the Grantee agrees that the Company and its affiliates shall be entitled to temporary, preliminary and permanent injunctive relief to prevent any such actual or threatened breach, without posting a bond or other security or limiting other available remedies. If a court finds Section 11 of this Agreement or any of its restrictions are ambiguous, unenforceable, or invalid, the Company and Grantee agree that the court will read Section 11 of the Agreement as a whole and interpret such restriction(s) to be enforceable and valid to the maximum extent allowed by law. If the court declines to enforce Section 11 of this Agreement in the manner provided in this Section 11(e), the Company and Grantee agree that Section 11 of this Agreement will be automatically modified to provide the Company with the maximum protection of its business interests allowed by law, and Grantee agrees to be bound by Section 11 of this Agreement as modified.

(f) **Termination of Agreement.** This Agreement and the Award shall terminate effective on the date on which Grantee engages in any activity in breach of any or all of Sections [11(a)], 11(b), or 11(c). This Agreement and the Award shall also terminate if at any time during Grantee's employment with the Company, or any of its subsidiaries or affiliates, or within one (1) year after the termination of such employment for any reason (whether voluntary or involuntary), Grantee (i) is convicted of a felony; (ii)

---

has been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or indirectly in personal enrichment at the expense of the Company, or any of its subsidiaries or affiliates; or (iii) is excluded from participating in any federal health care

program. In any of the aforementioned cases, in addition to injunctive relief as forth above, the Company may seek an order requiring Grantee to repay the Company any value, gain or other consideration received or realized by Grantee as a result of this Award or any Shares received pursuant to the Award. The provisions of this Section 11(f) are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies, or any laws or regulations. Notwithstanding the foregoing and any other language in this Agreement, for the avoidance of doubt, this Section 11(f) does not supersede or preclude the application or enforceability of Section 8 or any Clawback Policy.

(g) **Advice of Counsel; Review Period.** Grantee acknowledges and agrees that Grantee has carefully read and fully understands all of the provisions of this Section 11. The Company hereby advises Grantee to consult with an attorney of the Grantee's choosing and at the Grantee's cost before signing this Agreement and Award. Grantee acknowledges that Grantee has had at least fourteen (14) days (or such longer period as may be required under applicable law) to review this Agreement and the Award before agreeing to its terms.

(h) **Governing Law.** Notwithstanding anything in the Plan or this Agreement to the contrary, this Section 11 shall be construed and regulated under and by the laws of the state where Grantee resides. The parties agree that any and all actions or proceedings to enforce Section 11 shall be brought in the state or federal court where Grantee resides.

**12. Section 409A of the Code.** This Agreement and the Award are intended to be exempt from or meet the requirements of Section 409A of the Code, as applicable, and shall be interpreted and construed consistent with that intent and each settlement hereunder shall be considered a separate payment for purposes of Section 409A of the Code. Notwithstanding any other provisions of this Agreement, to the extent that the right to any issuance of Shares or payment to Grantee hereunder provides for non-qualified deferred compensation within the meaning of Section 409A(d)(1) of the Code that is subject to Section 409A of the Code, the issuance or payment shall be made in accordance with the following:

If Grantee is a "specified employee" within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of Grantee's "separation from service" within the meaning of Section 409A(a)(2)(A)(i) of the Code (the "Separation Date"), then no such issuance of Shares or payment shall be made during the period beginning on the Separation Date and ending on the date that is six months following the Separation Date or, if earlier, on the date of Grantee's death, if the earlier making of such issuance of Shares or payment would result in tax penalties being imposed on Grantee under Section 409A of the Code. The amount of any issuance of Shares or payment that would otherwise be made during this period shall instead be made on the first business day following the date that is six months following the Separation Date or, if earlier, the date of Grantee's death. If the Grantee is subject to an employment or other agreement that specifies a time and form of payment that differs from the time and form of payment set forth in Exhibit B, then this Award shall be settled in accordance with such employment or other agreement to the extent required to comply with Section 409A of the Code in a manner permissible under the Plan.

**13. Compliance with Policies.** It is understood and agreed upon that at all times Grantee will act in full compliance with the Company's policies and procedures as may be in effect from time to time, including without limitation, the Company's Code of Conduct, Joint Venture Arrangements Policy, Medical Director Agreements Compliance Handbook, Acceptance of Gifts Policy and/or credentialing process

---

(individually, each a "Policy" and, collectively, the "Policies"). If Grantee's conduct, whether related to the Award granted under this Agreement or otherwise, materially violates the requirements of the Policies, as determined by the independent directors of the Board (with respect to a Grantee who is the Chief Executive Officer of the Company), the Committee (with respect to a Grantee that is an "officer" under Section 16 of the Exchange Act other than the Chief Executive Officer) or the Company's Chief Executive Officer, Chief Compliance Officer or Chief Legal Officer (with respect to a Grantee that is not an "officer" under Section 16 of the Exchange Act), then the Company may require Grantee to forfeit any unvested portion of the Award granted under this Agreement and be subject to immediate disciplinary action, up to and including termination. The provisions of this Section 13 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies or any laws or regulations. If at any time Grantee has questions or concerns about the provisions in this Section 13, or suspects any improper conduct related to the Policies, Grantee should immediately contact his/her/their supervisor or Team Quest. Grantee also may anonymously and confidentially call the Company's Compliance Hotline.

**14. Compliance with Law.** No Shares shall be issued and delivered pursuant to this Award unless and until all applicable registration requirements of the Securities Act of 1933, as amended, all applicable listing requirements of any national securities exchange on which the Common Stock is then listed, and all other requirements of law or of any regulatory bodies having jurisdiction over such issuance and delivery, shall have been complied with. In particular, the Committee may require certain investment (or other) representations and undertakings in connection with the issuance of securities in connection with the Plan and this Award in order to comply with applicable law.

If any provision of this Agreement is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any

limitations required under applicable law. Furthermore, if any provision of this Agreement is determined to be illegal under any applicable law, such provision shall be null and void to the extent necessary to comply with applicable law, but the other provisions of this Agreement shall remain in full force and effect.

**15. Arbitration.** Except as otherwise set forth in Section 11, any dispute, controversy, or claim concerning this Award shall be resolved by final and binding arbitration administered by the American Arbitration Association under its Employment Arbitration Rules and Mediation Procedures then in effect (including with regards to discovery). Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall have the authority to award any remedy or relief that a court of competent jurisdiction could order or grant, including the issuance of an injunction, and may award the prevailing party legal fees and expenses and arbitration fees and expenses that are incurred by the prevailing party if the substantive law at issue, or other applicable law, permits. Either party may, without inconsistency with and without waiving this arbitration provision, apply to any court having jurisdiction over such dispute or controversy and seek interim provisional, injunctive or other equitable relief until the arbitration award is rendered or the controversy is otherwise resolved. The award of the arbitrator, which shall be in writing summarizing the basis for the decision, shall be final and binding upon the parties and subject only to limited review as permitted by law. Except as provided for in Section 11(d) or as necessary in court proceedings to enforce this arbitration provision or an award rendered hereunder, or to obtain interim relief, neither a party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of the Company and Grantee. The Company and Grantee acknowledge that this Agreement evidences a transaction involving interstate commerce.

---

Notwithstanding any choice of law provision included in this Agreement, the United States Federal Arbitration Act shall govern the interpretation and enforcement of this arbitration provision.

**16. Interpretation of Award.**

- (a) This Award is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it.
- (b) Any provision in this Award inconsistent with the Plan shall be superseded and governed by the Plan.
- (c) For all purposes under this Award, employment by the Company shall include employment by the Company or any Affiliate thereof.
- (d) This Award shall be subject to the terms of any written employment agreement between the Grantee and the Company or any Affiliate thereof to the extent permissible under the Plan.

**17. Electronic Delivery and Execution.** Grantee will not be able to initiate any stock transactions related to this Award until Grantee has accepted the terms of this Agreement. The Company may, in its sole discretion, decide to deliver any documents related to this Award or future awards made under the Plan by electronic means or request Grantee's consent to participate in the Plan by electronic means. Grantee hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through any online or electronic system established and maintained by the Company or another third party designated by the Company.

---

**DaVita Inc.**  
**Performance-Based Restricted Stock Unit Agreement**  
**Exhibit B – Performance and Vesting Conditions**

Shares issuable under this Agreement will be determined based on the level of performance achieved on specified Performance Goals. Except as set forth in this Exhibit B or the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date,

vesting in the right to receive the number of shares so determined shall be contingent on Grantee's continued employment by the Company on the Vesting Date (which, for the avoidance of doubt, shall be the date on which the Award is earned).

For purposes of this Exhibit:

- "Cause" shall mean: (a) a material breach by Grantee of his/her/their duties and responsibilities which do not differ in any material respect from the duties and responsibilities of Grantee during the ninety (90) days immediately prior to a Change of Control (for clarity, as defined below) (other than as a result of incapacity due to physical or mental illness) which is demonstrably willful and deliberate on Grantee's part, which is committed in bad faith or without reasonable belief that such breach is in the best interests of the Company and which is not remedied in a reasonable period of time after receipt of written notice from the Company specifying such breach; (b) willful misconduct or gross negligence which results in material harm to the Company; (c) the conviction of Grantee of, or a plea of *nolo contendere* by Grantee to, a felony or other crime involving fraud or dishonesty; or (d) willful violation of Company policies which results in material harm to the Company.

- "Change of Control" shall mean:

- (a) any transaction or series of transactions in which any Person becomes the direct or indirect Beneficial Owner, by way of a stock issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 35% of the total voting power (on a fully diluted basis as if all convertible securities had been converted and all warrants and options had been exercised) entitled to vote in the election of directors of the Company ("Company Voting Securities") (including any transaction in which the Company becomes a wholly-owned or majority-owned subsidiary of another corporation); provided, however, that the following acquisitions shall not be deemed to be a Change of Control: (i) acquisitions by the Company or any Subsidiary; (ii) acquisitions by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary; (iii) acquisitions by any underwriter temporarily holding securities pursuant to an offering of such securities; or (iv) any acquisition pursuant to a transaction described in subparagraph (b) of this definition; provided further, that a Change of Control shall not be deemed to occur solely because Berkshire Hathaway Inc., together with its Affiliates ("Berkshire") acquires Beneficial Ownership of more than 35% of the then-outstanding Company Voting Securities as a result of the acquisition of additional securities by the Company that reduces the number of Company Voting Securities outstanding (except if after such acquisition by the Company, Berkshire becomes the Beneficial Owner of additional Company Voting Securities that increase the percentage of outstanding Company Voting Securities beneficially owned by Berkshire, in which case a Change of Control of the Company shall then occur);

---

- (a) any merger or consolidation or reorganization of the Company other than a merger, consolidation or reorganization (i) immediately following which those individuals who, immediately prior to the consummation of such merger, consolidation or reorganization, constituted the Board, constitute a majority of the board of directors of the Company or the surviving or resulting entity or any parent thereof, (ii) which results in the Company Voting Securities outstanding immediately prior to such merger, consolidation or reorganization continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, greater than 50% of the combined voting power of the securities of the Company (or such surviving entity or any parent thereof) outstanding immediately after such merger or consolidation, and (iii) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 50% or more of the then-outstanding Company Voting Securities;

- (b) any transaction or series of transactions in which all or substantially all of the Company's assets are sold;
- (c) a complete liquidation or dissolution of the Company; or
- (d) during any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the "Incumbent Directors") cease for any reason to constitute at least a majority of the Board; provided that any Person becoming a director subsequent to the beginning of such period whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such Person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any Person other than the Board shall be deemed to be an Incumbent Director.

Solely for purposes of this definition, the following terms shall have the meaning specified: (A) "Affiliate" shall have the meaning set forth in Rule 12b-2 under Section 12 of the Exchange Act; (B) "Beneficial Owner" shall have the meaning set forth in Rule 13d-3 under the Exchange Act, except that a Person shall not be deemed to be the Beneficial Owner of any securities which are reflected on a Schedule 13G; and (C) "Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (w) the Company or any of its Affiliates; (x) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries; (y) an underwriter temporarily holding securities pursuant to an offering of such securities; or (z) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

---

#### Change of Control Vesting

In the event of a Change of Control (as defined above), this Award shall automatically vest in its entirety upon the earlier of the following two events: (i) immediately prior to the effective date of a Change of Control if the successor in such Change of Control (the "Acquiror") fails to effectively assume, convert or replace this Award, or (ii) if the Award is effectively assumed in a Change of Control, as of the date of termination of Grantee's employment if such termination occurs within twenty-four (24) months following such Change of Control by the Company (or the Acquiror) (a) other than for "Cause" (defined above) or (b) if applicable, by Grantee in accordance with the termination for "Good Reason" provisions of Grantee's employment agreement, if any; provided, however, that if the Award constitutes nonqualified deferred compensation within the meaning of Section 409A of the Code, then in the case of clause (i), if the Award is not effectively assumed, converted or replaced and the Change of Control was not a "change in control event" within the meaning of Section 409A of the Code or to the extent distribution would not be permissible under Section 409A of the Code without adverse tax consequences, then the vested Award shall be settled upon the normal Vesting Date or, if earlier and to the extent permitted by Section 409A of the Code, Grantee's termination of employment, provided that the Grantee would not satisfy the age and service requirements for Rule of 65 Vesting during the term of the Award, and in the case of clause (ii), if the Change of Control was not a "change in control event" within the meaning of Section 409A of the Code and the Grantee would satisfy the age and service requirements for Rule of 65 Vesting during the term of this Award, then the vested Award shall be settled, to the extent required by Section 409A of the Code, upon the Vesting Date, in accordance with the Rule of 65 provisions. In the event of such accelerated vesting due to a Change of Control, the number of Shares issuable for the portion of Condition Target PSUs assigned to the Performance Conditions described in Section A. with respect to any Performance Period that had not concluded on or prior to the date of such Change of Control shall be determined as specified in the Relative Total Shareholder Return Performance Condition described in Section B. below.

To be effectively assumed in the Change of Control, the award received in exchange for the Award in connection with a Change of Control: (i) must be of the same type as the Award; (ii) must have a value intended to preserve the value of the Award; (iii) must relate to publicly traded equity securities of the Company (or the Acquiror or another entity that is affiliated with the Company or the Acquiror); and (iv) must have other terms and conditions that are not less favorable to the Grantee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control but excluding the Performance Conditions). Without limiting the generality of the foregoing, the replaced Award may take the form of a continuation of the Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions for effectively assuming the Award have been satisfied shall be made by the Board, as constituted immediately before the Change of Control, in its sole discretion.

---

#### Rule of 65 Vesting

In the event that (i) the Grantee has remained continuously employed with the Company for at least one year from the Grant Date, (ii) the Grantee has satisfied the Rule of 65 (as defined below) at the time of his/her/their termination of employment and such termination of employment is not for Cause, and (iii) the Grantee is an "officer" under Section 16 of the Exchange Act at the time of such termination of employment, then the Award shall vest and shall be settled on its normal Vesting Date; provided, however, that if following the Grantee's termination of employment under this paragraph, there is a Change of Control (as defined above) and the Award is not effectively assumed, converted or replaced and the Change of Control is a "change in control event" within the meaning of

Section 409A of the Code, then the vested Award shall be settled upon such Change of Control to the extent permitted without adverse tax consequences by Section 409A of the Code, with the number of Shares issuable as determined above under Change of Control Vesting. If the Grantee satisfies the requirements of the preceding sentence but the Grantee's termination of employment occurs prior to the first anniversary of the Grant Date, then the number of Condition Target PSUs eligible for vesting shall be prorated based on the number of full months from the Grant Date to the Grantee's termination of employment divided by 12.

"Rule of 65" shall mean that the sum of the Grantee's age and years of service equals or exceeds 65, with a minimum age of 55 and a minimum of five years of continuous service.

#### Death or Disability

In the event of the Grantee's death or Disability while employed by the Company, any outstanding portion of the Condition Target PSUs shall vest at target level and be settled within 60 days following such death or Disability (or, if later and to the extent permitted under Section 409A of the Code, within 60 days following the conclusion of the Performance Period applicable to the underlying Performance Goals); provided, however, that if the Grantee's death or Disability occurs following the conclusion of the Performance Period, the Award shall vest based on the achievement of the applicable Performance Goal during such completed Performance Period.

"Disability" shall mean that the Grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, determined in accordance with Section 409A of the Code.

*[Performance Conditions Intentionally Omitted]*

**Exhibit 10.2**

#### **DaVita Inc.**

#### **Restricted Stock Unit Agreement under the DaVita Inc. 2020 Incentive Award Plan**

This **Restricted Stock Unit Agreement** (this "Agreement") is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the "Company"), and the Grantee indicated below pursuant to the **DaVita Inc. 2020 Incentive Award Plan** (the "Plan").

#### **Primary Terms**

**Grantee:** «Grantee»  
**Address:** «Address\_1»  
«City», «State» «Zip»  
**Grant Date:** «Grant Date»  
**Number of Units:** «RSU Award»  
**Vesting Schedule:** «RSU\_Vesting\_1»  
«RSU\_Vesting\_2»

**Plan Name:** 2020 Incentive Award Plan  
**Plan ID#:** 2020

This Agreement includes this cover page and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

[Exhibit A](#) – General Terms and Conditions  
[Exhibit B](#) – Events Causing Full Vesting of Awards

Grantee hereby expressly acknowledges and agrees that he/she/they is an employee at will and may be terminated by the Company or its applicable Affiliate at any time, with or without cause. By accepting this Award, Grantee hereby acknowledges he/she/they has a copy of the Plan, and accepts and agrees to the

terms and provisions of this Agreement and the Plan. Capitalized terms that are used but not defined in this Agreement shall have the meanings set forth in the Plan.

IN WITNESS WHEREOF, the Company and the Grantee have accepted this Agreement effective as of the Grant Date.

DaVita Inc.

Grantee\*

\*If permitted by the Company, this Agreement may be accepted electronically by the Grantee pursuant to the Company's third-party stock plan administrator's procedures.

DaVita Inc.

**Restricted Stock Unit Agreement Exhibit A – General Terms and Conditions**

For valuable consideration, the receipt of which is acknowledged, the parties hereto agree as follows:

- 1. Grant of Restricted Stock Units.** The Company hereby grants to Grantee this award (the "Award") of the number of restricted stock units indicated on the front page ("Restricted Stock Units") under the Plan, subject to adjustment, forfeiture and the other terms and conditions set forth below and in the Plan. This Award represents Grantee's right to receive shares of common stock of the Company ("Common Stock"), subject to Grantee's fulfillment of the vesting and other conditions set forth in this Agreement.
- 2. Vesting Conditions.** The Restricted Stock Units shall vest in accordance with the Vesting Schedule specified on the front page.
- 3. Conversion of Restricted Stock Units and Stock Issuance.** One share of Common Stock (each, a "Share") will become issuable to Grantee for each Restricted Stock Unit that vests pursuant to this Agreement, subject to any reduction in the number of Shares pursuant to Section 6 below, with such Shares to be distributed to the Grantee within 60 days following the applicable vesting date or vesting event, subject to Section 12 below and Exhibit B. The number of Shares issuable to Grantee, after any reduction pursuant to Section 6, shall be rounded down to the nearest whole number of Shares. Notwithstanding the foregoing, in the event Grantee's employment is transferred to a non-U.S. Affiliate, then immediately prior to such transfer this Award shall be cancelled and the Grantee shall have no further rights with respect to the Restricted Stock Units or any Shares with respect to such Restricted Stock Units.
- 4. Termination of Employment.** Except as set forth in Exhibit B or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, Restricted Stock Units will cease vesting upon the date Grantee's employment with the Company or any Affiliate is terminated for any reason. Upon the date that Grantee ceases being an Employee for any reason other than as expressly contemplated in Exhibit B or pursuant to the terms of any written employment agreement between the Grantee and the Company or an Affiliate thereof in effect on the Grant Date, Grantee will forfeit his/her/their right to any unvested Restricted Stock Units.
- 5. Rights to Shares.** Grantee shall not have any rights to the Shares subject to the Award, including without limitation, voting rights and rights to dividends, unless and until the Shares shall have been issued by the Company and held of record by or for the benefit of Grantee. The Restricted Stock Units shall include a right to Dividend Equivalents equal to the value of any dividends paid on the Common Stock for which the dividend record date occurs between the Grant Date and the date the Restricted Stock Units are settled or forfeited. Subject to vesting, each Dividend Equivalent entitles Grantee to receive the equivalent cash value of any such dividends paid on the number of Shares underlying the Restricted Stock Units that are outstanding during such period. Dividend Equivalents will be accrued (without interest) and will be subject to the same conditions as the Restricted Stock Units to which they are attributable, including, without limitation, the vesting conditions and the provisions governing the time and form of settlement of the Restricted Stock Units.

**6. Taxes**

(a) **Generally.** Grantee is ultimately liable and responsible for all taxes under all applicable federal, state, local or other laws or regulations (the "Required Tax Payments") owed in connection with the Award, regardless of any action the Company or any of its Affiliates takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any of its Affiliates makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant or vesting of the Award or the subsequent sale of Shares issuable pursuant to the Award. The Company and its Affiliates do not commit and are under no obligation to structure the Award to reduce or eliminate Grantee's tax liability.

(b) **Payment of Withholding Taxes.** As a condition precedent to the delivery to the Grantee of any Shares upon vesting of the Award, the Grantee shall satisfy the Required Tax Payments by the Company withholding from the Shares otherwise to be delivered to the Grantee pursuant to the Award a whole number of Shares having a Fair Market Value, determined as of the date the obligation to withhold or pay taxes first arises in connection with the Award (the "Tax Date"), equal to the Required Tax Payments, with the number of Shares withheld rounded up to the nearest whole Share to satisfy the Required Tax Payments; provided that the number of Shares to be withheld shall be based on the minimum statutory withholding rate or, at the election of Grantee in accordance with such procedures as may be established by the Administrator from time to time, such other withholding rates for federal, state, local and foreign income tax and payroll/employment tax purposes that are applicable to such taxable income and that have been determined by the Administrator to avoid adverse accounting consequences. For the avoidance of doubt, in no instance shall the withholding rate for any Grantee exceed the applicable maximum withholding rate. Notwithstanding the foregoing, the Company (or, in the case of a Grantee subject to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the Committee) may, in its sole discretion, establish alternative methods for the Grantee to satisfy the Required Tax Payments, which may include, without limitation, a cash payment, proceeds from the sale of Shares otherwise issuable to Grantee, or delivery (either actual delivery or by attestation procedures established by the Company) to the Company of previously owned whole Shares, in each case, having an aggregate value, determined as of the Tax Date, equal to the amount necessary to satisfy the Required Tax Payments.

7. **Assignment.** Grantee's interest in this Award may not be assigned or alienated, whether voluntarily or involuntarily.

8. **Clawback Provision.** Notwithstanding any other provision in this Agreement to the contrary, Grantee and this Award shall be subject to the Company's Dodd-Frank Policy on Recoupment of Incentive Compensation, Amended and Restated Incentive Compensation Clawback Policy, and any other clawback policy adopted by the Company, each as may be amended from time to time (each, a "Clawback Policy"), in each case, to the extent applicable to the Grantee and this Award. The provisions of this Section 8 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies (as defined herein below), or any laws or regulations.

9. **Amendments.** The Company may amend the provisions of this Agreement at any time; provided that, an amendment that would adversely affect the Grantee's rights under this Agreement in a material manner shall be subject to the written consent of the Grantee.

10. **Change of Control of the Company.** In the event of a Change of Control (as defined in Exhibit B below), the entire Award may vest immediately in accordance with the terms of the Plan. The specific provisions regarding circumstances in which full vesting would occur upon or following a Change of Control under this Agreement are set forth in Exhibit B.

---

11. **[Non-Competition]/Non-Solicitation/Non-Disclosure.**

(a) **[Non-Competition].** Grantee acknowledges and recognizes the highly competitive nature of the business of the Company and the unique access to the confidential business, goodwill, personnel, and customer and patient information of the Company, or any of its subsidiaries or affiliates, including trade secret information, that Grantee receives solely as a result of Grantee's employment with the Company, or any of its subsidiaries or affiliates, and accordingly agrees that while Grantee is an Employee, and for the one-year period following termination of such relationship for any reason (whether voluntary or involuntary) (the "Restricted Period"), Grantee shall not, directly or indirectly, as an employee, independent contractor, consultant, or in any other capacity, prepare to provide or provide any of the same or similar services that Grantee performed during his/her/their employment with or service to the Company, or any of its subsidiaries or affiliates, for any other individual, partnership, limited liability company, corporation, independent practice association, management

services organization, or any other entity (collectively, "Person") anywhere in the Restricted Territory that competes in any way with the area of business of the Company, or any of its subsidiaries or affiliates, in which Grantee worked and/or performed services during the last five years of Grantee's employment with the Company, or any of its subsidiaries or affiliates. For purposes of the above, preparing to provide any of the same or similar services includes, but is not limited to, planning with any Person on how best to compete with the Company, or any of its subsidiaries or affiliates, or discussing the Company's, or any of its subsidiaries' or affiliates', business plans or strategies with any Person.

Grantee further agrees that during the Restricted Period, Grantee shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any Person (other than the Company and its subsidiaries and affiliates) engaged in any activity that Grantee was responsible for during the last five years of Grantee's employment with or engagement by the Company, or any of its subsidiaries or affiliates, in the Restricted Territory where such activity is competitive with the activities carried on by the Company, or any of its subsidiaries or affiliates.

Grantee acknowledges that during the Restricted Period, Grantee may be exposed to confidential information and/or trade secrets relating to business areas of the Company, or any of its subsidiaries or affiliates, that are different from and in addition to the areas in which Grantee primarily works for the Company, or any of its subsidiaries or affiliates, (the "Additional Protected Areas of Business"). As a result, Grantee agrees, that during the Restricted Period, he/she/they shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise act for, act on behalf, or provide the same or similar services to, any Person (other than the Company and its subsidiaries and affiliates) that engages in the Additional Protected Areas of Business.

Notwithstanding the foregoing, nothing in this Section 11(a) prohibits Grantee from passively owning not in excess of 2% in the aggregate of any company's stock or other ownership interests that are publicly traded on any national or regional stock exchange.

For purposes of this Section 11(a), "Restricted Territory" means the territory or territories or other geographic areas in which the Company and its subsidiaries and affiliates does business and as to which Grantee provided services or had a material presence or influence, and/or about which Grantee learned confidential information and/or trade secrets. Grantee acknowledges and agrees that, given Grantee's role at the Company, or any of its subsidiaries or affiliates, the geographical limitations and duration of this covenant not to compete are reasonable and appropriate, it being understood that the business of the

---

<sup>1</sup> Applicability/inclusion in award agreement based on teammate jurisdiction and status.

Company and any of its subsidiaries and affiliates can be, and is, practiced throughout the United States, and that the restrictions set forth herein will not impose any undue hardship on Grantee.

To the extent that the provisions of this Section 11(a) conflict with any other agreement signed by Grantee relating to non-competition, the provisions that are most protective of the Company's, and any of its subsidiaries' or affiliates', interests shall govern.

This Section 11(a) (Non-competition) and the rights and obligations of Company hereunder may be assigned by Company and shall inure to the benefit of and shall be enforceable by any such assignee, as well as any of Company's successors in interest. This Section 11(a) (Non-competition) and the rights and obligations of Grantee hereunder may not be assigned by Grantee, but are binding upon Grantee's heirs, administrators, executors, and personal representatives.]

(b) **Non-Solicitation.** Grantee agrees that during the term of his/her/their employment and/or service to the Company or any of its subsidiaries or affiliates and for the one-year period following the termination of his/her/their employment and/or service by either party for any or no reason (whether voluntary or involuntary), Grantee shall not (i) solicit any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, to work for any Person (other than the Company or any of its subsidiaries or affiliates); (ii) hire any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates); or (iii) take any action that may reasonably result in any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, going to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates).

(c) **Non-Disclosure.** In exchange for Grantee's agreement not to disclose or use Information (as defined below) except as permitted in this Agreement and Grantee's agreement to comply with the restrictive covenants in this Section 11, the Company (or its subsidiaries or affiliates) will provide Grantee access to Information. Grantee agrees not to disclose or use for his/her/their own benefit or purposes or for the benefit or purposes of any Person other than the Company and any of its subsidiaries or affiliates, any trade secrets or other confidential information or data relating to or provided by the Company, or any of its subsidiaries or affiliates, or any of their respective customers including (without limitation) any information relating to development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company, or any of its subsidiaries or affiliates ("Information"); provided, however, the foregoing shall not apply to (i) Information which is generally known to the industry or the public other than as a result of Grantee's breach of any obligation to the Company, or any of its subsidiaries or affiliates; (ii) disclosure that is required by any applicable law, rule or regulation; or (iii) as otherwise provided in Section 11(d). If Grantee receives such a court order or subpoena to produce Information in his/her/their possession, Grantee shall provide the Company reasonable advance notice, in writing, prior to producing said Information, so as to give the Company reasonable time to object to Grantee producing said Information. Grantee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made (a) in confidence to a Federal, State, or local

---

government official, either directly or indirectly, or to an attorney, and (b) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Disclosures to attorneys, made under seal, or pursuant to court order are also protected in certain circumstances under 18 U.S.C. § 1833.

(d) **Protected Rights.** Nothing contained in this Agreement prohibits or limits Grantee's ability to file a charge or complaint with any federal, state or local governmental agency or commission, including but not limited to the U.S. Securities and Exchange Commission. This Agreement also does not prohibit or limit Grantee's ability to communicate with any federal, state or local governmental agency or commission (including but not limited to the U.S. Securities and Exchange Commission), or to otherwise participate in any investigation or proceeding that may be conducted by such an agency or commission (including but not limited to the U.S. Securities and Exchange Commission), including providing documents or other information. Moreover, nothing in this agreement prevents Grantee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Grantee has reason to believe is unlawful.

(e) **Remedies.** Grantee agrees that any breach of Section [11(a)] 11(b), or 11(c) will result in immediate and irreparable harm to the Company and its affiliates for which damages alone are an inadequate remedy and cannot readily be calculated. Accordingly, the Grantee agrees that the Company and its affiliates shall be entitled to temporary, preliminary and permanent injunctive relief to prevent any such actual or threatened breach, without posting a bond or other security or limiting other available remedies. If a court finds Section 11 of this Agreement or any of its restrictions are ambiguous, unenforceable, or invalid, the Company and Grantee agree that the court will read Section 11 of the Agreement as a whole and interpret such restriction(s) to be enforceable and valid to the maximum extent allowed by law. If the court declines to enforce Section 11 of this Agreement in the manner provided in this Section 11(e), the Company and Grantee agree that Section 11 of this Agreement will be automatically modified to provide the Company with the maximum protection of its business interests allowed by law, and Grantee agrees to be bound by Section 11 of this Agreement as modified.

(f) **Termination of Agreement.** This Agreement and the Award shall terminate effective on the date on which Grantee engages in any activity in breach of any or all of Sections [11(a)], 11(b), or 11(c). This Agreement and the Award shall also terminate if at any time during Grantee's employment with the Company, or any of its subsidiaries or affiliates, or within one (1) year after the termination of such employment for any reason (whether voluntary or involuntary), Grantee (i) is convicted of a felony; (ii) has been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or indirectly in personal enrichment at the expense of the Company, or any of its subsidiaries or affiliates; or (iii) is excluded from participating in any federal health care program. In any of the aforementioned cases, in addition to injunctive relief as forth above, the Company may seek an order requiring Grantee to repay the Company any value, gain or other consideration received or realized by Grantee as a result of this Award or any Shares received pursuant to the Award. The provisions of this Section 11(f) are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies, or any laws or regulations. Notwithstanding the foregoing and any other language in this Agreement, for the avoidance of doubt, this Section 11(f) does not supersede or preclude the application or enforceability of Section 8 or any Clawback Policy.

(g) **Advice of Counsel; Review Period.** Grantee acknowledges and agrees that Grantee has carefully read and fully understands all of the provisions of this Section 11. The Company hereby advises Grantee to consult with an attorney of the Grantee's choosing and at the Grantee's cost before signing this Agreement and Award. Grantee acknowledges that Grantee has had at least fourteen (14) days (or such

---

longer period as may be required under applicable law) to review this Agreement and the Award before agreeing to its terms.

(h) **Governing Law.** Notwithstanding anything in the Plan or this Agreement to the contrary, this Section 11 shall be construed and regulated under and by the laws of the state where Grantee resides. The parties agree that any and all actions or proceedings to enforce Section 11 shall be brought in the state or federal court where Grantee resides.

**12. Section 409A of the Code.** This Agreement and the Award are intended to be exempt from or meet the requirements of Section 409A of the Code, as applicable, and shall be interpreted and construed consistent with that intent and each settlement hereunder shall be considered a separate payment for purposes of Section 409A of the Code. Notwithstanding any other provisions of this Agreement, to the extent that the right to any issuance of Shares or payment to Grantee hereunder provides for non-qualified deferred compensation within the meaning of Section 409A(d)(1) of the Code that is subject to Section 409A of the Code, the issuance or payment shall be made in accordance with the following:

If Grantee is a "specified employee" within the meaning of Section 409A(a)(2)(B)(i) of the Code on the date of Grantee's "separation from service" within the meaning of Section 409A(a)(2)(A)(i) of the Code (the "Separation Date"), then no such issuance of Shares or payment shall be made during the period beginning on the Separation Date and ending on the date that is six months following the Separation Date or, if earlier, on the date of Grantee's death, if the earlier making of such issuance of Shares or payment would result in tax penalties being imposed on Grantee under Section 409A of the Code. The amount of any issuance of Shares or payment that would otherwise be made during this period shall instead be made on the first business day following the date that is six months following the Separation Date or, if earlier, the date of Grantee's death. If the Grantee is subject to an employment or other agreement that specifies a time and form of payment that differs from the time and form of payment set forth in Exhibit B, then this Award shall be settled in accordance with such employment or other agreement to the extent required to comply with Section 409A of the Code in a manner permissible under the Plan.

**13. Compliance with Policies.** It is understood and agreed upon that at all times Grantee will act in full compliance with the Company's policies and procedures as may be in effect from time to time, including without limitation, the Company's Code of Conduct, Joint Venture Arrangements Policy, Medical Director Agreements Compliance Handbook, Acceptance of Gifts Policy and/or credentialing process (individually, each a "Policy" and, collectively, the "Policies"). If Grantee's conduct, whether related to the Award granted under this Agreement or otherwise, materially violates the requirements of the Policies, as determined by the independent directors of the Board (with respect to a Grantee who is the Chief Executive Officer of the Company), the Committee (with respect to a Grantee that is an "officer" under Section 16 of the Exchange Act other than the Chief Executive Officer) or the Company's Chief Executive Officer, Chief Compliance Officer or Chief Legal Officer (with respect to a Grantee that is not an "officer" under Section 16 of the Exchange Act), then the Company may require Grantee to forfeit any unvested portion of the Award granted under this Agreement and be subject to immediate disciplinary action, up to and including termination. The provisions of this Section 13 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies or any laws or regulations. If at any time Grantee has questions or concerns about the provisions in this Section 13, or suspects any improper conduct related to the Policies, Grantee should immediately contact his/her/their supervisor or Team Quest. Grantee also may anonymously and confidentially call the Company's Compliance Hotline.

**14. Compliance with Law.** No Shares shall be issued and delivered pursuant to this Award unless and until all applicable registration requirements of the Securities Act of 1933, as amended, all applicable

---

listing requirements of any national securities exchange on which the Common Stock is then listed, and all other requirements of law or of any regulatory bodies having jurisdiction over such issuance and delivery, shall have been complied with. In particular, the Committee may require certain investment (or other) representations and undertakings in connection with the issuance of securities in connection with the Plan and this Award in order to comply with applicable law.

If any provision of this Agreement is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. Furthermore, if any provision of this Agreement is determined to be illegal under any applicable law, such provision shall be null and void to the extent necessary to comply with applicable law, but the other provisions of this Agreement shall remain in full force and effect.

**15. Arbitration.** Except as otherwise set forth in Section 11, any dispute, controversy, or claim concerning this Award shall be resolved by final and binding arbitration administered by the American Arbitration Association under its Employment Arbitration Rules and Mediation Procedures then in effect (including with regards to discovery). Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall have the authority to award any remedy or relief that a court of competent jurisdiction could order or grant, including the issuance of an injunction, and may award the prevailing party legal fees and expenses and arbitration fees and expenses that are incurred by the prevailing party if the substantive law at issue, or other applicable law, permits. Either party may, without inconsistency with and without waiving this arbitration provision, apply to any court having jurisdiction over such dispute or controversy and seek interim provisional, injunctive or other equitable relief until the arbitration award is rendered or the controversy is otherwise resolved. The award of the arbitrator, which shall be in writing summarizing the basis for the decision, shall be final and binding upon the parties and subject only to limited review as permitted by law. Except as provided for in Section 11(d) or as necessary in court proceedings to enforce this arbitration provision or an award rendered hereunder, or to obtain interim relief, neither a party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of the Company and Grantee. The Company and Grantee acknowledge that this Agreement evidences a transaction involving interstate commerce. Notwithstanding any choice of law provision included in this Agreement, the United States Federal Arbitration Act shall govern the interpretation and enforcement of this arbitration provision.

**16. Interpretation of Award.**

- (a) This Award is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it.
- (b) Any provision in this Award inconsistent with the Plan shall be superseded and governed by the Plan.
- (c) For all purposes under this Award, employment by the Company shall include employment by the Company or any Affiliate thereof.
- (d) This Award shall be subject to the terms of any written employment agreement between the Grantee and the Company or any Affiliate thereof to the extent permissible under the Plan.

**17. Electronic Delivery and Execution.** Grantee will not be able to initiate any stock transactions related to this Award until Grantee has accepted the terms of this Agreement. The Company may, in its sole discretion, decide to deliver any documents related to this Award or future awards made under the

---

Plan by electronic means or request Grantee's consent to participate in the Plan by electronic means. Grantee hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through any online or electronic system established and maintained by the Company or another third party designated by the Company.

---

**DaVita Inc.**

**Restricted Stock Unit Agreement Exhibit B – Events Causing Full Vesting Awards**

**Change of Control Vesting**

In the event of a Change of Control (as defined below), this Award shall automatically vest in its entirety upon the earlier of the following two events: (i) immediately prior to the effective date of a Change of Control if the successor in such Change of Control (the "Acquiror") fails to effectively assume, convert or replace this Award, or (ii) if the Award is effectively assumed in a Change of Control, as of the date of termination of Grantee's employment if such termination occurs within twenty-four (24) months following such Change of Control by the Company (or the Acquiror) (a) other than for "Cause" (defined below) or (b) if applicable, by Grantee in accordance with the termination for "Good Reason" provisions of Grantee's employment agreement, if any; provided, however, that if the Award constitutes nonqualified deferred compensation within the meaning of Section 409A of the Code, then in the case of clause (i), if the Award is not effectively assumed, converted or replaced and the Change of Control was not a "change in control event" within the meaning of Section 409A of the Code or

to the extent distribution would not be permissible under Section 409A of the Code without adverse tax consequences, then the vested Award shall be settled in accordance with the Award's normal Vesting Schedule or, if earlier and to the extent permitted by Section 409A of the Code, Grantee's termination of employment, provided that the Grantee would not satisfy the age and service requirements for Rule of 65 Vesting during the duration of the Vesting Schedule, and in the case of clause (ii), if the Change of Control was not a "change in control event" within the meaning of Section 409A of the Code and the Grantee would satisfy the age and service requirements for Rule of 65 Vesting during the duration of the Vesting Schedule, then the vested Award shall be settled in accordance with the normal Vesting Schedule, in accordance with the Rule of 65 provisions.

To be effectively assumed in the Change of Control, the award received in exchange for the Award in connection with a Change of Control: (i) must be of the same type as the Award; (ii) must have a value intended to preserve the value of the Award; (iii) must relate to publicly traded equity securities of the Company (or the Acquiror or another entity that is affiliated with the Company or the Acquiror); and (iv) must have other terms and conditions that are not less favorable to the Grantee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, the replaced Award may take the form of a continuation of the Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions for effectively assuming the Award have been satisfied shall be made by the Board, as constituted immediately before the Change of Control, in its sole discretion.

For purposes of this Exhibit:

- **"Cause"** shall mean: (a) a material breach by Grantee of his/her/their duties and responsibilities which do not differ in any material respect from the duties and responsibilities of Grantee during the ninety (90) days immediately prior to a Change of Control (for clarity, as defined herein below) (other than as a result of incapacity due to physical or mental illness) which is demonstrably willful and deliberate on Grantee's part, which is committed in bad faith or without reasonable belief that such breach is in the best interests of the Company and which is not remedied in a reasonable period of time after receipt of written notice from the Company specifying such breach; (b) willful misconduct or gross negligence which results in material harm

---

to the Company; (c) the conviction of Grantee of, or a plea of *nolo contendere* by Grantee to, a felony or other crime involving fraud or dishonesty; or (d) willful violation of Company policies which results in material harm to the Company.

- **"Change of Control"** shall mean:
  - (a) any transaction or series of transactions in which any Person becomes the direct or indirect Beneficial Owner, by way of a stock issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 35% of the total voting power (on a fully diluted basis as if all convertible securities had been converted and all warrants and options had been exercised) entitled to vote in the election of directors of the Company ("Company Voting Securities") (including any transaction in which the Company becomes a wholly-owned or majority-owned subsidiary of another corporation); provided, however, that the following acquisitions shall not be deemed to be a Change of Control: (i) acquisitions by the Company or any Subsidiary; (ii) acquisitions by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary; (iii) acquisitions by any underwriter temporarily holding securities pursuant to an offering of such securities; or (iv) any acquisition pursuant to a transaction described in subparagraph (b) of this definition; provided further, that a Change of Control shall not be deemed to occur solely because Berkshire Hathaway Inc., together with its Affiliates ("Berkshire") acquires Beneficial Ownership of more than 35% of the then-outstanding Company Voting Securities as a result of the acquisition of additional securities by the Company that reduces the number of Company Voting Securities outstanding (except if after such acquisition by the Company, Berkshire becomes the Beneficial Owner of additional Company Voting Securities that increase the percentage of outstanding Company Voting Securities beneficially owned by Berkshire, in which case a Change of Control of the Company shall then occur);
  - (b) any merger or consolidation or reorganization of the Company other than a merger, consolidation or reorganization (i) immediately following which those individuals who, immediately prior to the consummation of such merger, consolidation or reorganization, constituted the Board, constitute a majority of the board of directors of the Company or the surviving or resulting entity or any parent thereof, (ii) which results in the Company Voting Securities outstanding immediately prior to such merger, consolidation or reorganization continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, greater than 50% of the combined voting power of the securities of the Company (or such surviving entity or any parent thereof) outstanding immediately after such merger or consolidation, and (iii) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities

beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 50% or more of the then outstanding Company Voting Securities;

- (c) any transaction or series of transactions in which all or substantially all of the Company's assets are sold;
- (d) a complete liquidation or dissolution of the Company; or
- (e) during any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the "Incumbent Directors") cease for any reason to constitute at least a majority of the Board; provided that any Person becoming a director subsequent to the beginning of such period whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such Person is named as a nominee for director, without written objection to such nomination) shall be an

---

Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any Person other than the Board shall be deemed to be an Incumbent Director.

Solely for purposes of this definition, the following terms shall have the meaning specified: (A) "Affiliate" shall have the meaning set forth in Rule 12b-2 under Section 12 of the Exchange Act; (B) "Beneficial Owner" shall have the meaning set forth in Rule 13d-3 under the Exchange Act, except that a Person shall not be deemed to be the Beneficial Owner of any securities which are reflected on a Schedule 13G; and (C) "Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (w) the Company or any of its Affiliates; (x) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries; (y) an underwriter temporarily holding securities pursuant to an offering of such securities; or (z) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

#### Rule of 65 Vesting

In the event that (i) the Grantee has remained continuously employed with the Company for at least one year from the Grant Date, (ii) the Grantee has satisfied the Rule of 65 (as defined below) at the time of his/her/their termination of employment and such termination of employment is not for Cause, and (iii) the Grantee is an "officer" under Section 16 of the Exchange Act at the time of such termination of employment, then the Award shall vest and shall be settled in accordance with the normal Vesting Schedule set forth on the cover page of the Agreement; provided, however, that if following the Grantee's termination of employment under this paragraph, there is a Change of Control (as defined above) and the Award is not effectively assumed, converted or replaced and the Change of Control is a "change in control event" within the meaning of Section 409A of the Code, then the vested Award shall be settled upon such Change of Control to the extent permitted without adverse tax consequences by Section 409A of the Code. If the Grantee satisfies the requirements of the preceding sentence but the Grantee's termination of employment occurs prior to the first anniversary of the Grant Date, then the number of Shares eligible for vesting shall be prorated based on the number of full months from the Grant Date to the Grantee's termination of employment divided by 12.

"Rule of 65" shall mean that the sum of the Grantee's age and years of service equals or exceeds 65, with a minimum age of 55 and a minimum of five years of continuous service.

#### Death or Disability

In the event of the Grantee's death or Disability while employed by the Company, any outstanding portion of the Award shall fully vest and be settled within 60 days following such death or Disability.

"Disability" shall mean that the Grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months, determined in accordance with Section 409A of the Code.

Exhibit 10.3

**DaVita Inc.**  
**Stock Appreciation Rights Agreement under the DaVita Inc. 2020 Incentive Award Plan**

This **Stock Appreciation Rights Agreement** (this "Agreement") is dated as of the Grant Date indicated below by and between DaVita Inc., a Delaware corporation (the "Company"), and the Grantee indicated below pursuant to the **DaVita Inc. 2020 Incentive Award Plan** (the "Plan").

Primary Terms

**Grantee:** «Grantee»  
**Address:** «Address\_1»  
«City», «State» «Zip»  
**Grant Date:** «Grant Date»  
**Base Shares:** «SSAR\_Award»  
**Base Price per Share:** \$«Base\_Price»  
**Vesting Schedule:** «SSAR\_Vesting\_1»  
«SSAR\_Vesting\_2»  
  
**Expiration Date:** «Expiration\_Date»  
**Plan Name:** 2020 Incentive Award Plan  
**Plan ID#:** 2020

This Agreement includes this cover page and the following Exhibits, which are expressly incorporated by reference in their entirety herein:

[Exhibit A – General Terms and Conditions](#)

[Exhibit B – Events Causing Full Vesting of Awards](#)

Grantee hereby expressly acknowledges and agrees that he/she/they is an employee at will and may be terminated by the Company or its applicable Affiliate at any time, with or without cause. By accepting this Award, Grantee hereby acknowledges he/she/they has a copy of the Plan, and accepts and agrees to the terms and provisions of this Agreement and the Plan. Capitalized terms that are used but not defined in this Agreement shall have the meanings set forth in the Plan.

IN WITNESS WHEREOF, the Company and the Grantee have accepted this Agreement effective as of the Grant Date.

DaVita Inc.

Grantee\*

---

\*If permitted by the Company, this Agreement may be accepted electronically by the Grantee pursuant to the Company's third-party stock plan administrator's procedures.

---

DaVita Inc.

**Stock Appreciation Rights Agreement Exhibit A – General Terms and Conditions**

For valuable consideration, the receipt of which is acknowledged, the parties hereto agree as follows:

**1. Grant of Stock Appreciation Rights Award**

The Company hereby grants to Grantee an award of stock appreciation rights ("Award") covering the number of Base Shares of Common Stock indicated on the front page, pursuant to which the Grantee shall be eligible to receive a number of shares ("Gain Shares") of Common Stock with an aggregate value equal to (1) the number of Base Shares indicated on the front page, times (2) the difference between the Fair Market Value of one share of Common Stock on the last trading day prior to exercise of the Stock Appreciation Rights and the Base Price specified on the front page, subject to Grantee's fulfillment of the vesting and other conditions set forth in this Agreement.

## **2. Term of Stock Appreciation Rights Award**

- (a) This Award shall be effective for the period ("Term") from the Grant Date shown above through the Expiration Date specified on the front page.
- (b) In the case of the termination of Grantee's employment with the Company or any of its subsidiaries or Affiliates for any reason, whether voluntary or involuntary ("Severance"), the date upon which the Award shall terminate shall be determined based on the following:
  - (i) If Grantee dies while employed by the Company or during the three (3) month period immediately subsequent to his/her/their Severance, the Award shall terminate one (1) year from the date of the Severance.
  - (ii) If Grantee was disabled (as described in Exhibit B attached hereto) at the time of his/her/their Severance, the Award shall terminate one (1) year following the Severance.
  - (iii) If the Grantee satisfies the requirements for Rule of 65 vesting (as described in Exhibit B attached hereto) at the time of his/her/their Severance and such Severance is not for Cause (as defined in Exhibit B attached hereto), the Award shall terminate on the Expiration Date.
  - (iv) In all other cases, the Award shall terminate three (3) months following the Severance.
  - (v) Notwithstanding the foregoing, the Award shall terminate no later than the Expiration Date, regardless of whether or not Grantee remains in the employ of the Company.
- (c) If Grantee is transferred between the Company and an Affiliate thereof, or vice versa, or between Affiliates, Severance shall not be deemed to have occurred, unless the Grantee is transferred to a non-U.S. Affiliate, in which case, notwithstanding anything in this Agreement, the transfer shall be deemed a Severance and the Award shall terminate immediately at such Severance (and, for the avoidance of doubt, immediately prior to the effective time of the transfer to the non-U.S. Affiliate).

---

## **3. Exercisability**

- (a) The Base Shares subject to this Award shall become exercisable ("vest") on the dates indicated under the Vesting Schedule indicated on the front page such that this Award shall be fully exercisable on the last date listed on the table on the front page; provided, however, that such vesting shall cease at the time of Grantee's Severance; provided, further, that, if the Grantee is an "officer" under Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), at the time of death or Severance, then (i) the Award shall continue to vest on the dates indicated in the Vesting Schedule if the Grantee satisfies the requirements of Rule of 65 vesting (as set forth on Exhibit B) at the time of his/her/their Severance and his/her/their Severance is other than for Cause or (ii) the entire Award shall vest immediately upon the Grantee's Severance due to death or disability (as described in Exhibit B attached hereto). The specific provisions regarding circumstances in which vesting would occur upon death, disability or Rule of 65 are set forth in Exhibit B.
- (b) These installments shall be cumulative, so that this Award may be exercised as to any or all of the Base Shares covered by an installment at any time or times after the installment becomes vested and until this Award terminates.
- (c) Notwithstanding the foregoing, in the event of a Change of Control (as defined in Exhibit B below), the entire Award may vest immediately in accordance with the terms of the Plan. The specific provisions regarding circumstances in which full vesting would occur upon or following a Change of Control under this Agreement are set forth in Exhibit B.
- (d) Except as otherwise provided for herein, Grantee's Severance shall not accelerate the number of Base Shares with respect to which an Award may be exercised.

## **4. Method of Exercising**

This Award may be exercised by Grantee upon delivery of the following documents to the Company at its principal executive offices, or as otherwise required in accordance with a broker-assisted cashless exercise program:

- (a) Written notice, in the form of a completed exercise election form, specifying the number of Base Shares with respect to which the Award is being exercised;

(b) Such agreements or undertakings that are required by the Committee pursuant to the Plan;

and

(c) Provision for the payment of any taxes (including withholding taxes), which may be required by the Company, as described in Section 5.

#### **5. Taxes**

a. Grantee is ultimately liable and responsible for all taxes under all applicable federal, state, local or other laws or regulations (the "Required Tax Payments") owed in connection with the Award, regardless of any action the Company or any of its Affiliates takes with respect to any tax withholding obligations that arise in connection with the Award. Neither the Company nor any of its Affiliates makes any representation or undertaking regarding the treatment of any tax withholding in connection with the grant, vesting or exercise of the Award or the subsequent sale of the Gain Shares issuable pursuant to the Award. The Company and its Affiliates do not commit and are under no obligation to structure the Award to reduce or eliminate Grantee's tax liability.

b. As a condition precedent to the delivery to the Grantee of any Gain Shares upon exercise of the Award, the Grantee shall satisfy the Required Tax Payments by the Company withholding from the

---

Gain Shares otherwise to be delivered to the Grantee pursuant to the Award a whole number of Shares having a Fair Market Value, determined as of the date the obligation to withhold or pay taxes first arises in connection with the Award (the "Tax Date"), equal to the Required Tax Payments, with the number of Shares withheld rounded up to the nearest whole Share to satisfy the Required Tax Payments; provided that the number of Shares to be withheld shall be based on the minimum statutory withholding rate or, at the election of Grantee in accordance with such procedures as may be established by the Administrator from time to time, such other withholding rates for federal, state, local and foreign income tax and payroll/employment tax purposes that are applicable to such taxable income and that have been determined by the Administrator to avoid adverse accounting consequences. For the avoidance of doubt, in no instance shall the withholding rate for any Grantee exceed the applicable maximum withholding rate. Notwithstanding the foregoing, the Company (or, in the case of a Grantee subject to Section 16 of the Exchange Act, the Committee) may, in its sole discretion, establish alternative methods for the Grantee to satisfy the Required Tax Payments, which may include, without limitation, a cash payment, proceeds from the sale of the Gain Shares otherwise issuable to Grantee, or delivery (either actual delivery or by attestation procedures established by the Company) to the Company of previously owned whole Shares, in each case, having an aggregate value, determined as of the Tax Date, equal to the amount necessary to satisfy the Required Tax Payments.

#### **6. Settlement of Award**

Upon exercise of the Award, in whole or in part, the Company shall:

(a) provide for the registration in book-entry form for Grantee's benefit of the Gain Shares (rounded down to the nearest whole number, and which may be reduced by any Gain Shares required to be withheld or sold on behalf of Grantee to satisfy tax withholding requirements); or

(b) deliver to Grantee a stock certificate representing the Gain Shares (rounded down to the nearest whole number, and which may be reduced by any Gain Shares required to be withheld or sold on behalf of Grantee to satisfy tax withholding requirements).

#### **7. Clawback Provision**

Notwithstanding any other provision in this Agreement to the contrary, Grantee and this Award shall be subject to the Company's Dodd-Frank Policy on Recoupment of Incentive Compensation, Amended and Restated Incentive Compensation Clawback Policy, and any other clawback policy adopted by the Company, each as may be amended from time to time (each, a "Clawback Policy"), in each case, to the extent applicable to the Grantee and this Award. The provisions of this Section 7 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies (as defined herein below), or any laws or regulations.

#### **8. Assignments**

(a) Subject to Section 8(b) below, this Award shall be exercisable only by Grantee during Grantee's lifetime. In the event of Grantee's death while still employed by the Company or during the three (3) month period immediately subsequent to his/her/their Severance, this Award may be exercised by any of Grantee's executor, heirs or administrator to whom this Award may have been assigned or transferred.

(b) The rights of Grantee under this Award may not be assigned or transferred except by will or by the laws of descent and distribution.

## **9. No Rights as a Stockholder**

Grantee shall have no rights as a stockholder of any Base Shares or Gain Shares unless and until the Gain Shares are issued to Grantee upon the exercise of the Award.

## **10. Interpretation of Award**

- (a) This Award is granted under the provisions of the Plan and shall be interpreted in a manner consistent with it.
- (b) Any provision in this Award inconsistent with the Plan shall be superseded and governed by the Plan.
- (c) For all purposes under this Award, employment by the Company shall include employment by the Company or any Affiliate thereof.
- (d) This Award shall be subject to the terms of any written employment agreement between the Grantee and the Company or any Affiliate thereof to the extent permissible under the Plan.

## **11. Restrictions on Transfer of Shares**

Grantee acknowledges that any Gain Shares issued upon exercise of this Award may be subject to such transfer restrictions that prohibit any transfer, pledge, sale or disposition of the Gain Shares as the Company may deem necessary to comply with all applicable state and federal securities laws and regulations.

## **12. Amendments**

The Company may amend the provisions of this Agreement at any time; provided that, an amendment that would adversely affect the Grantee's rights under this Agreement in a material manner shall be subject to the written consent of the Grantee.

## **13. [Non-Competition/Non-Solicitation/Non-Disclosure]**

(a) **[Non-Competition]** Grantee acknowledges and recognizes the highly competitive nature of the business of the Company and the unique access to the confidential business, goodwill, personnel, and customer and patient information of the Company, or any of its subsidiaries or affiliates, including trade secret information, that Grantee receives solely as a result of Grantee's employment with the Company, or any of its subsidiaries or affiliates, and accordingly agrees that while Grantee is an Employee, and for the one-year period following termination of such relationship for any reason (whether voluntary or involuntary) (the "Restricted Period"), Grantee shall not, directly or indirectly, as an employee, independent contractor, consultant, or in any other capacity, prepare to provide or provide any of the same or similar services that Grantee performed during his/her/their employment with or service to the Company, or any of its subsidiaries or affiliates, for any other individual, partnership, limited liability company, corporation, independent practice association, management services organization, or any other entity (collectively, "Person") anywhere in the Restricted Territory that competes in any way with the area of business of the Company, or any of its subsidiaries or affiliates, in which Grantee worked and/or performed services during the last five years of Grantee's employment with the Company, or any of its subsidiaries or affiliates. For purposes of the above, preparing to provide any of the same or similar services includes, but is not limited to, planning with any Person on how best to compete with the

<sup>1</sup> Applicability/inclusion in award agreement based on teammate jurisdiction and status..

Company, or any of its subsidiaries or affiliates, or discussing the Company's, or any of its subsidiaries' or affiliates', business plans or strategies with any Person.

Grantee further agrees that during the Restricted Period, Grantee shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise engage in, act for, or act on behalf of any Person (other than the Company and its subsidiaries and affiliates) engaged in any activity that Grantee was responsible for during the last five years of Grantee's employment with or engagement by the Company, or any of its subsidiaries or affiliates, in the Restricted Territory where such activity is competitive with the activities carried on by the Company, or any of its subsidiaries or affiliates.

Grantee acknowledges that during the Restricted Period, Grantee may be exposed to confidential information and/or trade secrets relating to business areas of the Company, or any of its subsidiaries or affiliates, that are different from and in addition to the areas in which Grantee primarily works for the Company, or any of its subsidiaries or affiliates, (the "Additional Protected Areas of Business"). As a result, Grantee agrees, that during the Restricted Period, he/she/they shall not, directly or indirectly, own, manage, control, operate, invest in, acquire an interest in, or otherwise act for, act on behalf, or provide the same or similar services to, any Person (other than the Company and its subsidiaries and affiliates) that engages in the Additional Protected Areas of Business.

Notwithstanding the foregoing, nothing in this Section 13(a) prohibits Grantee from passively owning not in excess of 2% in the aggregate of any company's stock or other ownership interests that are publicly traded on any national or regional stock exchange.

For purposes of this Section 13(a), "Restricted Territory" means the territory or territories or other geographic areas in which the Company and its subsidiaries and affiliates does business and as to which Grantee provided services or had a material presence or influence, and/or about which Grantee learned confidential information and/or trade secrets. Grantee acknowledges and agrees that, given Grantee's role at the Company, or any of its subsidiaries or affiliates, the geographical limitations and duration of this covenant not to compete are reasonable and appropriate, it being understood that the business of the Company and any of its subsidiaries and affiliates can be, and is, practiced throughout the United States, and that the restrictions set forth herein will not impose any undue hardship on Grantee.

To the extent that the provisions of this Section 31(a) conflict with any other agreement signed by Grantee relating to non-competition, the provisions that are most protective of the Company's, and any of its subsidiaries' or affiliates', interests shall govern.

This Section 13(a) (Non-competition) and the rights and obligations of Company hereunder may be assigned by Company and shall inure to the benefit of and shall be enforceable by any such assignee, as well as any of Company's successors in interest. This Section 13(a) (Non-competition) and the rights and obligations of Grantee hereunder may not be assigned by Grantee, but are binding upon Grantee's heirs, administrators, executors, and personal representatives.]

(b) Non-Solicitation. Grantee agrees that during the term of his/her/their employment and/or service to the Company or any of its subsidiaries or affiliates and for the one-year period following the termination of his/her/their employment and/or service by either party for any or no reason (whether voluntary or involuntary), Grantee shall not (i) solicit any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, to work for any Person (other than the Company or any of its subsidiaries or affiliates); (ii) hire any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or

---

engagement with the Company, or any of its subsidiaries or affiliates, to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates); or (iii) take any action that may reasonably result in any of the Company's, or any of its subsidiaries' or affiliates', employees who are then employed or who have left employment within the past six (6) months and with whom Grantee worked on more than a de minimis basis or whom Grantee directly or indirectly supervised during Grantee's employment or engagement with the Company, or any of its subsidiaries or affiliates, going to work (as an employee or an independent contractor) for any Person (other than the Company or any of its subsidiaries or affiliates).

(c) Non-Disclosure. In exchange for Grantee's agreement not to disclose or use Information (as defined below) except as permitted in this Agreement and Grantee's agreement to comply with the restrictive covenants in this Section 13, the Company (or its subsidiaries or affiliates) will provide Grantee access to Information. Grantee agrees not to disclose or use for his/her/their own benefit or purposes or for the benefit or purposes of any Person other than the Company and any of its subsidiaries or affiliates, any trade secrets or other confidential information or data relating to or provided by the Company, or any of its subsidiaries or affiliates, or any of their respective customers including (without limitation) any information relating to development, programs, costs, marketing, trading, investment, sales activities, promotion, credit and financial data, financing methods, plans, or the business and affairs of the Company, or any of its subsidiaries or affiliates ("Information"); provided, however, the foregoing shall not apply to (i) Information which is generally known to the industry or the public other than as a result of Grantee's breach of any obligation to the Company, or any of its subsidiaries or affiliates; (ii) disclosure that is required by any applicable law, rule or regulation; or (iii) as otherwise provided in Section 13(d). If Grantee receives such a court order or subpoena to produce Information in his/her/their possession, Grantee shall provide the Company reasonable advance notice, in writing, prior to producing said Information, so as to give the Company reasonable time to object to Grantee producing said Information. Grantee shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (1) is made (a) in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and (b) solely for the purpose of reporting or investigating a suspected violation of law; or (2) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Disclosures to attorneys, made under seal, or pursuant to court order are also protected in certain circumstances under 18 U.S.C. § 1833.

(d) Protected Rights. Nothing contained in this Agreement prohibits or limits Grantee's ability to file a charge or complaint with any federal, state or local governmental agency or commission, including but not limited to the U.S. Securities and Exchange Commission. This Agreement also does not prohibit or limit Grantee's ability to communicate with any federal, state or local governmental agency or commission (including but not limited to the U.S. Securities and Exchange Commission), or to otherwise participate in any investigation or proceeding that may be conducted by such an agency or commission (including but not limited to the U.S. Securities and Exchange Commission), including providing documents or other information. Moreover, nothing in this agreement prevents Grantee from discussing or disclosing information about unlawful acts in the workplace, such as harassment or discrimination or any other conduct that Grantee has reason to believe is unlawful.

(e) Remedies. Grantee agrees that any breach of Section [13(a)] 13(b), or 13(c) will result in immediate and irreparable harm to the Company and its affiliates for which damages alone are an inadequate remedy and cannot readily be calculated. Accordingly, the Grantee agrees that the Company and its affiliates shall be entitled to temporary, preliminary and permanent injunctive relief to prevent any such actual or threatened breach, without posting a bond or other security or limiting other available remedies. If a court finds Section 13 of this Agreement or any of its restrictions are ambiguous, unenforceable, or invalid, the Company and Grantee agree that the court will read Section 13 of the Agreement as a whole and interpret such restriction(s) to be enforceable and valid to the maximum extent

---

allowed by law. If the court declines to enforce Section 13 of this Agreement in the manner provided in this Section 13(e), the Company and Grantee agree that Section 13 of this Agreement will be automatically modified to provide the Company with the maximum protection of its business interests allowed by law, and Grantee agrees to be bound by Section 13 of this Agreement as modified.

(f) Termination of Agreement. This Agreement and the Award shall terminate effective on the date on which Grantee engages in any activity in breach of any or all of Sections [13(a)], 13(b), or 13(c). This Agreement and the Award shall also terminate if at any time during Grantee's employment with the Company, or any of its subsidiaries or affiliates, or within one (1) year after the termination of such employment for any reason (whether voluntary or involuntary), Grantee (i) is convicted of a felony; (ii) has been adjudicated by a court of competent jurisdiction of having committed an act of fraud or dishonesty resulting or intending to result directly or indirectly in personal enrichment at the expense of the Company, or any of its subsidiaries or affiliates; or (iii) is excluded from participating in any federal health care program. In any of the aforementioned cases, in addition to injunctive relief as forth above, the Company may seek an order requiring Grantee to repay the Company any value, gain or other consideration received or realized by Grantee as a result of this Award or any Shares received pursuant to the Award. The provisions of this Section 13(f) are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies, or any laws or regulations. Notwithstanding the foregoing and any other language in this Agreement, for the avoidance of doubt, this Section 13(f) does not supersede or preclude the application or enforceability of Section 7 or any Clawback Policy.

(g) Advice of Counsel; Review Period. Grantee acknowledges and agrees that Grantee has carefully read and fully understands all of the provisions of this Section 13. The Company hereby advises Grantee to consult with an attorney of the Grantee's choosing and at the Grantee's cost before signing this Agreement and Award. Grantee acknowledges that Grantee has had at least fourteen (14) days (or such longer period as may be required under applicable law) to review this Agreement and the Award before agreeing to its terms.

(h) Governing Law. Notwithstanding anything in the Plan or this Agreement to the contrary, this Section 13 shall be construed and regulated under and by the laws of the state where Grantee resides. The parties agree that any and all actions or proceedings to enforce Section 13 shall be brought in the state or federal court where Grantee resides.

#### **14. Compliance with Policies.**

It is understood and agreed upon that at all times Grantee will act in full compliance with the Company's policies and procedures as may be in effect from time to time, including without limitation, the Company's Code of Conduct, Joint Venture Arrangements Policy, Medical Director Agreements Compliance Handbook, Acceptance of Gifts Policy and/or credentialing process (individually, each a "Policy," and, collectively, the "Policies"). If Grantee's conduct, whether related to the Award granted under this Agreement or otherwise, materially violates the requirements of the Policies, as determined by the independent directors of the Board (with respect to a Grantee who is the Chief Executive Officer of the Company), the Committee (with respect to a Grantee that is an "officer" under Section 16 of the Exchange Act other than the Chief Executive Officer) or the Company's Chief Executive Officer, Chief Compliance Officer or Chief Legal Officer (with respect to a Grantee that is not an "officer" under Section 16 of the Exchange Act), then the Company may require Grantee to forfeit any unvested portion of the Award granted under this Agreement and be subject to immediate disciplinary action, up to and including termination. The provisions of this Section 14 are in addition to and not in lieu of any other remedies available to the Company in the event Grantee violates the Policies or any laws or regulations. If at any time Grantee has questions or concerns about the provisions in this Section 14, or suspects any

---

improper conduct related to the Policies, Grantee should immediately contact his/her/their supervisor or Team Quest. Grantee also may anonymously and confidentially call the Company's Compliance Hotline.

#### **15. Compliance with Law**

No Shares shall be issued and delivered for a Gain Share unless and until all applicable registration requirements of the Securities Act of 1933, as amended, all applicable listing requirements of any national securities exchange on which the Common Stock is then listed, and all other requirements of law or of any regulatory bodies having jurisdiction over such issuance and delivery, shall have been complied with. In particular, the Committee may require certain investment (or other) representations and undertakings in connection with the issuance of securities in connection with the Plan and this Award in order to comply with applicable law.

If any provision of this Agreement is determined to be unenforceable or invalid under any applicable law, such provision will be applied to the maximum extent permitted by applicable law, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. Furthermore, if any provision of this Agreement is determined to be illegal under any applicable law, such provision shall be null and void to the extent necessary to comply with applicable law, but the other provisions of this Agreement shall remain in full force and effect.

#### **16. Arbitration**

Except as otherwise set forth in Section 13, any dispute, controversy, or claim concerning this Award shall be resolved by final and binding arbitration administered by the American Arbitration Association under its Employment Arbitration Rules and Mediation Procedures then in effect (including with regards to discovery). Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. The arbitrator shall have the authority to award any remedy or relief that a court of competent jurisdiction could order or grant, including the issuance of an injunction, and may award the prevailing party legal fees and expenses and arbitration fees and expenses that are incurred by the prevailing party if the substantive law at issue, or other applicable law, permits. Either party may, without inconsistency with and without waiving this arbitration provision, apply to any court having jurisdiction over such dispute or controversy and seek interim provisional, injunctive or other equitable relief until the arbitration award is rendered or the controversy is otherwise resolved. The award of the arbitrator, which shall be in writing summarizing the basis for the decision, shall be final and binding upon the parties and subject only to limited review as permitted by law. Except as provided for in Section 13(d) or as necessary in court proceedings to enforce this arbitration provision or an award rendered hereunder, or to obtain interim relief, neither a party nor an arbitrator may disclose the existence, content or results of any arbitration hereunder without the prior written consent of the Company and Grantee. The Company and Grantee acknowledge that this Agreement evidences a transaction involving interstate commerce. Notwithstanding any choice of law provision included in this Agreement, the United States Federal Arbitration Act shall govern the interpretation and enforcement of this arbitration provision.

**17. Electronic Delivery and Execution.** Grantee will not be able to initiate any stock transactions related to this Award until Grantee has accepted the terms of this Agreement. The Company may, in its sole discretion, decide to deliver any documents related to this Award or future awards made under the Plan by electronic means or request Grantee's consent to participate in the Plan by electronic means. Grantee hereby consents to receive such documents by electronic delivery and, if requested, agrees to participate in the Plan through any online or electronic system established and maintained by the Company or another third party designated by the Company.

---

**DaVita Inc.**  
**Stock Appreciation Rights Agreement**  
**Exhibit B – Events Causing Full Vesting Awards**

For purposes of this Exhibit:

- "Cause" shall mean: (a) a material breach by Grantee of his/her/their duties and responsibilities which do not differ in any material respect from the duties and responsibilities of Grantee during the ninety (90) days immediately prior to a Change of Control (for clarity, as defined below) (other than as a result of incapacity due to physical or mental illness) which is demonstrably willful and deliberate on Grantee's part, which is committed in bad faith or

without reasonable belief that such breach is in the best interests of the Company and which is not remedied in a reasonable period of time after receipt of written notice from the Company specifying such breach; (b) willful misconduct or gross negligence which results in material harm to the Company; (c) the conviction of Grantee of, or a plea of *nolo contendere* by Grantee to, a felony or other crime involving fraud or dishonesty; or (d) willful violation of Company policies which results in material harm to the Company.

- "Change of Control" shall mean:

- any transaction or series of transactions in which any Person becomes the direct or indirect Beneficial Owner, by way of a stock issuance, tender offer, merger, consolidation, other business combination or otherwise, of greater than 35% of the total voting power (on a fully diluted basis as if all convertible securities had been converted and all warrants and options had been exercised) entitled to vote in the election of directors of the Company ("Company Voting Securities") (including any transaction in which the Company becomes a wholly-owned or majority-owned subsidiary of another corporation); provided, however, that the following acquisitions shall not be deemed to be a Change of Control: (i) acquisitions by the Company or any Subsidiary; (ii) acquisitions by any employee benefit plan (or related trust) sponsored or maintained by the Company or any Subsidiary; (iii) acquisitions by any underwriter temporarily holding securities pursuant to an offering of such securities; or (iv) any acquisition pursuant to a transaction described in subparagraph (b) of this definition; provided further, that a Change of Control shall not be deemed to occur solely because Berkshire Hathaway Inc., together with its Affiliates ("Berkshire") acquires Beneficial Ownership of more than 35% of the then-outstanding Company Voting Securities as a result of the acquisition of additional securities by the Company that reduces the number of Company Voting Securities outstanding (except if after such acquisition by the Company, Berkshire becomes the Beneficial Owner of additional Company Voting Securities that increase the percentage of outstanding Company Voting Securities beneficially owned by Berkshire, in which case a Change of Control of the Company shall then occur);
- any merger or consolidation or reorganization of the Company other than a merger, consolidation or reorganization (i) immediately following which those individuals who, immediately prior to the consummation of such merger, consolidation or reorganization, constituted the Board, constitute a majority of the board of directors of

---

the Company or the surviving or resulting entity or any parent thereof, (ii) which results in the Company Voting Securities outstanding immediately prior to such merger, consolidation or reorganization continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any Subsidiary, greater than 50% of the combined voting power of the securities of the Company (or such surviving entity or any parent thereof) outstanding immediately after such merger or consolidation, and (iii) in which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities beneficially owned by such Person any securities acquired directly from the Company or its Affiliates) representing 50% or more of the then outstanding Company Voting Securities;

- any transaction or series of transactions in which all or substantially all of the Company's assets are sold;
- a complete liquidation or dissolution of the Company; or
- during any twenty-four (24) month period, individuals who, as of the beginning of such period, constitute the Board (the "Incumbent Directors") cease for any reason to constitute at least a majority of the Board; provided that any Person becoming a director subsequent to the beginning of such period whose election or nomination for election was approved by a vote of at least a majority of the Incumbent Directors then on the Board (either by a specific vote or by approval of the proxy statement of the Company in which such Person is named as a nominee for director, without written objection to such nomination) shall be an Incumbent Director; provided, however, that no individual initially elected or nominated as a director of the Company as a result of an actual or threatened election contest with respect to directors or as a result of any other actual or threatened solicitation of proxies by or on behalf of any Person other than the Board shall be deemed to be an Incumbent Director.

Solely for purposes of this definition, the following terms shall have the meaning specified: (A) "Affiliate" shall have the meaning set forth in Rule 12b-2 under Section 12 of the Exchange Act; (B) "Beneficial Owner" shall have the meaning set forth in Rule 13d-3 under the Exchange Act, except that a Person shall not be deemed to be the Beneficial Owner of any securities which are reflected on a Schedule 13G; and (C) "Person" shall have the meaning given in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (w) the Company or any of its Affiliates; (x) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or any of its Subsidiaries; (y) an underwriter temporarily holding securities pursuant to an offering of such securities; or (z) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as their ownership of stock of the Company.

#### Change of Control Vesting

In the event of a Change of Control (as defined above), this Award shall automatically vest in its entirety upon the earlier of the following two events: (i) immediately prior to the effective date of a Change of Control if the successor in such Change of Control (the "Acquiror") fails to effectively

---

assume, convert or replace this Award, or (ii) if the Award is effectively assumed in a Change of Control, as of the date of termination of Grantee's employment if such termination occurs within twenty-four (24) months following such Change of Control by the Company (or the Acquiror) (a) other than for "Cause" (defined above) or (b) if applicable, by Grantee in accordance with the termination for "Good Reason" provisions of Grantee's employment agreement, if any.

To be effectively assumed in the Change of Control, the award received in exchange for the Award in connection with a Change of Control: (i) must be of the same type as the Award; (ii) must have a value intended to preserve the value of the Award; (iii) must relate to publicly traded equity securities of the Company (or the Acquiror or another entity that is affiliated with the Company or the Acquiror); and (iv) must have other terms and conditions that are not less favorable to the Grantee than the terms and conditions of the Award (including the provisions that would apply in the event of a subsequent Change of Control). Without limiting the generality of the foregoing, the replaced Award may take the form of a continuation of the Award if the requirements of the preceding sentence are satisfied. The determination of whether the conditions for effectively assuming the Award have been satisfied shall be made by the Board, as constituted immediately before the Change of Control, in its sole discretion.

#### Rule of 65 Vesting

In the event that (i) the Grantee has remained continuously employed with the Company for at least one year from the Grant Date, (ii) the Grantee has satisfied the Rule of 65 (as defined below) at the time of his/her/their termination of employment and such termination of employment is not for Cause, and (iii) the Grantee is an "officer" under Section 16 of the Exchange Act at the time of such termination of employment, then the Award shall vest and become exercisable in accordance with its normal vesting schedule set forth on the cover page of the Agreement; provided, however, that if following the Grantee's termination of employment under this paragraph, there is a Change of Control (as defined above) and the Award is not effectively assumed, converted or replaced, then the Award shall vest and become exercisable upon such Change of Control. If the Grantee satisfies the requirements of the preceding sentence but the Grantee's termination of employment occurs prior to the first anniversary of the Grant Date, then the portion of the Award eligible for vesting shall be prorated based on the number of full months from the Grant Date to the Grantee's termination of employment divided by 12.

"Rule of 65" shall mean that the sum of the Grantee's age and years of service equals or exceeds 65, with a minimum age of 55 and a minimum of five years of continuous service.

#### Death or Disability

In the event of the Grantee's death or Disability while employed by the Company, any outstanding portion of the Award shall become exercisable upon such death or Disability.

"Disability" shall mean that the Grantee is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 12 months.

EXHIBIT 31.1

#### SECTION 302 CERTIFICATION

I, Javier J. Rodriguez, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DaVita Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/S/ JAVIER J. RODRIGUEZ

Javier J. Rodriguez

Chief Executive Officer

Date: November 7, 2023 May 2, 2024

EXHIBIT 31.2

#### SECTION 302 CERTIFICATION

I, Joel Ackerman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of DaVita Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in

which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Joel Ackerman

Joel Ackerman

Chief Financial Officer and Treasurer

Date: November 7, 2023 May 2, 2024

**EXHIBIT 32.1**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of DaVita Inc. (the "Company") on Form 10-Q for the quarter ended September 30, 2023 March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the "Periodic Report"), I, Javier J. Rodriguez, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ JAVIER J. RODRIGUEZ

Javier J. Rodriguez

Chief Executive Officer

November 7, 2023 May 2, 2024

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

**EXHIBIT 32.2**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of DaVita Inc. (the "Company") on Form 10-Q for the quarter ended **September 30, 2023** **March 31, 2024** as filed with the Securities and Exchange Commission on the date hereof (the "Periodic Report"), I, Joel Ackerman, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Periodic Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

**/s/ Joel Ackerman**

**Joel Ackerman**

**Chief Financial Officer and Treasurer**

**November 7, 2023** **May 2, 2024**

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

#### DISCLAIMER

THE INFORMATION CONTAINED IN THE REFINITIV CORPORATE DISCLOSURES DELTA REPORT™ IS A COMPARISON OF TWO FINANCIALS PERIODIC REPORTS. THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORT INCLUDING THE TEXT AND THE COMPARISON DATA AND TABLES. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED IN THIS REPORT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S ACTUAL SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

©2024, Refinitiv. All rights reserved. Patents Pending.